<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Pharmacol.</journal-id>
<journal-title>Frontiers in Pharmacology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Pharmacol.</abbrev-journal-title>
<issn pub-type="epub">1663-9812</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">1373711</article-id>
<article-id pub-id-type="doi">10.3389/fphar.2024.1373711</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pharmacology</subject>
<subj-group>
<subject>Review</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Metabolites of traditional Chinese medicine targeting PI3K/AKT signaling pathway for hypoglycemic effect in type 2 diabetes</article-title>
<alt-title alt-title-type="left-running-head">Feng et al.</alt-title>
<alt-title alt-title-type="right-running-head">
<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.3389/fphar.2024.1373711">10.3389/fphar.2024.1373711</ext-link>
</alt-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Yuhan</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ren</surname>
<given-names>Yan</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/validation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xia</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Songqin</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/visualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jiao</surname>
<given-names>Qian</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Qiuhong</given-names>
</name>
<role content-type="https://credit.niso.org/contributor-roles/investigation/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jiang</surname>
<given-names>Wenwen</given-names>
</name>
<xref ref-type="corresp" rid="c001">&#x2a;</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2635474/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/supervision/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/Writing - review &#x26; editing/"/>
</contrib>
</contrib-group>
<aff>
<institution>School of Pharmaceutical Sciences</institution>, <institution>Guizhou University</institution>, <addr-line>Guiyang</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>
<bold>Edited by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/16719/overview">Adolfo Andrade-Cetto</ext-link>, National Autonomous University of Mexico, Mexico</p>
</fn>
<fn fn-type="edited-by">
<p>
<bold>Reviewed by:</bold> <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2361389/overview">Priyanka Choudhury</ext-link>, Medical College of Wisconsin, United States</p>
<p>
<ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/284177/overview">Syed Anees Ahmed</ext-link>, East Carolina University, United States</p>
</fn>
<corresp id="c001">&#x2a;Correspondence: Wenwen Jiang, <email>wwjiang@gzu.edu.cn</email>
</corresp>
</author-notes>
<pub-date pub-type="epub">
<day>10</day>
<month>05</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="collection">
<year>2024</year>
</pub-date>
<volume>15</volume>
<elocation-id>1373711</elocation-id>
<history>
<date date-type="received">
<day>20</day>
<month>01</month>
<year>2024</year>
</date>
<date date-type="accepted">
<day>23</day>
<month>04</month>
<year>2024</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2024 Feng, Ren, Zhang, Yang, Jiao, Li and Jiang.</copyright-statement>
<copyright-year>2024</copyright-year>
<copyright-holder>Feng, Ren, Zhang, Yang, Jiao, Li and Jiang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Type 2 diabetes mellitus is a chronic metabolic disease characterized by insulin resistance, with high morbidity and mortality worldwide. Due to the tightly intertwined connection between the insulin resistance pathway and the PI3K/AKT signaling pathway, regulating the PI3K/AKT pathway and its associated targets is essential for hypoglycemia and the prevention of type 2 diabetes mellitus. In recent years, metabolites isolated from traditional Chinese medicine has received more attention and acceptance for its superior bioactivity, high safety, and fewer side effects. Meanwhile, numerous <italic>in vivo</italic> and <italic>in vitro</italic> studies have revealed that the metabolites present in traditional Chinese medicine possess better bioactivities in regulating the balance of glucose metabolism, ameliorating insulin resistance, and preventing type 2 diabetes mellitus via the PI3K/AKT signaling pathway. In this article, we reviewed the literature related to the metabolites of traditional Chinese medicine improving IR and possessing therapeutic potential for type 2 diabetes mellitus by targeting the PI3K/AKT signaling pathway, focusing on the hypoglycemic mechanism of the metabolites of traditional Chinese medicine in type 2 diabetes mellitus and elaborating on the significant role of the PI3K/AKT signaling pathway in type 2 diabetes mellitus. In order to provide reference for clinical prevention and treatment of type 2 diabetes mellitus.</p>
</abstract>
<abstract abstract-type="graphical">
<title>Graphical Abstract</title>
<p>
<graphic xlink:href="FPHAR_fphar-2024-1373711_wc_abs.tif" position="anchor"/>
</p>
</abstract>
<kwd-group>
<kwd>metabolites</kwd>
<kwd>traditional Chinese medicine</kwd>
<kwd>type 2 diabetes mellitus</kwd>
<kwd>insulin resistance</kwd>
<kwd>PI3K/AKT signaling pathway</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Ethnopharmacology</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1">
<title>1 Introduction</title>
<p>Nowadays, type 2 diabetes (T2DM) is one of the most severe and frequent chronic diseases of the modern era. It has become the third primary non-communicable disease after tumors and cardiovascular diseases, threatening human life and health on a wide scale. According to the statistics released by the International Diabetes Federation, more than 10% of the world&#x2019;s population became diabetic in 2021 (<xref ref-type="bibr" rid="B138">Sun et al., 2022</xref>). Moreover, the prevalence rate is expected to be more than 12% by 2045, which means that more than one in ten people worldwide are suffering from the double blow of diabetes to human health and economic burden, threatening the health of human life and quality of life, of which more than 90% of the patients are type 2 diabetes (<xref ref-type="bibr" rid="B138">Sun et al., 2022</xref>). However focusing on hyperglycemia that defines T2DM is mainly secondary to inadequate action of the primary glucose-lowering hormone insulin. Further, understanding insulin resistance and the mechanisms of insulin action is critical for the continued development of effective therapeutic strategies to combat T2DM, which is a major challenge for the medical community (<xref ref-type="bibr" rid="B111">Petersen and Shulman, 2018</xref>).</p>
<p>Insulin resistance (IR) is the pathological basis of T2DM and the core part of its pathogenesis, which plays a vital role in both the occurrence and development of T2DM. Generally, IR refers to the inability of insulin-target organs/tissues (e.g., skeletal muscle, adipose tissue, and liver) to produce a normal coordinated glucose-lowering response due to reduced responsiveness and sensitivity to insulin under the influence of a variety of factors, including inhibition of endogenous glucose production, inhibition of lipolysis, cellular uptake of available plasma glucose, and glycogen synthesis, resulting in the onset and worsening of glucose tolerance abnormalities and diabetes mellitus (<xref ref-type="bibr" rid="B111">Petersen and Shulman, 2018</xref>).</p>
<p>Clinically, IR is characterized by the inability of insulin to exert an effect proportional to blood concentration to maintain normoglycemia. At the cellular level, IR is defined as the lack of insulin signaling intensity associated with multiple mitogenic cellular functions from downstream receptors to final substrates (<xref ref-type="bibr" rid="B16">Camer et al., 2014</xref>). It also implies a corresponding inhibitory effect on the phosphorylation of insulin receptor substrate (IRS) and its triggered cascade of activation of the PI3K/AKT signaling pathway upon binding of insulin to the insulin receptor (<xref ref-type="bibr" rid="B126">Savova et al., 2023</xref>). Furthermore, the insulin-mediated PI3K/AKT pathway is crucial for regulating glucose homeostasis in the insulin signaling system, closely related to glucose-lipid metabolism and insulin resistance (<xref ref-type="bibr" rid="B91">Malik et al., 2019</xref>). Therefore, improving insulin resistance by modifying the PI3K/AKT pathway is a crucial therapeutic strategy for hypoglycemia in T2DM.</p>
<p>Currently, the primary drugs used in the clinical treatment of T2DM include biguanides, thiazolidinediones, and sulfonylureas (<xref ref-type="bibr" rid="B183">Zhang et al., 2019</xref>). Considering the limitations of the existing hypoglycemic drugs that need to be taken for long-term and have plenty of side effects, it is particularly urgent to continuously explore and develop practical, low-toxicity or non-toxic hypoglycemic drugs.</p>
<p>In the theory of traditional Chinese medicine (TCM), diabetes and thirst-quenching disease belong to the same category, and the first record of diabetes was found in the Yellow Emperor&#x2019;s Classic of Internal Medicine, also known as &#x201c;Huangdi Neijing&#x201d; (<xref ref-type="bibr" rid="B177">Zhang et al., 2021</xref>). Since ancient times, the threat of diabetes to the life and health of human beings has gradually been growing. Moreover, the research on treating diabetes utilizing traditional Chinese medicine and Chinese medicine approaches has never ceased (<xref ref-type="bibr" rid="B170">Yingrui et al., 2022</xref>). From the perspective of TCM, &#x201c;consuming thirst syndrome&#x201d; manifests as a deficiency of both Qi and Yin, and the corresponding treatment is to replenish Qi and nourish Yin (<xref ref-type="bibr" rid="B76">Li et al., 2004</xref>). Since centuries ago, Chinese people have been decocting Chinese medicine to treat diabetes based on benefiting Qi and nourishing Yin (<xref ref-type="bibr" rid="B86">Liu et al., 2022</xref>). For example, traditional Chinese medicine such as astragalus, ginseng, schizandra, and dendrobium are often found in Chinese herbal formulas for the treatment of T2DM, and they are commonly known to nourish yin and replenish qi (<xref ref-type="bibr" rid="B145">Tang et al., 2017</xref>; <xref ref-type="bibr" rid="B25">Chu et al., 2019</xref>; <xref ref-type="bibr" rid="B130">Shao et al., 2020</xref>). Moreover, Tianqi capsule, Jinlida granule, Shenqi jiang tang capsule, Qiyao xiaoke capsule, Shenqi jiang tang granule, which are proprietary Chinese medicines, are used for the treatment of T2DM and its related diseases (<xref ref-type="bibr" rid="B130">Shao et al., 2020</xref>). But, TCM is characterized by multiple courses of treatment, slow onset of action, and poor patient adherence (<xref ref-type="bibr" rid="B103">Nurcahyanti et al., 2021</xref>). Further, there are hundreds of metabolites in extracts, and the specific metabolites with beneficial effects and their targets of action are unknown (<xref ref-type="bibr" rid="B157">Xiong et al., 2010</xref>). Therefore, more and more researchers are deeply interested in the intervention of the TCM metabolites to improve insulin resistance and hyperglycemia. Subsequently, researchers have identified multiple bioactive metabolites isolated from TCM that have positive effects on improving insulin resistance and hypoglycemia, and these bioactive metabolites exhibit a promising therapeutic outlook owing to their biocompatibility and fewer adverse effects (<xref ref-type="bibr" rid="B77">Li et al., 2022</xref>). Among the multitude of metabolites present in TCM, the identification of specific active metabolites that can regulate the balance of glucose metabolism and improve insulin resistance is essential for controlling the incidence and progression of T2DM and its complications (<xref ref-type="bibr" rid="B156">Xiong et al., 2020</xref>).</p>
<p>Therefore, we conducted a literature search on the keywords &#x201c;Insulin resistance,&#x201d; &#x201c;Type 2 diabetes,&#x201d; &#x201c;PI3K/AKT signaling pathway,&#x201d; &#x201c;Traditional Chinese medicine&#x201d; and &#x201c;Metabolites.&#x201d; The following inclusion criteria were used in the selection of articles: 1) articles using <italic>in vitro</italic> or/and <italic>in vivo</italic> T2DM or T2DM-related disease models, and modeling methods with a blank control group and a positive control group to determine the success of the modeling; 2) articles in which the study was on a metabolite of TCM were identified as a metabolite reported in the literature or obtained by extraction and isolation from a TCM; 3) articles on the regulation of PI3K/AKT signaling pathway in the context of type 2 diabetes mellitus; 4) articles written in English and published within the last 15&#xa0;years. Nowadays, researchers are concerned about the advantages and potential of TCM metabolites in the prevention and treatment of chronic diseases, and there are numerous studies showing the positive effects of the metabolites of TCM in improving insulin resistance and hyperglycemia as well as elucidating their hypoglycemic mechanisms, but there is no review summarizing these studies. This review is aimed to provide a comprehensive perspective of the metabolites of TCM improving IR and possessing therapeutic potential for hyperglycemia in T2DM by targeting the PI3K/AKT signaling pathway. Further, it is expected to provide a theoretical basis and reference for future clinical studies.</p>
</sec>
<sec id="s2">
<title>2 PI3K/AKT signaling pathway</title>
<p>Phosphoinositide 3-kinase (PI3K) is a target of the insulin receptor substrate (IRS) and an intracellular phosphoinositol kinase with serine/threonine kinase activity (<xref ref-type="bibr" rid="B159">Xu et al., 2014</xref>). Meanwhile, it plays a prominent role in insulin signaling. PI3K can express three types of PI3K&#x2160;, PI3K&#x2161;, and PI3K&#x2162; in human cells (<xref ref-type="bibr" rid="B57">Jahandideh and Wu, 2022</xref>). Class I PI3Ks are divided into classes IA and IB PI3Ks (<xref ref-type="bibr" rid="B92">Meng et al., 2021</xref>). Heterodimers composed of catalytic subunit P110 and regulatory subunit P85 belong to class IA PI3K, which are involved in insulin signal transduction and have indispensable significance in maintaining glucose homeostasis (<xref ref-type="bibr" rid="B166">Yang et al., 2020</xref>).</p>
<p>As a serine/threonine kinase, AKT (protein kinase B) is one of the main effectors of the downstream signal network of PI3K (<xref ref-type="bibr" rid="B55">Huang et al., 2018</xref>). AKT is widely expressed in various body tissues, regulating many processes, including metabolism, proliferation, cell survival, growth, and angiogenesis (<xref ref-type="bibr" rid="B84">Liu et al., 2023</xref>). Due to its ability to regulate most of the PI3K-mediated metabolic activity of insulin by phosphorylating serine and/or threonine from downstream substrates, including other kinases, transcription factors, and signaling proteins, it is known as the central regulator of insulin action (<xref ref-type="bibr" rid="B130">Shao et al., 2020</xref>). Moreover, there are three subtypes of AKT expressed in mammalian cells, namely, AKT1/PKB&#x3b1;, AKT2/PKB&#x3b2;, and AKT3/PKB&#x3b3;, and each of these subtypes exerts different physiological effects (<xref ref-type="bibr" rid="B50">Hay, 2011</xref>). Among them, AKT1 is widely expressed in various body tissues (<xref ref-type="bibr" rid="B48">Hajiaghaalipour et al., 2015</xref>). AKT2 is selectively expressed in insulin-sensitive tissues such as muscle, fat, and liver, and plays a pivotal role in cell growth, proliferation, and glucose homeostasis (<xref ref-type="bibr" rid="B55">Huang et al., 2018</xref>). Meanwhile, AKT3 is highly expressed in the brain and testis (<xref ref-type="bibr" rid="B140">Sun et al., 2018</xref>). Furthermore, researches have found that all three subtypes of AKT are all expressed in pancreatic &#x3b2; cells (<xref ref-type="bibr" rid="B187">Zheng et al., 2016</xref>). Other studies have found that interrupting AKT2 may lead to severe insulin resistance, diabetes, and fat atrophy (<xref ref-type="bibr" rid="B30">Dewanjee et al., 2022</xref>). Further, AKT2 gene knockout mice exhibit glucose intolerance and systemic insulin resistance (<xref ref-type="bibr" rid="B5">Alshehade et al., 2022</xref>). Among the three subtypes, AKT2 appears to be the primary functional subtype of insulin response, which is closely relevant to IR (<xref ref-type="bibr" rid="B40">Fruman et al., 2017</xref>).</p>
<p>PI3K/AKT signaling pathway plays an indispensable role in insulin signal transduction and glucose metabolism regulation and participates in the entire process of T2DM occurrence and development (<xref ref-type="bibr" rid="B80">Lin et al., 2022</xref>). PI3K is the leading component of this pathway while AKT is a crucial downstream signal, representing the crucial regulatory node of this pathway (<xref ref-type="bibr" rid="B8">Barone et al., 2021</xref>). Insulin is the only hormone in the body to lower blood sugar and its physiological effect begins with the binding of insulin and insulin receptors (<xref ref-type="bibr" rid="B102">Norton et al., 2022</xref>). Upon insulin binding to the &#x3b1;-subunit of the insulin receptor, the &#x3b2;-subunit transitions to an activated state, causing its tyrosine residues to self-phosphorylate. Meanwhile, the activated insulin receptor recognizes and binds to the insulin receptor substrate 1 (IRS1), and the phosphorylation and activation of IRS1 can then be recognized and bound by downstream signals (<xref ref-type="bibr" rid="B103">Nurcahyanti et al., 2021</xref>). Activated IRS-1 can recognize and bind to PI3K through its regulatory subunit p85 and activate the catalytic activity of p110 and the catalytic subunit of PI3K and catalyze the conversion of phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-trisphosphate (PIP3) at the cellular membrane (<xref ref-type="bibr" rid="B57">Jahandideh and Wu, 2022</xref>). Further, PIP3, when generated and reached a specific concentration, recruits phosohoinositide-dependent kinase 1 (PDK1) and AKT to the vicinity of the plasma membrane and then recruits them through Pleckstrin homologous structures. After PIP3 is generated and reaches a specific concentration, it can recruit PDK1 and AKT to the vicinity of the plasma membrane and bind to it through the Pleckstrin homology domain, resulting in the aggregation of AKT at the plasma membrane and activation of AKT (<xref ref-type="bibr" rid="B40">Fruman et al., 2017</xref>). Moreover, the activation process of AKT consists of PDK1 directly or indirectly phosphorylating the Thr308 and Ser473 sites of AKT. Meanwhile, the activated AKT is released from the plasma membrane into the cytoplasm or nucleus to elicit a cascade of responses in the signal transduction pathway (<xref ref-type="bibr" rid="B56">Inam et al., 2018</xref>; <xref ref-type="bibr" rid="B5">Alshehade et al., 2022</xref>).</p>
<p>Activation of the PI3K/AKT signaling pathway can induce multiple downstream factors, including other kinases, transcription factors, and signal proteins (<xref ref-type="bibr" rid="B13">Bhattamisra et al., 2021</xref>). Among the numerous physiological effects that can be generated, T2DM-related effects on glucose metabolism include promoting glucose uptake and glycogen synthesis, and inhibiting gluconeogenesis. AKT can promote the transport of glucose-specific transporters GLUTs to the cell membrane, thereby allowing glucose in the blood to be transported into tissue cells, increasing glucose uptake (<xref ref-type="bibr" rid="B30">Dewanjee et al., 2022</xref>). After glucose is transported from extracellular to intracellular tissues, it is phosphorylated in tissues by glucokinase to form glucose-6-phosphate, which continues to undergo conversion to glycolysis or glycogen synthesis (<xref ref-type="bibr" rid="B179">Zhang et al., 2018</xref>). Therefore, the PI3K/AKT pathway plays a crucial role in insulin-stimulated glucose transport (<xref ref-type="bibr" rid="B130">Shao et al., 2020</xref>).</p>
<p>AKT can inhibit the activity of glycogen synthase kinase-3 (GSK3&#x3b2;) by phosphorylating its Ser9, thereby dephosphorylating and activating glycogen synthase (GS) to regulate insulin signal transduction and increase glycogen synthesis. Glycogen, as a reservoir of glucose, is mainly present in the skeletal muscle and liver of mammals, where it buffers changes in circulating glucose levels by phosphorylating excess glucose and polymerizing it to synthesize glycogen (<xref ref-type="bibr" rid="B102">Norton et al., 2022</xref>). Additionally, AKT can reduce the expression of two vital glycogenic enzymes, phosphoenolpyruvate carboxykinase (PEPCK) and glucose 6-phosphatase (G6Pase) by inhibiting the activity of forkhead transcription factor family member (FoxO1) (<xref ref-type="bibr" rid="B150">Wang et al., 2015</xref>). Moreover, FoxO1 is located in the nucleus and trans-activates two gluconeogenesis without insulin. Under insulin stimulation, the activated AKT then phosphorylates FoxO1, inducing FoxO1 translocation to the cytoplasm, thereby reducing its transcriptional activity, reducing the expression of its decisive target genes PEPCK and G6Pase, and inhibiting gluconeogenesis to reduce glucose levels (<xref ref-type="bibr" rid="B48">Hajiaghaalipour et al., 2015</xref>). Therefore, abnormalities in any PI3K/AKT signaling pathway and downstream factors can affect insulin signal transduction and promote the occurrence of IR and T2DM. On the contrary, the upregulation of PI3K and AKT molecules caused by insulin and other factors can initiate the transmission of the entire PI3K/AKT signal pathway, acting on a variety of substrate receptor molecules such as GLUT-4, GSK3, and FoxO1 through a series of signal transduction, playing a prominent role in increasing glucose uptake, inhibiting liver glycogen synthesis, reducing gluconeogenesis, and improving IR. Therefore, the PI3K/AKT signaling pathway is the primary mechanism for developing insulin resistance.</p>
</sec>
<sec id="s3">
<title>3 Mechanism of PI3K/AKT signaling pathway in hypoglycemic effect</title>
<p>The PI3K/AKT signaling pathway is intimately linked to insulin resistance, and any defects in the pathway along downstream molecules may contribute to insulin resistance, in addition, the activated PI3K/AKT pathway is primarily involved in the glucose metabolism function of insulin via three notable routes (<xref ref-type="bibr" rid="B184">Zhang et al., 2019</xref>). Peripheral control of glucose homeostasis is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>.<list list-type="simple">
<list-item>
<p>1) Glucose uptake: The cellular uptake of glucose is an essential physiological process associated with glucose homeostasis and glucose translocation from the extracellular space to the cell cytoplasm, and is responsible for fourteen members of the glucose transporter protein family (GLUT) (<xref ref-type="bibr" rid="B162">Yan, 2017</xref>). Available evidence from multiple research in the area of diabetes suggests that GLUT4 mediates insulin-dependent glucose uptake and that the PI3K/AKT pathway regulates the movement of GLUT4 between the plasma membrane and intracellular vesicles in an insulin-dependent manner, and thus GLUT4 dysfunction could induce insulin resistance (<xref ref-type="bibr" rid="B19">Chang et al., 2023</xref>). Thus, in skeletal muscles and mature adipocytes, the activated PI3K/AKT pathway promotes GLUT4 membrane translocation to uptake glucose for storage or utilization (<xref ref-type="bibr" rid="B126">Savova et al., 2023</xref>).</p>
</list-item>
<list-item>
<p>2) Glycogen synthesis: In skeletal muscle and liver, excess glucose is taken up into the cell for storage in the form of synthesized glycogen, thereby increasing the disposal of glucose (<xref ref-type="bibr" rid="B17">Carnagarin et al., 2015</xref>). Glycogen synthase kinase-3 (GSK-3), a serine/threonine kinase, is well recognized as a key regulator involved in the regulation of glycogen synthesis and has been suggested as a potential target for the treatment of diabetes (<xref ref-type="bibr" rid="B147">Teli and Gajjar, 2023</xref>). Phosphorylation of Ser9 of GSK3&#x3b2; in a PI3K/AKT-dependent manner decreases its activity towards GS, resulting in the promotion of dephosphorylation of glycogen synthase, ultimately leading to an increase in glycogen synthesis to promote glucose metabolism (<xref ref-type="bibr" rid="B128">Seo et al., 2008</xref>; <xref ref-type="bibr" rid="B2">Agius, 2015</xref>; <xref ref-type="bibr" rid="B12">Beurel et al., 2015</xref>).</p>
</list-item>
<list-item>
<p>3) Gluconeogenesis: Glycemic control is achieved by suppressing hepatic gluconeogenesis, which is one of the strategies for the treatment of diabetes (<xref ref-type="bibr" rid="B60">Jitrapakdee, 2012</xref>; <xref ref-type="bibr" rid="B101">Nirmalan and Nirmalan, 2023</xref>). Gluconeogenesis is largely controlled by the transcriptional regulation of key rate-limiting enzymes, and PEPCK and G6Pase serve as key rate-limiting enzymes, and the regulation of their expression is affected by the phosphorylation of the transcription factor FoxO1 (<xref ref-type="bibr" rid="B104">Onyango, 2022</xref>). FoxO1 is activated by dephosphorylation and translocates into the nucleus, leading to increased transcriptional induction of G6Pase and PEPCK as well as hepatic glucose production, whereas when activation of the PI3K/AKT pathway phosphorylates FoxO1, it induces the translocation of FoxO1 to the cytoplasm, thereby decreasing its transcriptional activity, reducing the expression of PEPCK and G6Pase, and inhibiting gluconeogenesis so as to lower blood glucose levels (<xref ref-type="bibr" rid="B60">Jitrapakdee, 2012</xref>; <xref ref-type="bibr" rid="B179">Zhang et al., 2018</xref>).</p>
</list-item>
</list>
</p>
<fig id="F1" position="float">
<label>FIGURE 1</label>
<caption>
<p>Peripheral control of glucose homeostasis.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g001.tif"/>
</fig>
</sec>
<sec id="s4">
<title>4 Metabolites of traditional Chinese medicine regulate the PI3K/AKT signaling pathway for hypoglycemic effect</title>
<p>Metabolites isolated from TCM are active substances with various practical activities due to their specific molecular formula and spatial structure (<xref ref-type="bibr" rid="B189">Zhou et al., 2021</xref>). Recent studies have clarified that numerous metabolites of TCM addressing complex and comprehensive targets have the potential for hypoglycemic effect in T2DM by regulating the PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="B103">Nurcahyanti et al., 2021</xref>). Further, relevant phytochemicals include flavonoids, polyphenols, alkaloids, terpenoids, quinones, saponins and others. These metabolites of TCM may provide promising candidates for improving insulin resistance in the treatment of T2DM, and the effects of the metabolites of TCM on T2DM via the PI3K/AKT signaling pathway are summarized in <xref ref-type="table" rid="T1">Table 1</xref>.</p>
<table-wrap id="T1" position="float">
<label>TABLE 1</label>
<caption>
<p>The effect of metabolites of TCM for hypoglycemic effect in T2DM via the PI3K/AKT signaling pathway.</p>
</caption>
<table>
<thead valign="top">
<tr>
<th align="left">Type</th>
<th align="left">Name</th>
<th align="left">Study design</th>
<th align="left">
<italic>Vivo</italic>/<italic>Vitro</italic>
</th>
<th align="left">Dosage of administration</th>
<th align="left">Targets</th>
<th align="left">Mechanism</th>
<th align="left">References</th>
</tr>
</thead>
<tbody valign="top">
<tr>
<td align="left" rowspan="20">Flavonoids</td>
<td align="left" rowspan="3">Baicalein</td>
<td align="left">Male C57BL/6&#xa0;J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">400&#xa0;mg/kg Baicalein for 3 weeks</td>
<td align="left">p-IRS1&#x2191; p-AKT&#x2191; p-AMPK&#x3b1;&#x2191; p-ACC&#x2191;</td>
<td align="left">Improving dyslipidemia and insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B113">Pu et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; glucose &#x002B; DXMS</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">12.5, 25&#xa0;&#x3bc;M Baicalein for 24&#xa0;h</td>
<td align="left">p-IRS1/2&#x2191; PI3K&#x2191; p-AKT&#x2191; p-GSK3&#x3b2;&#x2191; GLUT4&#x2191;</td>
<td align="left">Promoting glucose consumption and glycogen synthesis</td>
<td align="left">
<xref ref-type="bibr" rid="B94">Miao et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; glucose &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 10&#xa0;&#x3bc;M Baicalein for 24&#xa0;h</td>
<td align="left">p-IRS1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; GLUT2&#x2191; G6Pase&#x2193; PEPCK&#x2193;</td>
<td align="left">Promoting glucose uptake and glycolysis, inhibiting gluconeogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B168">Yang et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Chrysin</td>
<td align="left">Male C57BL/6&#xa0;J mice fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">15, 30&#xa0;mg/kg Chrysin for 5 weeks</td>
<td align="left" rowspan="2">p-AMPKThr172&#x2191; p-IRS1Tyr612&#x2191; p-AKTSer473&#x2191; GSK3&#x3b2;Ser9&#x2191; p-GSSer641&#x2193;</td>
<td align="left" rowspan="2">Modulating glucose and lipid metabolism</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B189">Zhou et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; glucose &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 15&#xa0;&#x3bc;M chrysin for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">Diosmetin</td>
<td align="left">KK-Ay diabetic mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">20, 60&#xa0;mg/kg Diosmetin for 4 weeks</td>
<td align="left">p-IRS1&#x2191; PI3K&#x3b2;&#x2191; PI3K&#x3b1;&#x2191; p-AKT&#x2191; p-GSK3&#x3b2;&#x2193; GS&#x2191; GLUT4&#x2191; p-AS160&#x2191;</td>
<td align="left">Ameliorating glucose metabolism</td>
<td align="left">
<xref ref-type="bibr" rid="B46">Gong et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Tricin</td>
<td align="left">Male C57BL/6 mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">16, 64, 160&#xa0;mg/kg Tricin for 7 days</td>
<td align="left" rowspan="2">p-IRS1&#x2191; p-PI3KTyr199&#x2191; p-AKTThr308&#x2191; p-AS160Thr642&#x2191;</td>
<td align="left" rowspan="2">Increasing glucose uptake</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B66">Kim et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left">C2C12 Myotubes &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">5, 10, 20&#xa0;&#xb5;M Tricin for 24&#xa0;h</td>
</tr>
<tr>
<td align="left" rowspan="6">HM-Chromanone</td>
<td align="left">Male C57BL/KsJ-db/db mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">30&#xa0;mg/kg HM-Chromanone for 6 weeks</td>
<td align="left">p-IRS1Tyr612&#x2191; PI3K&#x2191; p-AKTSer473&#x2191; PM-GLUT4&#x2191;</td>
<td align="left">Reduceing hyperglycemia and ameliorating dyslipidemia</td>
<td align="left">
<xref ref-type="bibr" rid="B171">Yoo et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">L6 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 25, 50&#xa0;&#xb5;M HM-Chromanone for 24&#xa0;h</td>
<td align="left">p-IRS1Tyr612&#x2191; p-IRS1Ser307&#x2193; PI3K&#x2191; p-AKT&#x2191; p-AS160&#x2191; PM-GLUT4&#x2191; p-GSK3&#x3b1;/&#x3b2;&#x2191; p-GS&#x2193;</td>
<td align="left">Stimulating glucose uptake and glycogen synthesis, and improving insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B109">Park et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">L6 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 20&#xa0;&#xb5;M HM-Chromanone for 24&#xa0;h</td>
<td align="left">p-IRS1Tyr612&#x2191; PI3K&#x2191; p-AKT&#x2191; p-AMPK&#x2191; p-AS160&#x2191; p-GSK3&#x3b1;/&#x3b2;&#x2191; p-GS&#x2193; PM-GLUT4&#x2191;</td>
<td align="left">Stimulating glucose uptake and glycogen synthesis</td>
<td align="left">
<xref ref-type="bibr" rid="B110">Park et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B;33&#xa0;mM glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 20, 50&#xa0;&#xb5;M HM-Chromanone for 24&#xa0;h</td>
<td align="left">p-IRS1Tyr612&#x2191; p-IRS1Ser307&#x2193; p-AKT&#x2191; GSK3&#x3b2;Ser9&#x2191; p-GSSer641&#x2193; G6Pase&#x2193; PEPCK&#x2193;</td>
<td align="left">Suppressing glucose production and stimulating glycogen synthesis</td>
<td align="left">
<xref ref-type="bibr" rid="B107">Park and Han, (2022)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">15, 30, 60&#xa0;&#xb5;M HM-Chromanone for 24&#xa0;h</td>
<td align="left">p-IRS1 Tyr612&#x2191; p-IRS1 Ser307&#x2193; PI3K&#x2191; p-AKT&#x2191; p-FoxO1&#x2191; PEPCK&#x2193; G6Pase&#x2193;</td>
<td align="left">Suppressing hepatic glucose production</td>
<td align="left">
<xref ref-type="bibr" rid="B107">Park and Han, (2022)</xref>
</td>
</tr>
<tr>
<td align="left">3T3-L1 adipocytes &#x002B; DXMS &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 20&#xa0;&#xb5;M HM-Chromanone for 24&#xa0;h</td>
<td align="left">p-IRS1&#x2191; PI3K&#x2191; p-AKT&#x2191; p-AMPK&#x2191; p-ACC&#x2191; PM-GLUT4&#x2191;</td>
<td align="left">Enhancing glucose uptake and insulin sensitivity</td>
<td align="left">
<xref ref-type="bibr" rid="B109">Park et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="5">Puerarin</td>
<td align="left">Male Wistar rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">300&#xa0;mg/kg puerarin for 4 weeks</td>
<td align="left" rowspan="2">p-AKT&#x2191; PI3K&#x2191; p-FoxO1&#x2191; G6Pase&#x2193; PEPCK&#x2193;</td>
<td align="left" rowspan="2">Suppressing gluconeogenesis</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B88">Liu et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 100, 1000&#xa0;&#x3bc;M puerarin</td>
</tr>
<tr>
<td align="left">Male C57BL/6 mice &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100&#xa0;mg/kg puerarin for 4 days</td>
<td align="left" rowspan="2">p-AKT&#x2191; BCL2&#x2191;</td>
<td align="left" rowspan="2">Protecting pancreatic b-cell function and survival via direct effects on b-cells</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B79">Li et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">MIN6 cells &#x002B; CoCl2</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.1, 1, 10&#xa0;mM puerarin for 8&#xa0;h</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 10, 100&#xa0;&#x3bc;M puerarin</td>
<td align="left">p-AKT1&#x2191; p-GSK-3&#x3b2;&#x2191;</td>
<td align="left">improving glucose and lipid metabolism disorders</td>
<td align="left">
<xref ref-type="bibr" rid="B88">Liu et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">&#x3b1;-Methyl artoflavanocoumarin (MAFC)</td>
<td align="left">HepG2 cells &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">12.5, 25, 50&#xa0;&#xb5;M MAFC for 24&#xa0;h</td>
<td align="left">PTP1B&#x2193; p-IRS1Ser307&#x2193; p-PI3KTyr508&#x2191; p-AKTSer473&#x2191; p-ERK1Tyr204&#x2191;</td>
<td align="left">Increasing glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B61">Jung et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="15"/>
<td align="left" rowspan="2">Loureirin B</td>
<td align="left">Male C57BL/6&#xa0;J mice fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">45&#xa0;mg/kg Loureirin B for 4 weeks</td>
<td align="left" rowspan="2">IRS1&#x2191; PI3K&#x2191; p-AKT&#x2191; FoxO1&#x2193; PEPCK&#x2193; GLUT4&#x2191;</td>
<td align="left" rowspan="2">Increasing insulin sensitivity, and regulating glucose uptake and production</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B32">Ding et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; glucose &#x002B; DXMS</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.1, 1, 10&#xa0;&#x3bc;M Loureirin B</td>
</tr>
<tr>
<td align="left" rowspan="2">Fisetin</td>
<td align="left">Male C57BL/6 mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">20, 40&#xa0;mg/kg Fisetin for 16 weeks</td>
<td align="left">p-IRS1&#x2191; p-AKT&#x2191; p-GSK3&#x3b2;&#x2191; p-FoxO1&#x2191;</td>
<td align="left">Improving insulin resistance and inflammatory response</td>
<td align="left">
<xref ref-type="bibr" rid="B44">Ge et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">25, 50&#xa0;&#x3bc;M Fisetin for 24&#xa0;h</td>
<td align="left">p-IRS1&#x2191; p-AKT&#x2191;</td>
<td align="left">Improving hepatic insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B75">Li et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="4">Kaempferol</td>
<td align="left">Male C57BL/6&#xa0;J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Kaempferol for 6 weeks</td>
<td align="left">p-AKT&#x2191;</td>
<td align="left">Ameliorating hepatic gluconeogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B4">Alkhalidy et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">Male C57BL/6&#xa0;J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Kaempferol for 5 days</td>
<td align="left" rowspan="2">p-AKT&#x2191; p-AMPK&#x2191;</td>
<td align="left" rowspan="2">Improving glucose uptake</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B98">Moore et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">Primary human SkM cells</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10&#xa0;&#x3bc;M Kaempferol for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">HepG2 cells</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.1, 1, 10&#xa0;&#x3bc;M Kaempferol for 24&#xa0;h</td>
<td align="left">p-AKT&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left">Improving glucose consumption</td>
<td align="left">
<xref ref-type="bibr" rid="B37">Fang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="4">Quercetin</td>
<td align="left">Male Wistar rats &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Quercetin for 2 months</td>
<td align="left">p-IRS1&#x2191; p-PI3K&#x2191; p-AKT1&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving glucose homeostasis in the brain</td>
<td align="left">
<xref ref-type="bibr" rid="B125">Sandeep and Nandhini, (2017)</xref>
</td>
</tr>
<tr>
<td align="left">Male C57BL/6&#xa0;J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Quercetin for 10 weeks</td>
<td align="left" rowspan="2">p-IRS1&#x2191; p-AKT1&#x2191; GLUT4&#x2191; p-FoxO1&#x2191; PEPCK&#x2193; G6Pase&#x2193;</td>
<td align="left" rowspan="2">Suppressing gluconeogenesis</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B82">Liu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10&#xa0;&#x3bc;M Quercetin for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">5, 10&#xa0;&#x3bc;M Quercetin for 24&#xa0;h</td>
<td align="left">p-IRS2&#x2191; PI3Kp85&#x2191; p-AKT1&#x2191; p-FoxO1&#x2191;</td>
<td align="left">Improving hepatic insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B23">Cheng et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">Apigenin</td>
<td align="left">HepG2 cells &#x002B; glucose &#x002B; DXMS</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">6.25, 12.5&#xa0;&#x3bc;M Apigenin for 16&#xa0;h</td>
<td align="left">IRS1/2&#x2191; PI3K&#x2191; p-AKT&#x2191; p-GSK3&#x3b2;&#x2191; GLUT4&#x2191;</td>
<td align="left">Increasing insulin sensitivity and glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B94">Miao et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">Poncirin</td>
<td align="left">C2C12 cells &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">5, 1o &#x3bc;M Poncirin for 16&#xa0;h</td>
<td align="left">p-IRS1&#x2191; p-PI3K&#x2191; p-AKT1&#x2191; p-GSK3&#x3b2;&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving insulin sensitivity and suppressing glycation-induced protein oxidation</td>
<td align="left">
<xref ref-type="bibr" rid="B172">Yousof Ali et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">Naringenin</td>
<td align="left">Male Wistar rats &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Naringenin for 2 months</td>
<td align="left">p-IRS1&#x2191; p-PI3K&#x2191; p-AKT1&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving glucose homeostasis in the brain</td>
<td align="left">
<xref ref-type="bibr" rid="B125">Sandeep and Nandhini, (2017)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="9">Polyphenols</td>
<td align="left" rowspan="9">Resveratrol</td>
<td align="left">Male Wistar rats fed standard rodent diet &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">10&#xa0;mg/kg Resveratrol for 4 weeks</td>
<td align="left">insulin R&#x3b2;&#x2191; IRS-1&#x2191; eNOS&#x2191; PI3K&#x2191; p-AKT&#x2191;</td>
<td align="left">Improving both hepatic inflammation and insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B123">Sadi et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">Male C57BL/6N mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">30&#xa0;mg/kg Resveratrol for 2 weeks</td>
<td align="left">p-IRS-1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; p-PDK1&#x2191; p-GSK-3&#x2191;</td>
<td align="left">Restored the phosphorylation levels of proteins involved in the insulin signaling pathway</td>
<td align="left">
<xref ref-type="bibr" rid="B51">Hong et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">Male Wistar rats &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">0.05, 0.1, 0.5, 3.0, 6.0, 10.0&#xa0;mg/kg Resveratrol for 7 days</td>
<td align="left">p-AKTSer473&#x2191; GLUT4&#x2191; PEPCK&#x2193;</td>
<td align="left">Increasing insulin secretion and enhancing glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B24">Chi et al. (2007)</xref>
</td>
</tr>
<tr>
<td align="left">Male KKAy mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">2, 4&#xa0;g/kg Resveratrol for 12 weeks</td>
<td align="left">p-AMPK&#x3b1;&#x2191; p-IRS1&#x2191; p-AKT&#x2191; Sirt1&#x2191;</td>
<td align="left">Improving the insulin sensitivity</td>
<td align="left">
<xref ref-type="bibr" rid="B22">Chen et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left">Male Sprague-Dawley rats fed HCF</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">1&#xa0;mg/kg Resveratrol for 15 days</td>
<td align="left">p-InsR&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Enhancing muscular glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B29">Deng et al. (2008)</xref>
</td>
</tr>
<tr>
<td align="left">Male C57BL/6J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100&#xa0;mg/kg Resveratrol for 6 weeks</td>
<td align="left">p-PI3K&#x2191; p-AKT&#x2191; FoxO1&#x2193; G6Pase&#x2193;</td>
<td align="left">Reducing the Glucose Concentration and inhibiting glycoisogen</td>
<td align="left">
<xref ref-type="bibr" rid="B133">Shu et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">25&#xa0;&#x3bc;M Resveratrol for 24&#xa0;h</td>
<td align="left"/>
<td align="left"/>
<td align="left"/>
</tr>
<tr>
<td align="left">Male ob/ob mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">10&#xa0;mg/kg Resveratrol for 10 weeks</td>
<td align="left" rowspan="2">PI3K&#x2191; p-AKT&#x2191; p-FoxO1&#x2191; PEPCK&#x2193; G6Pase&#x2193; Sirt1&#x2191; PGC-1&#x3b1;&#x2191;</td>
<td align="left" rowspan="2">Enhancing glucose production and restraining dapagliflozin-induced renal gluconeogenesis</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B141">Sun et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HK-2 cells</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10&#xa0;&#x3bc;M Resveratrol for 12&#xa0;h</td>
</tr>
<tr>
<td align="left" rowspan="9"/>
<td align="left" rowspan="2">Pterostilbene</td>
<td align="left">Male Sprague-Dawley rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">20, 40, 80&#xa0;mg/kg Pterostilbene for 8 weeks</td>
<td align="left">PPAR&#x3b3;&#x2191; PI3K&#x2191; p-AKT&#x2191; GLUT4&#x2191; IRS-1&#x2191;</td>
<td align="left">Controling serum glucose, improving insulin lipid profile and insulin sensitivity</td>
<td align="left">
<xref ref-type="bibr" rid="B137">Sun et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">5, 10&#xa0;&#x3bc;M Pterostilbene for 24&#xa0;h</td>
<td align="left">p-IRS-1ser307&#x2191; p-AKTser473&#x2191; p-GSK3&#x3b2;ser9&#x2191; p-FoxO1&#x2191; PEPCK&#x2193; G6Pase&#x2193;</td>
<td align="left">Reducing lipid accumulation and alleviating inflammatory response</td>
<td align="left">
<xref ref-type="bibr" rid="B91">Malik et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="4">Curcumin</td>
<td align="left">Male C57BL/6J mice fed HFS</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">4&#xa0;g/kg curcumim for 16 weeks</td>
<td align="left">PI3Kp110/p85&#x2191; p-AKT&#x2191;</td>
<td align="left">Improving insulin clearance, mediating the insulin pathway signaling</td>
<td align="left">
<xref ref-type="bibr" rid="B67">Kim et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">Male Sprague-Dawley rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100, 300&#xa0;mg/kg curcumim for 8 weeks</td>
<td align="left">p-PI3K&#x2191; p-AKT&#x2191;</td>
<td align="left">Improving liver function and ameliorating the tissue structure of the liver and pancreas</td>
<td align="left">
<xref ref-type="bibr" rid="B152">Xia et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B;50&#xa0;mM D-glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10&#xa0;&#x3bc;M curcumim for 24&#xa0;h</td>
<td align="left">p-AKT&#x2191; p-PI3K&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left">Improving insulin sensitivity, enhancing glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B73">Li et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">MIN6 &#x3b2;-cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10&#xa0;&#x3bc;M curcumim for 1&#xa0;h</td>
<td align="left">p-AKT&#x2191; p-FoxO1&#x2191;</td>
<td align="left">Improving glucose-induced insulin secretory function</td>
<td align="left">
<xref ref-type="bibr" rid="B49">Hao et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="3">Gallic acid</td>
<td align="left">Male Sprague-Dawley rats fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">10, 30&#xa0;mg/kg Gallic acid for 4 weeks</td>
<td align="left">IRS-1&#x2191; PI3K&#x2191; AKT&#x2191; GLUT-2&#x2191;</td>
<td align="left">Improving glucose uptake and decreasing hyperglycemia</td>
<td align="left">
<xref ref-type="bibr" rid="B53">Huang et al. (2016)</xref>
</td>
</tr>
<tr>
<td align="left">Male Wistar rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">20&#xa0;mg/kg Gallic acid for 10 days</td>
<td align="left">PPAR&#x3b3;&#x2191; PI3K&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Enhancing insulin dependent glucose uptake and improving hyperlipemia</td>
<td align="left">
<xref ref-type="bibr" rid="B42">Gandhi et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; FFA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">50&#xa0;&#x3bc;M Gallic acid for 24&#xa0;h</td>
<td align="left">p-IRS-1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; p-FoxO1&#x2191;</td>
<td align="left">Increasing glucose consumption</td>
<td align="left">
<xref ref-type="bibr" rid="B71">Lee and Lee, (2021)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="7">Alkaloids</td>
<td align="left">Tetramethylpyrazine</td>
<td align="left">Male Wistar rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100, 150, 200&#xa0;mg/kg TMP for 28 days</td>
<td align="left">p-PI3Kp85&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Reducing insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B117">Rai et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="3">Hirsutine</td>
<td align="left">Male C57BL/6J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">5, 10, 20&#xa0;mg/kg Hirsutine for 8 weeks</td>
<td align="left" rowspan="3">p-AKT&#x2191; p-PDK1&#x2191; p-GSK3&#x3b2;&#x2191; p-AMPK&#x2191; G6Pase&#x2193; PEPCK&#x2193; PGC-1&#x3b1;&#x2193; FoxO1&#x2193;</td>
<td align="left" rowspan="3">Enhancing glucose consumption, glycogen synthesis, and suppressing gluconeogenesis</td>
<td align="left" rowspan="3">
<xref ref-type="bibr" rid="B52">Hu et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; D-glucose &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left" rowspan="2">0.01, 0.1, 1&#xa0;&#x3bc;M Hirsutine for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">H9c2 cells &#x002B; D-glucose &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
</tr>
<tr>
<td align="left" rowspan="3">1-Deoxynojirimycin</td>
<td align="left">Male ob/ob mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">40, 80&#xa0;mg/kg 1-Deoxynojirimycin for 4 weeks</td>
<td align="left">p-PI3Kp85&#x2191; p-AKTser473&#x2191; p-IRS1tyr612&#x2191; p-IR&#x3b2;tyr1361&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving insulin sensitivity and enhancing glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B85">Liu et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">Male ob/ob mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">40&#xa0;mg/kg 1-Deoxynojirimycin for 35 days</td>
<td align="left">PPAR&#x3b3;&#x2191; PGC-1&#x3b1;&#x2191; GLUT4&#x2191; IRS-1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; p-GSK3&#x3b2;&#x2191; p-GS&#x2191;</td>
<td align="left">Enhancing glucose consumption, glycogen synthesis, and suppressing gluconeogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B63">Kang et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">3T3-L1 adipocytes &#x002B; DXMS &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.1, 0.5, 1, 5, 10&#xa0;&#x3bc;M 1-Deoxynojirimycin for 24&#xa0;h</td>
<td align="left">IR&#x2191; IRS-1&#x2191; PI3K&#x2191; AKT&#x2191; AMPK&#x2191; GLUT4&#x2191;</td>
<td align="left">Enhancing glucose uptake</td>
<td align="left">
<xref ref-type="bibr" rid="B74">Li et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="5">Terpenoids</td>
<td align="left" rowspan="2">Mogroside V</td>
<td align="left">Male Wistar rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">30, 75, 150&#xa0;mg/kg Mogroside V for 5 weeks</td>
<td align="left" rowspan="2">IRS-1&#x2191; PI3KP110/P85&#x2191; p-AKT&#x2191; GLUT2&#x2191; GS&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left" rowspan="2">Improving insulin sensitivity, glucose homeostasis and liver damage</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B87">Liu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 5, 10&#xa0;&#x3bc;M Mogroside V for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">Siamenoside I</td>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 5, 10&#xa0;&#x3bc;M Siamenoside I for 24&#xa0;h</td>
<td align="left">IRS-1&#x2191; PI3KP110/P85&#x2191; p-AKT&#x2191; GLUT2&#x2191; GS&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left">Improving insulin sensitivity, glucose homeostasis and liver damage</td>
<td align="left">
<xref ref-type="bibr" rid="B87">Liu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">Mogroside III</td>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 5, 10&#xa0;&#x3bc;M MogrosideIII for 24&#xa0;h</td>
<td align="left">IRS-1&#x2191; PI3KP110/P85&#x2191; p-AKT&#x2191; GLUT2&#x2191; GS&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left">Improving insulin sensitivity, glucose homeostasis and liver damage</td>
<td align="left">
<xref ref-type="bibr" rid="B87">Liu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">Mogroside IV</td>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 5, 10&#xa0;&#x3bc;M Mogroside IV for 24&#xa0;h</td>
<td align="left">IRS-1&#x2191; PI3KP110/P85&#x2191; p-AKT&#x2191; GLUT2&#x2191; GS&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left">Improving insulin sensitivity, glucose homeostasis and liver damage</td>
<td align="left">
<xref ref-type="bibr" rid="B87">Liu et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="14"/>
<td align="left" rowspan="5">Catalpol</td>
<td align="left">Male C57BL/6N mice fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100, 200&#xa0;mg/kg Catalpol for 4 weeks</td>
<td align="left">IRS-1&#x2191; PI3KR1&#x2191; AKT2&#x2191; AMPK&#x2191; p-AMPK&#x2191; GLUT4&#x2191; PGC-1&#x3b1;&#x2191; SIRT1&#x2191; PPAR-&#x3b3;&#x2191;</td>
<td align="left">Improving insulin sensitivity and mitochondrial respiration</td>
<td align="left">
<xref ref-type="bibr" rid="B169">Yap et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">Male db/db mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">200&#xa0;mg/kg Catalpol for 8 weeks</td>
<td align="left" rowspan="2">p-IRS1Ser307&#x2191; PI3K&#x2191; p-AKTSer473&#x2191; GLUT4&#x2191;</td>
<td align="left" rowspan="2">Improving insulin sensitivity, and enhancing myogenesis ans glucose uptake</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B158">Xu et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">C2C12 cells &#x002B;50&#xa0;mM D-glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 30, 100&#xa0;&#x3bc;M Catalpol for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">C57BL/6J mice fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100, 200&#xa0;mg/kg Catalpol for 4 weeks</td>
<td align="left" rowspan="2">p-IRS1Ser307&#x2191; p-AKTSer473&#x2191; p-GSK3ser9&#x3b2;&#x2191; G6Pase&#x2193; PEPCK&#x2193; p-GSser641&#x2193; p-FoxO1ser256&#x2191;</td>
<td align="left" rowspan="2">Ameliorating hepatic insulin resistance</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B161">Yan et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B;18&#xa0;mM glucosamine</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">20, 40, 80&#xa0;&#x3bc;M Catalpol for 24&#xa0;h</td>
</tr>
<tr>
<td align="left" rowspan="3">Oleanolic Acid</td>
<td align="left">Male db/db mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">250&#xa0;mg/kg Oleanolic Acid for 28 days</td>
<td align="left">p-AKT&#x2191; p-PI3K&#x2191; p-AMPK&#x2191; p-ACC&#x2191; G6pase&#x2193; PEPCK1&#x2193; GLUT2&#x2193;</td>
<td align="left">Reducing gluconeogenesis, glycogenolysis and hepatic glucose production</td>
<td align="left">
<xref ref-type="bibr" rid="B150">Wang et al. (2015)</xref>
</td>
</tr>
<tr>
<td align="left">Male Wistar rats fed fructose</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">5, 25&#xa0;mg/kg Oleanolic Acid for 10 weeks</td>
<td align="left">p-IRS-1&#x2191; PI3K&#x2191; p-AKT&#x2191;</td>
<td align="left">Attenuating adipose tissue insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B78">Li et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">C57BL/6J mice fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">100&#xa0;mg/kg Oleanolic Acid for 2 weeks</td>
<td align="left">p-AKTSer473&#x2191; p-FoxO1ser256&#x2191; G6Pase&#x2193; PEPCK&#x2193;</td>
<td align="left">Improving glucose homeostasis and reducing gluconeogenesis</td>
<td align="left">
<xref ref-type="bibr" rid="B175">Zeng et al. (2012)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Asiatic Acid</td>
<td align="left">Male Wistar rats &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">20&#xa0;mg/kg Asiatic Acid for 45 days</td>
<td align="left">IR&#x2191; IRS-1/2&#x2191; PI3K&#x2191; AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Increasing insulin secretion and glucose uptake into skeletal muscle</td>
<td align="left">
<xref ref-type="bibr" rid="B120">Ramachandran and Saravanan, (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Male db/db mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Asiatic Acid for 4 weeks</td>
<td align="left">IRS-1&#x2191; PI3K&#x2191; AKT1&#x2191; GSK-3&#x3b2;&#x2193; G6pase&#x2193;</td>
<td align="left">Improving glycogen synthesis</td>
<td align="left">
<xref ref-type="bibr" rid="B139">Sun et al. (2017)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Glycyrrhetinic acid</td>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">20, 35, 50&#xa0;&#x3bc;M Glycyrrhetinic acid for 24&#xa0;h</td>
<td align="left">PI3K&#x2191; p-AKT&#x2191; GSK3&#x3b2;&#x2191;</td>
<td align="left">Regulating the insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B149">Wang et al. (2023)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; insulin/FFA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">5, 10&#xa0;&#x3bc;M Glycyrrhetinic acid for 24&#xa0;h</td>
<td align="left">p-IRS1&#x2193; p-AKT&#x2191; p-GSK3&#x3b2;&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving glucose uptake and reversing insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B178">Zhang et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Maslinic acid</td>
<td align="left">Preadipocytes</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.5, 1&#xa0;&#x3bc;M Maslinic acid for 24&#xa0;h</td>
<td align="left">PI3K&#x2191; AKT&#x2191;</td>
<td align="left">Inhibiting adipocyte differentiation and lipid accumulation</td>
<td align="left">
<xref ref-type="bibr" rid="B127">Savova et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.1, 1, 10&#xa0;&#x3bc;M Maslinic acid for 24&#xa0;h</td>
<td align="left">p-AKT&#x2191; GSK3&#x3b2;&#x2191;</td>
<td align="left">Modulating glycogen metabolism</td>
<td align="left">
<xref ref-type="bibr" rid="B83">Liu et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="4">Quinones</td>
<td align="left" rowspan="2">Aloin</td>
<td align="left">Male mice fed HFSD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">90&#xa0;mg/kg Aloin for 4 weeks</td>
<td align="left" rowspan="2">IRS1&#x2191; PI3K&#x2191; AKT&#x2191; JNK&#x2191;</td>
<td align="left" rowspan="2">Enhancing glucose tolerance and glucose consumption</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B188">Zhong et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; DEX</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1, 10, 50, 100, 200&#xa0;&#x3bc;M Aloin for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">Embelin</td>
<td align="left">Male Wistar rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Embelin for 30 days</td>
<td align="left">PPAR&#x3b3;&#x2191; PI3K&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving insulin sensitivity, protecting &#x3b2;-cell from damage and maintaining glucose homeostasis</td>
<td align="left">
<xref ref-type="bibr" rid="B43">Gandhi et al. (2013)</xref>
</td>
</tr>
<tr>
<td align="left">Emodin</td>
<td align="left">KK-Ay diabetic mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">12.5, 50&#xa0;mg/kg Emodin for 8 weeks</td>
<td align="left">p-IRS1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; GLUT2&#x2191; GLUT4&#x2191; PPAR&#x3b3;&#x2191;</td>
<td align="left">Enhancing insulin sensitivity and resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B160">Xuezheng et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="4">Saponins</td>
<td align="left">Astragaloside IV</td>
<td align="left">3T3-L1 adipocytes &#x002B; PA &#x002B; glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 50, 100, 200&#xa0;&#x3bc;M Astragaloside IV for 24&#xa0;h</td>
<td align="left">PI3K&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving insulin resistance and inflammation in adipocytes</td>
<td align="left">
<xref ref-type="bibr" rid="B181">Zhang et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Ginsenoside Rb2</td>
<td align="left">DIO mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">50&#xa0;mg/kg Ginsenoside Rb2 for 10 days</td>
<td align="left" rowspan="2">IR&#x3b2;&#x2191; IRS1&#x2191; PI3Kp85&#x2191; p-AKTser473&#x2191;</td>
<td align="left" rowspan="2">Improving insulin sensitivity and reducing fat mass</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B27">Dai et al. (2018)</xref>
</td>
</tr>
<tr>
<td align="left">3T3-L1 adipocytes &#x002B; DXMS &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">25&#xa0;&#x3bc;M Ginsenoside Rb2 for 30&#xa0;min</td>
</tr>
<tr>
<td align="left">Ginsenoside Rg5</td>
<td align="left">Male db/db mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">90&#xa0;mg/kg Ginsenoside Rg5 for 8 weeks</td>
<td align="left">p-IRS1tyr&#x2191; p-IRS1ser&#x2193; p-PI3K&#x2191; p-AKT&#x2191; GSK-3&#x3b2;&#x2191; GS&#x2193;</td>
<td align="left">Promoting glycogen synthesis, improving glycolipid metabolism and insulin secretion</td>
<td align="left">
<xref ref-type="bibr" rid="B151">Wei et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="14">Others</td>
<td align="left" rowspan="3">Beta-sitosterol</td>
<td align="left">Adult Male Albino rats fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">20&#xa0;mg/kg Beta-sitosterol for 30 days</td>
<td align="left">IR&#x2191; p-IRS1tyr632&#x2191; p-IRS1ser632&#x2193; p-AKTser473&#x2191; p-AKT thr308&#x2191; GLUT4&#x2191;</td>
<td align="left">Improving insulin resistance</td>
<td align="left">
<xref ref-type="bibr" rid="B6">Babu et al. (2020)</xref>
</td>
</tr>
<tr>
<td align="left">L6 cells &#x002B; glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">1&#xa0;&#x3bc;g/mL, 100&#xa0;ng/mL Beta-sitosterol for 6, 8, 12&#xa0;h</td>
<td align="left">p-IRS-1&#x2191; PI3Kp85&#x2191; p-AKT&#x2191; PKC&#x2191; GLUT4&#x2191;</td>
<td align="left">Stimulating glucose transport</td>
<td align="left">
<xref ref-type="bibr" rid="B136">Sujatha et al. (2010)</xref>
</td>
</tr>
<tr>
<td align="left">Preadipocytes &#x002B; DXMS &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">0.1, 1, 10, 100, 1,000, 10,000&#xa0;&#x3bc;M Beta-sitosterol for 24&#xa0;h</td>
<td align="left">PI3K&#x2191; AKT&#x2191; GLUT4&#x2191;</td>
<td align="left">Regulating glucose uptake, adipogenesis, and lipolysis in adipocytes</td>
<td align="left">
<xref ref-type="bibr" rid="B18">Chai et al. (2011)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">Taurine</td>
<td align="left">Male SD rats fed HFD &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">400, 600&#xa0;mg/mL Taurine for 7 weeks</td>
<td align="left" rowspan="2">PI3K&#x2191; AKT&#x2191; GLUT4&#x2191;</td>
<td align="left" rowspan="2">Stimulating glucose consumption and ameliorating oxidative stress</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B20">Chen et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 100, 500&#xa0;&#x3bc;g/mL Taurine for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">1,7-Diphenyl-4E-en-3-heptanone (DPH5)</td>
<td align="left">HepG2 cells &#x002B; glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 20, 40&#xa0;&#x3bc;M DPH5 for 24&#xa0;h</td>
<td align="left">p-PI3Kp85&#x2191; p-AKT&#x2191; GLUT4&#x2191; p-GSK3&#x3b2;&#x2191; GCK&#x2191; PK&#x2191; PEPCK&#x2193; G6Pase&#x2193;</td>
<td align="left">Promoting glucose uptake and glucose consumption, regulating glucose metabolism and enhancing insulin sensitivity</td>
<td align="left">
<xref ref-type="bibr" rid="B181">Zhang et al. (2022)</xref>
</td>
</tr>
<tr>
<td align="left" rowspan="2">(R)-5-hydroxy-1,7-diphenyl-3-heptanone (DPHC)</td>
<td align="left">Male C57BL/KsJ db/db mice</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">80, 140&#xa0;mg/mL DPHC for 8 weeks</td>
<td align="left" rowspan="2">IRS1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left" rowspan="2">Regulating blood glucose level and glucose tolerance, improving glucose metabolism</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B177">Zhang et al. (2021)</xref>
</td>
</tr>
<tr>
<td align="left">HepG2 cells &#x002B; glucose</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">10, 20, 40&#xa0;&#x3bc;M DPHC for 24&#xa0;h</td>
</tr>
<tr>
<td align="left" rowspan="6">Esculin</td>
<td align="left">Male C57BL/6J mice fed HFD</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">40, 80&#xa0;mg/kg Esculin for 4 weeks</td>
<td align="left" rowspan="2">IRS1&#x2191; p-PI3K&#x2191; p-AKT&#x2191; GLUT4&#x2191;</td>
<td align="left" rowspan="2">Improving adipose tissue remodeling and increasing glucose uptake</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B167">Yang et al. (2024)</xref>
</td>
</tr>
<tr>
<td align="left">3T3-L1 adipocytes &#x002B; PA</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">50, 100&#xa0;&#x3bc;M Esculin for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">Male ICR mice &#x002B; DXMS</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">40&#xa0;mg/kg Esculin for 21 days</td>
<td align="left" rowspan="2">p-AKT&#x2191; p-AMPK&#x2191; GLUT4&#x2191;</td>
<td align="left" rowspan="2">Promoting glucose uptake and improving insulin resistance</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B96">Mo et al. (2019)</xref>
</td>
</tr>
<tr>
<td align="left">C2C12 Myotubes &#x002B; DXMS</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">25, 50, 100&#xa0;&#x3bc;M Esculin for 24&#xa0;h</td>
</tr>
<tr>
<td align="left">Male ICR mice &#x002B; STZ</td>
<td align="left">
<italic>in vivo</italic>
</td>
<td align="left">200&#xa0;mg/kg Esculin for 14 days</td>
<td align="left" rowspan="2">IR&#x2191; p-AKT&#x2191; p-GSK3&#x3b2;&#x2191;</td>
<td align="left" rowspan="2">Increasing glucose uptake and improving insulin sensitivity</td>
<td align="left" rowspan="2">
<xref ref-type="bibr" rid="B64">Kang et al. (2014)</xref>
</td>
</tr>
<tr>
<td align="left">C2C12 Myotubes &#x002B; insulin</td>
<td align="left">
<italic>in vitro</italic>
</td>
<td align="left">50&#xa0;&#x3bc;M Esculin for 24&#xa0;h</td>
</tr>
</tbody>
</table>
</table-wrap>
<sec id="s4-1">
<title>4.1 Flavonoids</title>
<p>Being commonly found in Chinese herbal medicine, flavonoids are a group of ubiquitous compounds of in nature that have proven to have medicinal value (<xref ref-type="bibr" rid="B135">Sok Yen et al., 2021</xref>). Due to their wide range of beneficial activities, such as antioxidant, anti-inflammatory, anti-viral, anti-atherosclerotic, anti-diabetic and anti-tumor, flavonoids have great potential in clinical application and clinical development (<xref ref-type="bibr" rid="B190">Zhou et al., 2023</xref>). In recent years, flavonoids extracted from dietary sources and medicinal plants have been widely used in treating and preventing various diseases, and the hypoglycemic potential activities of flavonoids are being explored (<xref ref-type="bibr" rid="B3">Ahad et al., 2014</xref>). Moreover, various <italic>in vitro</italic> and <italic>in vivo</italic> experiments have demonstrated the efficacy of flavonoids in improving insulin resistance and preventing T2DM (<xref ref-type="bibr" rid="B190">Zhou et al., 2023</xref>), such as baicalein, chrysin, diosmetin, tricin, HM-chromanone, puerarin, &#x3b1;-Methyl artoflavanocoumarin, loureirin B, fisetin, kaempferol, quercetin, apigenin, poncirin and naringenin. The chemical structures of fourteen flavonoids are shown in <xref ref-type="fig" rid="F2">Figure 2</xref>.</p>
<fig id="F2" position="float">
<label>FIGURE 2</label>
<caption>
<p>The chemical structures of fourteen flavonoids.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g002.tif"/>
</fig>
<sec id="s4-1-1">
<title>4.1.1 Baicalein</title>
<p>Baicalein (5, 6, 7-trihydroxyflavone), one of the representative active metabolites of the medicinal plant <italic>Scutellaria baicalensis Georgi</italic> (known as hu&#xe1;ng q&#xed;n), is a naturally occurring hypoglycemic agent that can directly promote insulin secretion and preserve pancreatic islet mass (<xref ref-type="bibr" rid="B41">Fu et al., 2014</xref>). Besides, orally given baicalein (400&#xa0;mg/kg/day) to C57BL/6 mice induced by a high-fat diet, the disorders of dyslipidemia, fatty liver, diabetes and insulin resistance in mice were effectively normalized after oral medication and all of these improvements were mediated by inhibition of the MAPKs pathway and activation of the IRS1/PI3K/AKT pathway involving multiple intracellular signaling pathways (<xref ref-type="bibr" rid="B113">Pu et al., 2012</xref>). Meanwhile, baicalein can also promote glucose consumption and glycogen synthesis and inhibit gluconeogenesis to improve glucose metabolism and the mechanism of the anti-diabetic effect in IR-induced HepG2 cells related to activation of IRS1/PI3K/AKT signaling pathways and the expression of proteins downstream of the pathway (<xref ref-type="bibr" rid="B168">Yang et al., 2019</xref>; <xref ref-type="bibr" rid="B94">Miao et al., 2023</xref>). The above results show that baicalein might have a promising potential in preventing and treating diabetes and need more exploration in clinical application.</p>
</sec>
<sec id="s4-1-2">
<title>4.1.2 Chrysin</title>
<p>Chrysin (5, 7-di-OH-flavone), a flavone, is a promising phytochemical discovered in a variety of TCM which has been reported emphasizing benefits in numerous metabolic malfunctions such as anti-diabetic effects, anti-cancer and anti-inflammatory role (<xref ref-type="bibr" rid="B124">Samarghandian et al., 2017</xref>; <xref ref-type="bibr" rid="B100">Naz et al., 2019</xref>). Depending on its adjuvant therapy effects for glucose and lipid metabolism disorders such as IR, oxidative stress, inflammation, and liver injury in both IR-HepG2 cells and HFD/STZ-induced C57BL/6J mice, they found that Chrysin intervention could modify glycogen synthesis and fatty acid oxidation and suppress gluconeogenesis and fatty acid synthesis by regulating the AMPK/PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="B191">Zhou et al., 2021</xref>).</p>
</sec>
<sec id="s4-1-3">
<title>4.1.3 Diosmetin</title>
<p>Diosmetin (3&#x2032;, 5, 7-trihydroxy-4&#x2032;-methoxyflavone), a naturally occurring flavonoid, has a superior diabetic alleviating effect due to its targeting of &#x3b1;-glucosidase and the PTP-1B signaling pathways (<xref ref-type="bibr" rid="B21">Chen et al., 2019</xref>). The treatment of mice with low and high doses of diosmetin remarkably ameliorated glucose metabolism in KK-Ay diabetic mice and regulated the expression of glucose metabolism and insulin resistance related signaling proteins in the liver and skeletal muscle. Hence, they suggested that it ameliorated glucose metabolism and insulin resistance via up-regulating IRS/PI3K/AKT signaling pathway to promote glycogen synthesis and GLUT4 translocation (<xref ref-type="bibr" rid="B46">Gong et al., 2021</xref>).</p>
</sec>
<sec id="s4-1-4">
<title>4.1.4 Tricin</title>
<p>As a cereal flavone, Tricin (5, 7, 4&#x2032;-trihydroxy-3&#x2032;, 5&#x2032;-dimethoxyflavone) is widely distributed in the husks of various cereal crops and multiple TCM. tricin possesses an anti-adipogeneic effect, which was reported and suggested for the first time that tricin exhibits a significant inhibitory activity toward adipogenesis and lipogenesis by blocking the AKT/mTOR/S6K signaling pathway (<xref ref-type="bibr" rid="B70">Lee et al., 2015</xref>; <xref ref-type="bibr" rid="B69">Lee et al., 2016</xref>). However, in a dissimilar way, tricin could enhance GLUT4 translocation and glucose uptake by activating the insulin-dependent PI3K/AKT/AS160 signaling pathway in C2C12 myotubes and the oral administration of Tricin significantly lowered blood glucose levels in glucose-loaded C57BL/6 mice (<xref ref-type="bibr" rid="B66">Kim et al., 2017</xref>). These findings indicate that tricin has promising prospects to act as a functional agent for glycemic control.</p>
</sec>
<sec id="s4-1-5">
<title>4.1.5 HM-chromanone</title>
<p>(E)-5-hydroxy-7-methoxy-3-(2&#x2032;-hydroxybenzyl)-4-chromanone (HM-chromanone), a sapanin homoisoflavonoid that derived from <italic>Portulaca oleracea</italic> L., has an extensively potential in promoting insulin secretion and anti-diabetes effect of a substance isolated from TCM. <italic>In vivo</italic>, HM-chromanone can reduce hyperglycemia and ameliorate dyslipidemia in C57BL/Ksj-db/db mice, the effect of 30&#xa0;mg/kg HM-chromanone for 6&#xa0;weeks on levels of HbA1c, plasma insulin, HOMA-IR and serum lipid significantly normalized. Furthermore, the ability of HM-chromanone supplementation to promote the activation of insulin signaling pathways and lead to glucose uptake into skeletal muscle cells was also clarified (<xref ref-type="bibr" rid="B171">Yoo et al., 2023</xref>). <italic>In vitro</italic>, HM-Chromanone was found to improve glucose uptake, glycogen synthesis and other cellular functions related to glucose metabolism in L6 skeletal muscle cells, 3T3-L1 adipocytes and HepG2 cells by activating the PI3K/AKT signaling pathway or acting in conjunction with the AMPK signaling pathway (<xref ref-type="bibr" rid="B109">Park et al., 2019</xref>; <xref ref-type="bibr" rid="B110">Park et al., 2021</xref>; <xref ref-type="bibr" rid="B107">Park and Han, 2022</xref>; <xref ref-type="bibr" rid="B108">Park and Han, 2022</xref>). Therefore, it shows a more positive effect in all three primary target insulin groups to improve insulin resistance and its potential to prevent and treat diabetes.</p>
</sec>
<sec id="s4-1-6">
<title>4.1.6 Puerarin</title>
<p>Puerarin, the major isoflavone glycoside isolated from the traditional Chinese medicine <italic>Radix puerariae</italic>, is widely used to treat diabetes and its complications. Mediated by the PI3K/AKT pathway, it is potent and directly protects &#x3b2;-cell survival and insulin secretion (<xref ref-type="bibr" rid="B79">Li et al., 2014</xref>). Moreover, the effect of 100&#xa0;mg/kg puerarin for 4&#xa0;days on C57BL/6 male mice with pancreatic &#x3b2;-cell toxic STZ significantly lowered blood glucose, reduced the incidence of diabetes, and directly protected the function and survival of pancreatic &#x3b2;-cell. Activating the PI3K/AKT pathway, considerably upregulated the p-AKT and Bcl-2 expression, and AKT phosphorylation was blocked when the LY 294002 inhibitor was involved. The mechanism of its action against lipid and glucose metabolism dysfunction was investigated after treatment with 300&#xa0;mg/kg puerarin for 4&#xa0;weeks in T2DM rats, fasting insulin, glycated hemoglobin, glucose tolerance and lipid profile were significantly normalized recovery and the expression level of PI3K, p-AKT, and p-FoxO1 was increased while PEPCK and G6Pase decreased (<xref ref-type="bibr" rid="B88">Liu et al., 2021</xref>). Further, its effect of suppressing gluconeogenesis and promoting glucose consumption by stimulating the PI3K/AKT pathway is also clarified in insulin resistance HepG2 cells (<xref ref-type="bibr" rid="B132">Shen et al., 2019</xref>; <xref ref-type="bibr" rid="B88">Liu et al., 2021</xref>).</p>
</sec>
<sec id="s4-1-7">
<title>4.1.7 &#x3b1;-Methyl artoflavanocoumarin</title>
<p>&#x3b1;-Methyl artoflavanocoumarin (MAFC), a flavanocoumarin, is extracted from the heart part of <italic>Juniperus chinensis</italic> L. (Cupressaceae) (<xref ref-type="bibr" rid="B105">Orhan et al., 2011</xref>). As a novel PTP1B inhibitor, it inhibits PTP1B activity and upregulates the expression of PTP1B. Additionally, it also found that MAFC could significantly increase glucose uptake and dose-dependently enhance the protein levels of IRS-1, phosphorylated PI3K, and AKT, thus activating the IRS-1/PI3K/AKT signaling pathway in IR-HepG2 cells (<xref ref-type="bibr" rid="B61">Jung et al., 2017</xref>).</p>
</sec>
<sec id="s4-1-8">
<title>4.1.8 Loureirin B</title>
<p>Loureirin B, a dihydrochalcone analog, extracted from Sanguis Draconis, which promotes insulin secretion and hypoglycemia (<xref ref-type="bibr" rid="B38">Fang et al., 2022</xref>). According to the research on loureirin B, 4&#xa0;weeks of treatment with 45&#xa0;mg/kg loureirin B in the HFD/STZ-induced T2DM mice model restored normalization of the liver index, insulin sensitivity, serum lipid content and liver glycogen content, and loureirin B at a concentration of 10&#x2013;5 to 10&#x2013;7&#xa0;mol/L in IR-HepG2 cells affected the IRS1/PI3K/AKT/FoxO1 signaling pathway and regulated the expression of several essential genes and proteins in the pathway, thereby increasing glucose uptake and consumption, accelerating the conversion of glucose to glycogen, inhibiting hepatic gluconeogenesis, enhancing hepatic glycogen content and reducing insulin resistance (<xref ref-type="bibr" rid="B32">Ding et al., 2021</xref>).</p>
</sec>
<sec id="s4-1-9">
<title>4.1.9 Fisetin</title>
<p>Fisetin, a flavonoid, is widely presented in natural plants. As an &#x3b1;-glucosidase inhibitor, it was identified to be a promising candidate for the treatment of T2DM (<xref ref-type="bibr" rid="B131">Shen et al., 2021</xref>). Fisetin supplementation could ameliorate hyperlipidemia and insulin resistance through regulating the IRS1<sup>Tyr608</sup>/AKT/GSK3&#x3b2;/FoxO1 signaling pathway, the expression of phosphorylated IRS1<sup>Tyr608</sup>, AKT, FoxO1 and GSK3&#x3b2; was markedly decreased by the intervention of fisetin in the kidneys of HFD-fed mice (<xref ref-type="bibr" rid="B44">Ge et al., 2019</xref>). Further, <italic>in vitro</italic> experiments have shown that fisetin increased the EGFR expression through IRS activating PI3K/AKT signaling pathway to alleviate hepatic IR (<xref ref-type="bibr" rid="B75">Li et al., 2023</xref>).</p>
</sec>
<sec id="s4-1-10">
<title>4.1.10 Kaempferol</title>
<p>Kaempferol is a important dietary flavonoid that has been identified in many TCM (<xref ref-type="bibr" rid="B39">Fang et al., 2019</xref>). Kaempferol exhibits anti-diabetic effect in regulating hepatic gluconeogenesis and ameliorating fasting hyperglycemia and glucose intolerance through increasing AKT phosphorylation, oral administration of kaempferol improved insulin sensitivity and insulin resistance in HFD-fed mice (<xref ref-type="bibr" rid="B4">Alkhalidy et al., 2018</xref>). Moreover, kaempferol increased AKT phosphorylation in human SkM cells and in muscle of obese mice to stimulate glucose uptake and insulin resistance (<xref ref-type="bibr" rid="B98">Moore et al., 2023</xref>). Furthermore, kaempferol metabolites induce AKT and GSK3&#x3b2; phosphorylation and improve glucose metabolism (<xref ref-type="bibr" rid="B37">Fang et al., 2021</xref>).</p>
</sec>
<sec id="s4-1-11">
<title>4.1.11 Quercetin</title>
<p>Quercetin is a naturally occurring flavonoid, ubiquitously present in fruits and vegetables (<xref ref-type="bibr" rid="B39">Fang et al., 2019</xref>; <xref ref-type="bibr" rid="B31">Dhanya, 2022</xref>). Quercetin has been shown to altering glucose homeostasis via glucose transporters and insulin signalling molecules, acts as potentiates IRS1, PI3K and AKT1 phosphorylation in brain of STZ-induced diabetic rats (<xref ref-type="bibr" rid="B125">Sandeep and Nandhini, 2017</xref>). In addition, a study showed that HFD-induced mice and PA-induced HepG2 cells treated with quercetin saw a enhancement alleviation of insulin resistance via the IRS-1/AKT/FoxO1 pathway, and stimulated expressions of p-IRS1, <italic>p</italic>-AKT and GLUT4 in liver (<xref ref-type="bibr" rid="B23">Cheng et al., 2021</xref>; <xref ref-type="bibr" rid="B82">Liu et al., 2022</xref>).</p>
</sec>
<sec id="s4-1-12">
<title>4.1.12 Apigenin</title>
<p>Apigenin, a flavonoid, is widely distributed in folk medicines for diabetes treatment (<xref ref-type="bibr" rid="B116">Qin et al., 2016</xref>; <xref ref-type="bibr" rid="B65">Kashyap et al., 2021</xref>). Apigenin significantly increases glucose consumption and glycogen synthesis, suppresses the production of ROS and AGEs, and improves insulin resistance in IR-HepG2 cells, and elevated the level of protein expression of IRS-1, IRS-2, PI3K, and p-AKT is observed in IR-HepG2 cells (<xref ref-type="bibr" rid="B94">Miao et al., 2023</xref>). Therefore, the activation of the IRS-1/IRS-2/PI3K/AKT signaling pathway and regulation of its targets, including GLUT4 and GSK-3&#x3b2;, may play important roles in preventing diabetes (<xref ref-type="bibr" rid="B39">Fang et al., 2019</xref>; <xref ref-type="bibr" rid="B94">Miao et al., 2023</xref>).</p>
</sec>
<sec id="s4-1-13">
<title>4.1.13 Poncirin</title>
<p>Poncirin, a natural flavonoid glycoside derivative present in the fruits of <italic>Poncirus trifoliata</italic>, possesses multiple biological activities (<xref ref-type="bibr" rid="B72">Li et al., 2022</xref>). Naringenin significantly increased glucose uptake and GLUT4 expression level via activating the IRS-1/PI3K/AKT/GSK-3 signaling pathway, and decreased the expression of PTP1B in IR-C2C12 skeletal muscle cells (<xref ref-type="bibr" rid="B172">Yousof Ali et al., 2020</xref>). Enhanced the phosphorylation of IRS-1, PI3K, GSK3&#x3b2; and AKT, and thus stimulated the glucose uptake and insulin sensitivity.</p>
</sec>
<sec id="s4-1-14">
<title>4.1.14 Naringenin</title>
<p>Naringenin, a citrus flavonoid, has the ability to increase insulin secretion in the primary rat islets, protect &#x3b2; cell function and reverse glucose dysregulation in diabetic rats (<xref ref-type="bibr" rid="B81">Lin et al., 2023</xref>). Likewise, naringenin reduces lipid accumulation and insulin resistance through promoting AMPK phosphorylation level in liver of diabetic mice (<xref ref-type="bibr" rid="B15">Cai et al., 2023</xref>). Further, naringenin administration significantly altering glucose homeostasis, as well as significantly restored GLUT1 and GLUT3 expression, and increased the phosphorylated forms of IRS1, PI3K and AKT in a rat model of T2DM (<xref ref-type="bibr" rid="B125">Sandeep and Nandhini, 2017</xref>).</p>
</sec>
</sec>
<sec id="s4-2">
<title>4.2 Polyphenols</title>
<p>Polyphenols are a group of chemicals formed by the combination of at least one aromatic ring with one or more hydroxyl functional groups attached to it, which are considered secondary metabolites and abundantly found in fruits, vegetables, and medicinal plants (<xref ref-type="bibr" rid="B95">Mirza-Aghazadeh-Attari et al., 2020</xref>). Meanwhile, Polyphenols were known to be instrumental in each of the vital processes of glucose metabolism. It prefers to arrest intestinal glucose absorption, increase pancreatic insulin secretion, enhance the capacity of muscle and adipocytes to utilize glucose and hinder glucose secretion by the liver (<xref ref-type="bibr" rid="B129">Shahwan et al., 2022</xref>), including resveratrol, pterostilbene, curcumin and gallic acid. The chemical structures of four polyphenols are shown in <xref ref-type="fig" rid="F3">Figure 3</xref>.</p>
<fig id="F3" position="float">
<label>FIGURE 3</label>
<caption>
<p>The chemical structures of four polyphenols.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g003.tif"/>
</fig>
<sec id="s4-2-1">
<title>4.2.1 Resveratrol</title>
<p>Found in <italic>Polygonum cuspidatum</italic>, Resveratrol (3, 5, 4&#x2032;-trihydroxystilbene, RSV) is a type of non-flavonoid polyphenolic with phytoalexin properties, which is particularly high in resveratrol and can be used as a TCM (<xref ref-type="bibr" rid="B185">Zhao et al., 2019</xref>). A series of studies have verified a broad spectrum activity of resveratrol in association with diabetes and its complications (<xref ref-type="bibr" rid="B143">Szkudelska and Szkudelski, 2010</xref>). In a metabolic action study in humans, it was shown that oral administration of 10&#xa0;mg of RSV for 4&#xa0;weeks significantly reduced insulin resistance and improved insulin sensitivity in humans and resulted in more efficient transduction of insulin signaling through the AKT pathway (<xref ref-type="bibr" rid="B14">Brasnyo et al., 2011</xref>). What counts is that researchers found that RSV restores the phosphorylation levels of AKT and PI3K in the liver of insulin resistance mice, which are involved in the insulin signaling pathway and were decreased by a high-fat diet (<xref ref-type="bibr" rid="B51">Hong et al., 2014</xref>; <xref ref-type="bibr" rid="B123">Sadi et al., 2015</xref>; <xref ref-type="bibr" rid="B133">Shu et al., 2020</xref>). Furthermore, RSV could also increase insulin secretion and produce a hypoglycemic effect in STZ-induced rats, KKAy mice, and HCF-fed rats via PI3K/AKT signaling pathway to enhance glucose uptake into skeletal muscles (<xref ref-type="bibr" rid="B24">Chi et al., 2007</xref>; <xref ref-type="bibr" rid="B29">Deng et al., 2008</xref>; <xref ref-type="bibr" rid="B22">Chen et al., 2012</xref>). In addition, the combination therapy of dapagliflozin with RSV has better glucose-lowering effects than the single SGLT2i therapy in T2D treatment, and the therapeutic effects of enhancing glucose production and inhibiting gluconeogenesis were also produced by modulating the PI3K/AKT pathway (<xref ref-type="bibr" rid="B141">Sun et al., 2021</xref>).</p>
</sec>
<sec id="s4-2-2">
<title>4.2.2 Pterostilbene</title>
<p>Pterostilbene (trans-3, 5-dimethoxy-4&#x2032;-hydroxystilbene; PTE), a polyphenol and a naturally occurring dimethylated analog, can be obtained from grapes and blueberries and be found in several TCM. Pterostilbene exhibits anti-diabetic effects both by normalizing the significant enzymes of glucose metabolism and regulating the insulin resistance signaling pathway (<xref ref-type="bibr" rid="B106">Pari and Satheesh, 2006</xref>). Furthermore, it can also reverse insulin resistance by decreasing the oxidative stress effect (<xref ref-type="bibr" rid="B35">Elango et al., 2016</xref>). The treatment of STZ-induced diabetic rats with pterostilbene at different concentrations (20, 40, and 80&#xa0;mg/kg) for 8&#xa0;weeks normalized the body weight, FBG, OGTT, serum lipid profile, and insulin levels in a dose-dependent manner (<xref ref-type="bibr" rid="B137">Sun et al., 2019</xref>). Moreover, the expression of PPAR&#x3b3; was increased, and the expression of PI3K and p-AKT was upregulated in adipose tissue of diabetic rats after treatments. The above results show that the mechanism of the anti-diabetic effect of pterostilbene in high-fat diet and STZ-induced diabetic rats may be related to the PI3K/AKT signaling pathway. A similar therapeutic effect of reversing insulin resistance was also demonstrated in HepG2 cells induced by palmitic acid <italic>in vitro</italic>. Meanwhile, pterostilbene can also regulate triglyceride accumulation and FFA metabolism and reduce oxidative damage to lipids via regulating the PI3K/AKT signaling pathway and the expression of genes coding for gluconeogenic enzymes (<xref ref-type="bibr" rid="B91">Malik et al., 2019</xref>).</p>
</sec>
<sec id="s4-2-3">
<title>4.2.3 Curcumin</title>
<p>Curcumin (1, 7-bis (4-hydroxy-3-methoxyphenyl)-1, 6-heptadiene-3, 5-dione), a natural phenol found in <italic>Curcuma longa</italic> plants, has been shown to prevent hyperglycemia and hyperlipidemia as well as liver damage (<xref ref-type="bibr" rid="B152">Xia et al., 2020</xref>). Data indicated that administration of dietary curcumin reinstates PI3K and AKT levels in the liver of diet-induced obese mice and T2MD rats (<xref ref-type="bibr" rid="B67">Kim et al., 2019</xref>; <xref ref-type="bibr" rid="B153">Xia et al., 2020</xref>), ameliorates the tissue structure of the liver and pancreas and decreases blood glucose and lipid levels. It ameliorated insulin sensitivity via strengthening the PI3K/AKT/GSK3&#x3b2; signal pathway in high-glucose-induced IR HepG2 cells (<xref ref-type="bibr" rid="B73">Li et al., 2020</xref>). Additionally, the mechanistic basis of curcumin is a potential therapeutic strategy for the protection of pancreatic &#x3b2;-cells in T2DM, and it shows that curcumin protected MIN6 &#x3b2;-cells from palmitate-induced apoptosis by modulating the PI3K/AKT/FoxO1 signaling pathway and the mitochondrial survival pathway (<xref ref-type="bibr" rid="B49">Hao et al., 2015</xref>).</p>
</sec>
<sec id="s4-2-4">
<title>4.2.4 Gallic acid</title>
<p>Gallic acid (3, 4, 5-trihydroxybenzoic acid), a naturally occurring phenolic acid, has been shown to possess anti-hyperglycemic and anti-diabetic activities in STZ-induced diabetic rats (<xref ref-type="bibr" rid="B114">Punithavathi et al., 2011</xref>; <xref ref-type="bibr" rid="B115">Punithavathi et al., 2011</xref>). <italic>In vivo</italic>, Gallic acid can improve insulin resistance in the liver, adipose, and skeletal muscle tissues of diabetic rats through translocation and activation of GLUT4 in the PI3K/AKT signaling pathway, and slightly upregulated the mRNA and protein expression levels of PPAR&#x3b3; (<xref ref-type="bibr" rid="B42">Gandhi et al., 2014</xref>). Its effects on hepatic glucose metabolism via regulating the PI3K/AKT pathway in HFD-induced diabetic rats were also confirmed (<xref ref-type="bibr" rid="B53">Huang et al., 2016</xref>). <italic>In vitro</italic>, the anti-diabetic effect of Gallic acid was found to protect against free fatty acid (FFA)-induced IR through the miR-1271/IRS-1/PI3K/AKT/FoxO1 pathway at dose of 50&#xa0;&#x3bc;mol/L (<xref ref-type="bibr" rid="B71">Lee and Lee, 2021</xref>).</p>
</sec>
</sec>
<sec id="s4-3">
<title>4.3 Alkaloid</title>
<p>Alkaloids are significant and excellent phytoconstituents found in medicinal plants and represent the beginning of the interesting potential for new approaches to the treatment of diabetes, and multiple <italic>in vitro</italic> and <italic>in vivo</italic> experiments have proven the relatively bright potential of alkaloids in the treatment of diabetes and its complications (<xref ref-type="bibr" rid="B11">Behl et al., 2022</xref>). Alkaloids such as tetramethylpyrazine, hirsutine, and 1-Deoxynojirimycin can regulate the balance between glycolipid metabolic and moderate insulin resistance. The chemical structures of three alkaloids are shown in <xref ref-type="fig" rid="F4">Figure 4</xref>.</p>
<fig id="F4" position="float">
<label>FIGURE 4</label>
<caption>
<p>The chemical structures of three alkaloids.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g004.tif"/>
</fig>
<sec id="s4-3-1">
<title>4.3.1 Tetramethylpyrazine</title>
<p>Tetramethylpyrazine (TMP), also known as ligustrazine, is an alkaloid extracted from the plant Ligusticum chuanxiong with biological efficacy in improving glucose homeostasis and systemic insulin sensitivity (<xref ref-type="bibr" rid="B154">Xiang et al., 2020</xref>). Its anti-diabetic affection produced by reducing insulin resistance suppressing oxidative stress in HFD-STZ-induced T2D rats and STZ-NCT-induced T2D rats and suggested that the dose-dependent hypoglycemic activity and potential molecular mechanisms of the oral administration of TMP assessed by calculating the expression levels of phosphorylated PI3K and AKT proteins and mRNA in skeletal muscle, heart and adipose tissue of T2D rats (<xref ref-type="bibr" rid="B118">Rai et al., 2019</xref>; <xref ref-type="bibr" rid="B117">Rai et al., 2019</xref>). Therefore, it can be concluded that TMP improves insulin resistance and produces anti-diabetic activity by activating the PI3K/AKT signaling pathway.</p>
</sec>
<sec id="s4-3-2">
<title>4.3.2 Hirsutine</title>
<p>Hirsutine is a potent drug-like indole alkaloid extracted from the <italic>Uncaria rhynchophylla</italic>. Hirsutine beneficially regulates glucose homeostasis, improving hepatic and cardiac IR in HFD-induced diabetic mice (<xref ref-type="bibr" rid="B59">Jiang et al., 2023</xref>). The ability of pharmacological anti-diabetic to promote glucose consumption and glycogen synthesis and to inhibit gluconeogenesis was also demonstrated adjuvantly in the IR model of HepG2 and H9c2 cells using high glucose and high insulin induction, and the mechanism of action was achieved through activation of PI3K/AKT/GSK3&#x3b2; signaling pathway (<xref ref-type="bibr" rid="B52">Hu et al., 2022</xref>).</p>
</sec>
<sec id="s4-3-3">
<title>4.3.3 1-Deoxynojirimycin</title>
<p>1-Deoxynojirimycin, as an inhibitor of intestinal &#x251;-glucosidase, the primary alkaloid isolated from mulberry leaves (<italic>Morus alba</italic> L.), has been reported as the critical practical bioactive material basis. Depending on previous research, the administration of purified 1-Deoxynojirimycin appeared to have antioxidant and anti-inflammatory roles in STZ-induced diabetic rats. It explains at least part of the mechanism by which it ameliorates blood glucose (<xref ref-type="bibr" rid="B54">Huang et al., 2014</xref>). Its therapeutic effect on hyperglycemia was evidenced by the reduction of blood glucose, serum insulin levels and HOMA-IR index while improving glucose tolerance and insulin sensitivity in skeletal muscle of db/db mice via activating insulin signaling PI3K/AKT pathway (<xref ref-type="bibr" rid="B85">Liu et al., 2015</xref>). Meanwhile, its mechanism of glucose homeostasis regulation effect in differentiated 3T3-L1 adipocytes by up-regulating the genes/proteins and mRNA expression of PI3K/AKT and AMPK signaling pathways from ADIPO to GLUT4 and from IR to GlUT4 (<xref ref-type="bibr" rid="B74">Li et al., 2019</xref>). Additionally, 1-Deoxynojirimycin supplementation appeared to improve muscle insulin resistance by modulating the IRS-1/PI3K/AKT pathway in the skeletal muscle of db/db mice (<xref ref-type="bibr" rid="B63">Kang et al., 2022</xref>).</p>
</sec>
</sec>
<sec id="s4-4">
<title>4.4 Terpenoids</title>
<p>Terpenoids are widely distributed in nature among the most diverse phytochemicals, possessing a wide range of biological activities. Such compounds have been shown to modulate glycolipid metabolism and improve insulin resistance in terms of anti-diabetic activity (<xref ref-type="bibr" rid="B142">Szakiel et al., 2012</xref>). Terpenoids include siamenoside I, mogroside III, mogroside IV, mogroside V, catalpol, oleanolic acid, asiatic acid, glycyrrhetinic acid and maslinic acid. The chemical structures of nine terpenoids are presented in <xref ref-type="fig" rid="F5">Figure 5</xref>.</p>
<fig id="F5" position="float">
<label>FIGURE 5</label>
<caption>
<p>The chemical structures of nine terpenoids.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g005.tif"/>
</fig>
<sec id="s4-4-1">
<title>4.4.1 Mogroside</title>
<p>
<italic>Siraitia grosvenorii</italic>, as a medicine food homology plant, possesses both nutritional and medicinal values. The fruit of S. <italic>grosvenorii</italic> is naturally enriched with sweetener compounds such as Mogroside III, Mogroside IV, Mogroside V, and Siamenoside I belong to triterpenoid constituents (<xref ref-type="bibr" rid="B148">Thakur et al., 2023</xref>). Researchers evaluated the hypoglycemic effect of four mogrosides, namely, Mogroside III, Mogroside IV, Mogroside V, and Siamenoside I. They reversed insulin resistance in IR-HepG2 cells by activating the PI3K signaling pathway, which can play a role in the regulation of glucose metabolism. Moreover, Mogroside V is the most significant curative effect compared with others. It has been found to alleviate glucose levels and insulin sensitivity in T2DM rats by regulating the PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="B87">Liu et al., 2019</xref>).</p>
</sec>
<sec id="s4-4-2">
<title>4.4.2 Catalpol</title>
<p>Catalpol, an iridoid glycoside with pharmacological benefits for the prevention of diabetes and diabetic complications, is mainly found in the roots of <italic>Radix Rehmanniae</italic> (<xref ref-type="bibr" rid="B7">Bai et al., 2019</xref>). The therapeutic effects of catalpol in controlling glycemic parameters in HFD/STZ-induced diabetic mice and its potential molecular mechanisms indicate that mRNA levels of IRS-1, PI3K, AKT2, and GLUT-4 in skeletal muscle were significantly improved by treatment (<xref ref-type="bibr" rid="B169">Yap et al., 2020</xref>). Meanwhile, catalpol improves insulin sensitivity and increases glucose uptake by enhancing MyoD/MyoG-mediated myogenesis. Moreover, in accordance with the research of <italic>in vitro</italic> and <italic>in vivo</italic> the mechanism of catalpol hypoglycemia in skeletal muscle involves modulation of the PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="B158">Xu et al., 2018</xref>). Furthermore, the mechanism by which catalpol alleviates hepatic insulin resistance by regulating the expression of the PI3K/AKT pathway and its downstream glucose metabolism-related proteins has been demonstrated in T2D mice and IR-HepG2 cells models (<xref ref-type="bibr" rid="B161">Yan et al., 2018</xref>).</p>
</sec>
<sec id="s4-4-3">
<title>4.4.3 Oleanolic acid</title>
<p>Oleanolic acid (3&#x3b2;-hydroxyolean-12-en-28-oic acid), a glycogen phosphorylase (GP) inhibitor, is a naturally occurring pentacyclic triterpene widely found in a range of foods and TCM and has enormous potential in hypoglycemic effects. Oleanolic acid could improve blood glucose and insulin homeostasis by enhancing the phosphorylation of ATK and AMPK in the liver of db/db diabetic mice and significantly improve hepatic gluconeogenesis and hepatic pathological changes (<xref ref-type="bibr" rid="B150">Wang et al., 2015</xref>). Further, additional research data manifest that the sustained modification of glucose homeostasis by oleanolic acid is due, at least in part, to the repression of AKT/FoxO1 axis-mediated gluconeogenesis in liver (<xref ref-type="bibr" rid="B175">Zeng et al., 2012</xref>). Meanwhile, oleanolic acid attenuated adipose tissue insulin resistance induced by fructose over-consumption in rats via IRS-1/PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="B78">Li et al., 2014</xref>).</p>
</sec>
<sec id="s4-4-4">
<title>4.4.4 Asiatic acid</title>
<p>Asiatic acid is a natural pentacyclic triterpenoid derived from <italic>Centella Asiatica</italic> (L.) Urban and exhibited potent hepatoprotective biological function. Oral administration of asiatic acid to STZ-induced diabetic rats restored the key carbohydrate-metabolizing and lipid metabolic enzymes and lipid peroxidation products to nearly normal levels. Reliable research data found it positively lowered blood sugar, lipid, and lipid peroxidation (<xref ref-type="bibr" rid="B119">Ramachandran and Saravanan, 2013</xref>; <xref ref-type="bibr" rid="B120">Ramachandran and Saravanan, 2013</xref>; <xref ref-type="bibr" rid="B121">Ramachandran and Saravanan, 2015</xref>). Additionally, it also found that its hypoglycemic effect may activate the PI3K/AKT signaling pathway to significantly improve glucose uptake and insulin resistance in skeletal muscle tissue of STZ-induced diabetic rats and improve glucose homeostasis (<xref ref-type="bibr" rid="B121">Ramachandran and Saravanan, 2015</xref>). Its anti-diabetic effects have also been demonstrated in T2DM (db/db) mouse models, and it promoted glycogen synthesis by activating PI3K/AKT/GSK-3&#x3b2; signaling pathway in liver tissue (<xref ref-type="bibr" rid="B139">Sun et al., 2017</xref>).</p>
</sec>
<sec id="s4-4-5">
<title>4.4.5 Glycyrrhetinic acid</title>
<p>Glycyrrhetinic acid, a triterpenoid, is one of the main bioactive components in licorice (<xref ref-type="bibr" rid="B144">Tan et al., 2022</xref>). Glycyrrhetinic acid prevented hyperglycemia and hyperlipidemia in STZ-induced diabetic rats and improved to normalcy (<xref ref-type="bibr" rid="B62">Kalaiarasi et al., 2009</xref>). In addition, glycyrrhetinic acid elicits its anti-diabetic activity mainly through regulating the PI3K/AKT/GSK-3&#x3b2; signaling pathway (<xref ref-type="bibr" rid="B165">Yang et al., 2020</xref>; <xref ref-type="bibr" rid="B144">Tan et al., 2022</xref>; <xref ref-type="bibr" rid="B93">Meng et al., 2023</xref>). Moreover, glycyrrhetinic acid was found to decrease the activation of the phosphorylation of IRS1ser307 and increased the phosphorylation of AKTser473 and GSK-3&#x3b2;ser9 in IR-HepG2 cells, thus improving insulin-response pathway and glucose consumption levels (<xref ref-type="bibr" rid="B178">Zhang et al., 2019</xref>; <xref ref-type="bibr" rid="B149">Wang et al., 2023</xref>).</p>
</sec>
<sec id="s4-4-6">
<title>4.4.6 Maslinic acid</title>
<p>Maslinic acid is a pentacyclic triterpene acid that possesses a variety of biological activities, and has been shown to regulate glycogen metabolism in HFD-induced diabetic mice as a glycogen phosphorylase inhibitor (<xref ref-type="bibr" rid="B83">Liu et al., 2014</xref>; <xref ref-type="bibr" rid="B163">Yan et al., 2023</xref>). In addition, maslinic acid intervention on IR-HepG2 cells elevated the phosphorylation levels of AKT and GSK-3&#x3b2;, and PI3K inhibitor blocked the phosphorylation of AKT<sup>Ser473</sup>, thus proving its potential to regulate glycogen metabolism (<xref ref-type="bibr" rid="B83">Liu et al., 2014</xref>). Further, identified that maslinic acid has potent anti-adipogenic effects to target adipocyte function and prevent obesity, and target activation of PI3K/AKT signaling pathway (<xref ref-type="bibr" rid="B127">Savova et al., 2021</xref>).</p>
</sec>
</sec>
<sec id="s4-5">
<title>4.5 Quinones</title>
<p>Quinones are a class of aromatic dicarbonyl that are widely found in nature and possess a wide range of biological activities, of which anthraquinone is the largest naturally occurring quinone, such as aloin, embelin and emodin (<xref ref-type="bibr" rid="B164">Yang et al., 2020</xref>). The chemical structures of three quinones are shown in <xref ref-type="fig" rid="F6">Figure 6</xref>.</p>
<fig id="F6" position="float">
<label>FIGURE 6</label>
<caption>
<p>The chemical structures of three quinones.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g006.tif"/>
</fig>
<sec id="s4-5-1">
<title>4.5.1 Aloin</title>
<p>Aloin, isolated from the leaf secretion of <italic>Aloe vera</italic> (L.) Burm. f., belonging to anthraquinone compounds (<xref ref-type="bibr" rid="B58">Jiang et al., 2018</xref>). Both <italic>in vivo</italic> and <italic>in vitro</italic> studies of aloin have shown its hypoglycemic effects (<xref ref-type="bibr" rid="B176">Zhang et al., 2020</xref>), with <italic>in vivo</italic> studies demonstrating that aloin improves glucose tolerance and fasting serum insulin activity in T2D mice and has hepatoprotective effect, which is mediated by activation of the IRS1/PI3K/AKT pathway (<xref ref-type="bibr" rid="B26">Cui et al., 2014</xref>), and <italic>in vitro</italic> studies demonstrating that aloin markedly improves glucose consumption and stimulates the activity of key enzymes of glucose metabolism in IR-HepG2 cells (<xref ref-type="bibr" rid="B188">Zhong et al., 2022</xref>).</p>
</sec>
<sec id="s4-5-2">
<title>4.5.2 Embelin</title>
<p>Embelin (2, 5-dihydroxy-3-undecyl-1, 4-benzoquinone), a naturally occurring alkyl-substituted hydroxyl benzoquinone, isolated from <italic>Embelia ribes</italic> Burm, which has been extensively evaluated for its anti-diabetic activity (<xref ref-type="bibr" rid="B34">Durg et al., 2017</xref>). Embelin treatment of HFD-STZ-induced T2DM rats shows that it regulates glucose uptake by regulating GLUT4 transposition and activation in epididymal adipose tissue mediated by insulin-dependent PI3K/AKT pathway, manifesting that it plays a positive role in improving adipose tissue insulin sensitivity, enhancing blood glucose control, protecting &#x3b2; cells from damage and maintaining adipose tissue glucose homeostasis in animal models (<xref ref-type="bibr" rid="B43">Gandhi et al., 2013</xref>).</p>
</sec>
<sec id="s4-5-3">
<title>4.5.3 Emodin</title>
<p>Emodin, an anthraquinone, was characterized being an active agent in lowering blood lipids and modulating glucose utilization (<xref ref-type="bibr" rid="B174">Yu et al., 2023</xref>). It was demonstrated that emodin improves hepatic glucose utilization, muscle and fat glucose uptake by targeting the IRS/PI3K/AKT/FoxO1 pathway, resulting in enhancing insulin sensitivity and resistance, the protein expression of IRS1, PI3K, and p-AKT ser473 in hepatic, muscle, and adipose tissue of diabetic mice was upregulated (<xref ref-type="bibr" rid="B160">Xuezheng et al., 2018</xref>).</p>
</sec>
</sec>
<sec id="s4-6">
<title>4.6 Saponins</title>
<p>Saponins, surface-active glycosides widely found in TCM, usually consist of a structure linking both a glycoside and a hydrophobic glycosidic ligand (saponin element), which in nature can be triterpenoids or steroids in nature (<xref ref-type="bibr" rid="B36">Elekofehinti, 2015</xref>). Their anti-diabetic properties have been demonstrated by their reported activities of regulating glucose-lipid metabolic homeostasis, promoting insulin secretion and enhancing insulin sensitivity as shown <italic>in vivo</italic> and <italic>in vitro</italic> models of insulin resistance. Astragaloside IV, ginsenoside Rb2 and ginsenoside Rg5 are examples of saponins. The chemical structures of three saponins are shown in <xref ref-type="fig" rid="F7">Figure 7</xref>.</p>
<fig id="F7" position="float">
<label>FIGURE 7</label>
<caption>
<p>The chemical structures of three saponins.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g007.tif"/>
</fig>
<sec id="s4-6-1">
<title>4.6.1 Astragaloside IV</title>
<p>Astragaloside IV, a glycoside of cyclobutane-type triterpene obtained from <italic>Astragalus membranaceus</italic>, has the effect of preventing diabetes by inducing a decrease in blood glucose concentration and an increase in plasma insulin levels (<xref ref-type="bibr" rid="B173">Yu et al., 2006</xref>). It can reduce blood glucose levels in HFD-STZ-induced diabetic mice, glycogen phosphorylase (GP) and glucose-6-phosphatase (G6Pase), two glucose-regulated enzymes, were inhibited to improve glucose metabolism in the liver (<xref ref-type="bibr" rid="B89">Lv et al., 2010</xref>). Additionally, it inhibits lipolysis and reduces hepatic glucose production in HFD-fed mice through AKT-dependent PDE3b expression (<xref ref-type="bibr" rid="B33">Du et al., 2018</xref>). Its mechanism of action is reducing insulin resistance in adipocytes by regulating CTRP3 and PI3K/AKT signaling (<xref ref-type="bibr" rid="B181">Zhang et al., 2022</xref>).</p>
</sec>
<sec id="s4-6-2">
<title>4.6.2 Ginsenosides</title>
<p>Ginsenosides, obtained from ginseng, have been demonstrated to possess anti-diabetic activity, such as Ginsenoside Rb2, Ginsenoside Rg5, etc. Ginsenoside Rg5 may be a potential natural product in the treatment of T2DM for the first time, which can remarkably improve glucose and lipid metabolism, increase insulin secretion, and protect damaged tissues in T2D mice. Further, it improves liver insulin resistance in db/db mice and alleviates T2DM by regulating IRS1/PI3K/AKT/GSK3&#x3b2; signaling pathway (<xref ref-type="bibr" rid="B151">Wei et al., 2020</xref>). Ginsenoside Rb2 can jointly improve insulin resistance of 3T3-L1 adipocytes and DIO mice by regulating various pathways such as PI3K/AKT, MAPK and NF-&#x3ba;B, showing various therapeutic effects such as upregulation of inflammatory factors, reduction of fat accumulation and improvement of glucose metabolism (<xref ref-type="bibr" rid="B27">Dai et al., 2018</xref>).</p>
</sec>
</sec>
<sec id="s4-7">
<title>4.7 Others</title>
<p>There are some other metabolites of TCM, including beta-sitosterol, taurine, 1, 7-Diphenyl-4E-en-3-heptanone (DPH5), (R)-5-hydroxy-1, 7-diphenyl-3-heptanone (DPHC) and esculin, are also used to treat T2DM. The chemical structures are presented in <xref ref-type="fig" rid="F8">Figure 8</xref>.</p>
<fig id="F8" position="float">
<label>FIGURE 8</label>
<caption>
<p>The chemical structures of five others.</p>
</caption>
<graphic xlink:href="fphar-15-1373711-g008.tif"/>
</fig>
<sec id="s4-7-1">
<title>4.7.1 Beta-sitosterol</title>
<p>Previous studies have found that the serum insulin level in patients with type 2 diabetes is negatively correlated with the plasma non-cholesterol sterols concentration, which suggests that supplementation of phytosterols may have beneficial effects on lowering blood glucose levels and preventing T2DM (<xref ref-type="bibr" rid="B134">&#x160;mahelov&#xe1; et al., 2005</xref>). Beta-sitosterol is one of the most common phytosterols, widely distributed in many plants and often found in herbal formulations to treat hypercholesterolemia, coronary artery disease, and prostatic hyperplasia (<xref ref-type="bibr" rid="B112">Ponnulakshmi et al., 2019</xref>). Studies have shown that it can protect the expression of insulin signaling molecules in adipose tissue and skeletal muscle of rats with T2DM induced by a high-fat diet and sucrose and improve blood glucose metabolism by enhancing the expression level of insulin receptor (IR) and GLUT4 and regulating the IRS-1/AKT mediated signaling pathway (<xref ref-type="bibr" rid="B6">Babu et al., 2020</xref>). It was suggested that beta-sitosterol has anti-diabetic potential. Furthermore, it affected glucose transport and lipid mobilization in primary preadipocytes from male rats by activating and regulating the PI3K/AKT signaling pathway and GLUT4 expression level (<xref ref-type="bibr" rid="B18">Chai et al., 2011</xref>). The anti-diabetic potential in a skeletal muscle model established using L6 myotube cells and found that it promoted glucose transport and glucose uptake in L6 myotube cells by activating IRS-1/PI3K/AKT signaling pathway and improving GLUT4 expression level (<xref ref-type="bibr" rid="B136">Sujatha et al., 2010</xref>). The above results manifest that insulin-like property is one of the mechanisms of improving insulin resistance <italic>in vitro</italic>.</p>
</sec>
<sec id="s4-7-2">
<title>4.7.2 Taurine</title>
<p>Taurine, obtained from <italic>Bos taurus</italic> domesticus Gmelin, is a sulfur-containing amino acid (<xref ref-type="bibr" rid="B122">Rashid et al., 2013</xref>). It can regulate a variety of the body&#x2019;s normal physiological activities, such as participating in the beta cell function, regulating insulin signaling pathways and glucolipid metabolism of the liver (<xref ref-type="bibr" rid="B28">Das et al., 2012</xref>; <xref ref-type="bibr" rid="B10">Batista et al., 2013</xref>; <xref ref-type="bibr" rid="B146">Tang et al., 2019</xref>; <xref ref-type="bibr" rid="B186">Zhao et al., 2019</xref>). Taurine could improve insulin resistance by activating the PI3K/AKT/GLUT4 pathway in HFD/STZ-induced T2DM rats and PA-induced IR-HepG2 and the regulatory effects of taurine on the insulin signaling pathway in the liver, the target organ of insulin. Moreover, its potential to prevent T2DM was evaluated <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="B20">Chen et al., 2021</xref>).</p>
</sec>
<sec id="s4-7-3">
<title>4.7.3 Diarylheptanoid</title>
<p>1,7-Diphenyl-4E-en-3-heptanone (DPH5) and (R)-5-hydroxy-1,7-diphenyl-3-heptanone (DPHC) are diarylheptanoid present in the rhizome of <italic>Alpinia officinarum</italic> Hance (<xref ref-type="bibr" rid="B155">Xin et al., 2017</xref>; <xref ref-type="bibr" rid="B1">Abubakar et al., 2018</xref>). These metabolites are considered the most active bioactive metabolites extracted from this plant and have favorable hypoglycemic effects. DPH5 could promote glucose uptake and consumption of IR-HepG2 cells, accelerate glucose utilization, and improve insulin resistance and insulin sensitivity by regulating PI3K/AKT-GSK3&#x3b2; signaling pathway and increasing the expression of GLUT4 and GSK3&#x3b2; proteins (<xref ref-type="bibr" rid="B182">Zhang et al., 2022</xref>). Additionally, DPHC could regulate glucose metabolism and hypoglycemic activity well in both db/db mouse models and <italic>in vitro</italic> high-glucose induced IR-HepG2 cells, and its mechanism improves insulin resistance by regulating IRS1/PI3K/AKT/GLUT4 signaling pathway, showing potential for T2DM treatment (<xref ref-type="bibr" rid="B180">Zhang et al., 2021</xref>).</p>
</sec>
<sec id="s4-7-4">
<title>4.7.4 Esculin</title>
<p>Esculin, a plant derived natural coumarin extracted from <italic>Cortex fraxini</italic>, is considered to exert multiple anti-diabetic properties (<xref ref-type="bibr" rid="B99">Naseem et al., 2023</xref>). Esculin amelioration of unhealthy AT remodeling was also proven for the first time as a novel therapeutic strategy for obesity-induced IR. Intervention with esculin could enhance insulin sensitivity and improve adipose tissue remodeling in obese IR C57BL/6J mice (<xref ref-type="bibr" rid="B45">Ghosh et al., 2022</xref>). In PA-treated adipocytes, esculin could promoted glucose uptake through increasing the enhancement of GLUT4 translocation and the expression of p-PI3K p85<sup>Tyr467</sup>, p-AKT<sup>Ser473</sup>, and p-IRS1<sup>Ser307</sup> (<xref ref-type="bibr" rid="B167">Yang et al., 2024</xref>). In addition, esculin restored blood glucose level and glucose tolerance in STZ-induced diabetic mice and dexamethasone-induced diabetic mice, and enhance the phosphorylation of AKT in C2C12 myotubes, indicating a potential for the improvement of insulin resistance (<xref ref-type="bibr" rid="B64">Kang et al., 2014</xref>; <xref ref-type="bibr" rid="B96">Mo et al., 2019</xref>).</p>
</sec>
</sec>
</sec>
<sec id="s5">
<title>5 Future directions and perspective</title>
<sec id="s5-1">
<title>5.1 The role of the PI3K/AKT signaling pathway for hypoglycemic effect in T2DM</title>
<p>As a chronic metabolic disease, the pathogenesis of T2DM has not yet been fully elucidated. The available therapeutic drugs can only alleviate the symptoms of the disease, failing to achieve a completely curative effect, and tend to be accompanied by a multitude of adverse effects. According to extensive research, the PI3K/AKT signaling pathway holds a significant advantage for hypoglycemic effect in T2DM, as it can effectively ameliorate insulin resistance in peripheral target organs of insulin. To some extent, it compensates for the shortcomings of the commonly used anti-diabetes drug, metformin (an AMPK agonist), in clinical treatments. However, it is worth noting that the role of the PI3K/AKT signaling pathway is quite extensive, having connections with numerous diseases, This review found that extensive preclinical studies have demonstrated that activation of the PI3K/AKT signaling pathway can significantly improve various abnormal indicators of T2DM <italic>in vivo</italic> and <italic>in vivo</italic>, and regulating glucose and lipid metabolism levels in insulin target organs and target cells, to some extent, improving insulin resistance and exerting hypoglycemic effects. Although there is no recent progress in clinical studies on the metabolites of TCM as the signaling pathway modulators, the performance of the metabolites of TCM in basic research provides a valuable theoretical basis for entering clinical studies in the future. However, it is worth noting that the PI3K/AKT signaling pathway has quite a wide range of roles and has been associated with numerous diseases, and thus further insight is needed as to whether activation of this pathway directly benefits T2DM without triggering other effects. Moreover, regulating the expression of the PI3K/AKT pathway and its downstream effector proteins is far from sufficient, and the precise targets and mechanisms of diabetes treatment need to be further elucidated in detail.</p>
<p>Moreover, as the TCM exert an immeasurable potential in the treatment of chronic diseases and due to the characteristics of many TCM as homologous with food and medicine, the metabolites of TCM also tend to have lower and fewer side effects and exhibit higher clinical efficacy, attracting considerable attention from relevant academic researchers. Upon these studies, we found that these active metabolites could not only improve glycogen synthesis and glucose uptake, but also inhibit gluconeogenesis through the PI3K/AKT signaling pathway, so that they could improve insulin resistance and exert hypoglycemic effects. In addition, a lot of metabolites of TCM could regulate glucose metabolism and play a comprehensive regulatory role in treatment of T2DM. Therefore, we strongly believe that the TCM are on the verge of breaking new ground in the treatment of T2DM.</p>
</sec>
<sec id="s5-2">
<title>5.2 Characters of metabolites of traditional Chinese medicine in regulating PI3K/AKT signaling pathway</title>
<p>
<list list-type="simple">
<list-item>
<p>1) Flavonoids, polyphenols and terpenoids</p>
</list-item>
</list>
</p>
<p>On the basis of compound categorization, researchers have studied the metabolites of flavonoids, polyphenols and terpenoids in metabolites of TCM more extensively compared to alkaloids, quinones and saponins. The effects of flavonoids, polyphenols and terpenoids on regulating the expression levels of glycogen synthesis, gluconeogenesis and glucose uptake-related proteins mediated by the PI3K/AKT signaling pathway were explored more deeply and roundly.</p>
<p>Flavonoid demonstrate significant activity and simpler structures, giving them a slight advantage in terms of druglikeness and bioavailability. It is also possible to further modify and optimize their structures and develop new dosage forms to improve the pharmacokinetic properties of these metabolites of TCM so that more efficient drugs with fewer toxic side effects can be designed.<list list-type="simple">
<list-item>
<p>2) Quinones and saponins</p>
</list-item>
</list>
</p>
<p>Quinones and saponins have been shown to activate the PI3K/AKT signaling pathway in the preclinical stage, and p-PI3K and p-AKT showed an increase in protein and/or mRNA expression levels upon drug action, but the effects on the downstream proteins of the pathway have been less studied, and need to be further explored in depth.<list list-type="simple">
<list-item>
<p>3) Alkaloids</p>
</list-item>
</list>
</p>
<p>It is noteworthy that probably the researchers took into account that alkaloids often contain toxicity, so the number of alkaloid with hypoglycemic properties in our collection was relatively small. However, they showed different degrees of enhancement on the PI3K/AKT signaling pathway and its downstream-mediated effector proteins, and all of them demonstrated high improvement of insulin resistance and hypoglycemic bioactivities <italic>in vivo</italic> and <italic>in vivo</italic> studies. Therefore, alkaloids metabolites of TCM have great development prospect in treatment of T2DM.</p>
<p>Furthermore, in preclinical studies, metabolites of TCM have exhibited considerable potential activity. However, given the complex structures of some metabolites, their corresponding druglikeness, bioavailability and toxicity require further scrutiny, as do their synthetic processes examples, including terpenoids, quinones and saponins.</p>
<p>Relevant illustrations of the conversion of the potentially metabolites of TCM from preclinical to clinical studies demonstrate the hypoglycemic activity of stevioside and rebaudioside A extracted from <italic>Stevia rebaudiana</italic> Bertoni in human subjects (<xref ref-type="bibr" rid="B97">Mohammed et al., 2022</xref>). For instance, in an acute, paired cross-over study, supplementation of the test meal with 1&#xa0;g of stevioside resulted in a reduction in postprandial blood glucose, with stevioside reducing the incremental area under the glucose-response curve by 18% compared to the control group (<xref ref-type="bibr" rid="B47">Gregersen et al., 2004</xref>; <xref ref-type="bibr" rid="B9">Barriocanal et al., 2008</xref>). Furthermore, the chronic intake of 1,000&#xa0;mg/d of rebaudioside A was well-tolerated without hypoglycemia or alteration of blood pressure in patients with type 2 diabetes mellitus (<xref ref-type="bibr" rid="B90">Maki et al., 2008</xref>). Additionally, supplementation with the natural polyphenol resveratrol 150&#xa0;mg/day for 30 days inhibited postprandial glucagon responses in patients with obesity and did not affect postprandial incretin hormone responses (<xref ref-type="bibr" rid="B68">Knop et al., 2013</xref>). Despite the abundance of metabolites of TCM that have demonstrated better activity in preclinical studies, their corresponding clinical studies are relatively scarce. Moreover, direct studies on the effects of metabolites of TCM on the PI3K/AKT pathway in T2DM are not available so far, but a large number of basic studies provide a solid foundation for future clinical studies. Nonetheless, the clinical application of TCM as modulators of the PI3K/AKT pathway in the context of T2DM still needs to be further developed and explored.</p>
</sec>
</sec>
<sec id="s6" sec-type="conclusion">
<title>6 Conclusion</title>
<p>In conclusion, the metabolites of TCM operates on both <italic>in vivo</italic> and <italic>in vitro</italic> models, activating the PI3K/AKT signaling pathway, enhancing glycogen synthesis and glucose uptake, and inhibiting gluconeogenesis in insulin-targeted organs, thus ameliorating insulin resistance and exerting hypoglycemic effects. Research on metabolites of traditional Chinese medicine for treating T2DM predominantly remain at the primary stage, however, these studies lay a robust foundation for future clinical investigations.</p>
</sec>
</body>
<back>
<sec id="s7">
<title>Author contributions</title>
<p>YF: Conceptualization, Data curation, Investigation, Methodology, Visualization, Writing&#x2013;original draft, Writing&#x2013;review and editing. YR: Supervision, Validation, Writing&#x2013;review and editing. XZ: Supervision, Writing&#x2013;review and editing, Investigation. SY: Data curation, Visualization, Writing&#x2013;review and editing. QJ: Investigation, Writing&#x2013;review and editing. QL: Investigation, Writing&#x2013;review and editing. WJ: Conceptualization, Supervision, Writing&#x2013;original draft, Writing&#x2013;review and editing.</p>
</sec>
<sec id="s8" sec-type="funding-information">
<title>Funding</title>
<p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Guizhou Provincial Science and Technology Plan Project (QKHZC 2023-13) and the Science and Technology Project of Guizhou Province of China ([2019]1120).</p>
</sec>
<sec id="s9" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s10" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Abubakar</surname>
<given-names>I. B.</given-names>
</name>
<name>
<surname>Malami</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Yahaya</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sule</surname>
<given-names>S. M.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>A review on the ethnomedicinal uses, phytochemistry and pharmacology of Alpinia officinarum Hance</article-title>. <source>J. Ethnopharmacol.</source> <volume>224</volume>, <fpage>45</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2018.05.027</pub-id>
</citation>
</ref>
<ref id="B2">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Agius</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Role of glycogen phosphorylase in liver glycogen metabolism</article-title>. <source>Mol. Aspects Med.</source> <volume>46</volume>, <fpage>34</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.mam.2015.09.002</pub-id>
</citation>
</ref>
<ref id="B3">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ahad</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mujeeb</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ahsan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>W. A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Prophylactic effect of baicalein against renal dysfunction in type 2 diabetic rats</article-title>. <source>Biochimie</source> <volume>106</volume>, <fpage>101</fpage>&#x2013;<lpage>110</lpage>. <pub-id pub-id-type="doi">10.1016/j.biochi.2014.08.006</pub-id>
</citation>
</ref>
<ref id="B4">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alkhalidy</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>McMillan</surname>
<given-names>R. P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Kaempferol ameliorates hyperglycemia through suppressing hepatic gluconeogenesis and enhancing hepatic insulin sensitivity in diet-induced obese mice</article-title>. <source>J. Nutr. Biochem.</source> <volume>58</volume>, <fpage>90</fpage>&#x2013;<lpage>101</lpage>. <pub-id pub-id-type="doi">10.1016/j.jnutbio.2018.04.014</pub-id>
</citation>
</ref>
<ref id="B5">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alshehade</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Alshawsh</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Murugaiyah</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Asif</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alshehade</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Almoustafa</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>The role of protein kinases as key drivers of metabolic dysfunction-associated fatty liver disease progression: new insights and future directions</article-title>. <source>Life Sci.</source> <volume>305</volume>, <fpage>120732</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2022.120732</pub-id>
</citation>
</ref>
<ref id="B6">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Babu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Krishnan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rajagopal</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Periyasamy</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Veeraraghavan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Govindan</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Beta-sitosterol attenuates insulin resistance in adipose tissue via IRS-1/Akt mediated insulin signaling in high fat diet and sucrose induced type-2 diabetic rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>873</volume>, <fpage>173004</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2020.173004</pub-id>
</citation>
</ref>
<ref id="B7">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Catalpol in diabetes and its complications: a review of pharmacology, pharmacokinetics, and safety</article-title>. <source>Molecules</source> <volume>24</volume> (<issue>18</issue>), <fpage>3302</fpage>. <pub-id pub-id-type="doi">10.3390/molecules24183302</pub-id>
</citation>
</ref>
<ref id="B8">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barone</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Di Domenico</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Perluigi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Butterfield</surname>
<given-names>D. A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>The interplay among oxidative stress, brain insulin resistance and AMPK dysfunction contribute to neurodegeneration in type 2 diabetes and Alzheimer disease</article-title>. <source>Free Radic. Biol. Med.</source> <volume>176</volume>, <fpage>16</fpage>&#x2013;<lpage>33</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2021.09.006</pub-id>
</citation>
</ref>
<ref id="B9">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barriocanal</surname>
<given-names>L. A.</given-names>
</name>
<name>
<surname>Palacios</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Benitez</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Benitez</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>J. T.</given-names>
</name>
<name>
<surname>Jimenez</surname>
<given-names>N.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in Type 1 and Type 2 diabetics</article-title>. <source>Regul. Toxicol. Pharmacol.</source> <volume>51</volume> (<issue>1</issue>), <fpage>37</fpage>&#x2013;<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1016/j.yrtph.2008.02.006</pub-id>
</citation>
</ref>
<ref id="B10">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Batista</surname>
<given-names>T. M.</given-names>
</name>
<name>
<surname>Ribeiro</surname>
<given-names>R. A.</given-names>
</name>
<name>
<surname>da Silva</surname>
<given-names>P. M.</given-names>
</name>
<name>
<surname>Camargo</surname>
<given-names>R. L.</given-names>
</name>
<name>
<surname>Lollo</surname>
<given-names>P. C.</given-names>
</name>
<name>
<surname>Boschero</surname>
<given-names>A. C.</given-names>
</name>
<etal/>
</person-group> (<year>2013</year>). <article-title>Taurine supplementation improves liver glucose control in normal protein and malnourished mice fed a high-fat diet</article-title>. <source>Mol. Nutr. Food Res.</source> <volume>57</volume> (<issue>3</issue>), <fpage>423</fpage>&#x2013;<lpage>434</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.201200345</pub-id>
</citation>
</ref>
<ref id="B11">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Behl</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gupta</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Albratty</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Najmi</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Meraya</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Alhazmi</surname>
<given-names>H. A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Alkaloidal phytoconstituents for diabetes management: exploring the unrevealed potential</article-title>. <source>Molecules</source> <volume>27</volume> (<issue>18</issue>), <fpage>5851</fpage>. <pub-id pub-id-type="doi">10.3390/molecules27185851</pub-id>
</citation>
</ref>
<ref id="B12">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beurel</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Grieco</surname>
<given-names>S. F.</given-names>
</name>
<name>
<surname>Jope</surname>
<given-names>R. S.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases</article-title>. <source>Pharmacol. Ther.</source> <volume>148</volume>, <fpage>114</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1016/j.pharmthera.2014.11.016</pub-id>
</citation>
</ref>
<ref id="B13">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bhattamisra</surname>
<given-names>S. K.</given-names>
</name>
<name>
<surname>Koh</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Choudhury</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Pandey</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Molecular and biochemical pathways of catalpol in alleviating diabetes mellitus and its complications</article-title>. <source>Biomolecules</source> <volume>11</volume> (<issue>2</issue>), <fpage>323</fpage>. <pub-id pub-id-type="doi">10.3390/biom11020323</pub-id>
</citation>
</ref>
<ref id="B14">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brasnyo</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Molnar</surname>
<given-names>G. A.</given-names>
</name>
<name>
<surname>Mohas</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marko</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Laczy</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cseh</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2011</year>). <article-title>Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients</article-title>. <source>Br. J. Nutr.</source> <volume>106</volume> (<issue>3</issue>), <fpage>383</fpage>&#x2013;<lpage>389</lpage>. <pub-id pub-id-type="doi">10.1017/S0007114511000316</pub-id>
</citation>
</ref>
<ref id="B15">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Naringenin inhibits lipid accumulation by activating the AMPK pathway <italic>in vivo</italic> and vitro</article-title>. <source>Food Sci. Hum. Wellness</source> <volume>12</volume> (<issue>4</issue>), <fpage>1174</fpage>&#x2013;<lpage>1183</lpage>. <pub-id pub-id-type="doi">10.1016/j.fshw.2022.10.043</pub-id>
</citation>
</ref>
<ref id="B16">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Camer</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Szabo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X. F.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>The molecular mechanisms underpinning the therapeutic properties of oleanolic acid, its isomer and derivatives for type 2 diabetes and associated complications</article-title>. <source>Mol. Nutr. Food Res.</source> <volume>58</volume> (<issue>8</issue>), <fpage>1750</fpage>&#x2013;<lpage>1759</lpage>. <pub-id pub-id-type="doi">10.1002/mnfr.201300861</pub-id>
</citation>
</ref>
<ref id="B17">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Carnagarin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Dharmarajan</surname>
<given-names>A. M.</given-names>
</name>
<name>
<surname>Dass</surname>
<given-names>C. R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Molecular aspects of glucose homeostasis in skeletal muscle &#x2013; a focus on the molecular mechanisms of insulin resistance</article-title>. <source>Mol. Cell. Endocrinol.</source> <volume>417</volume>, <fpage>52</fpage>&#x2013;<lpage>62</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2015.09.004</pub-id>
</citation>
</ref>
<ref id="B18">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chai</surname>
<given-names>J. W.</given-names>
</name>
<name>
<surname>Lim</surname>
<given-names>S. L.</given-names>
</name>
<name>
<surname>Kanthimathi</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Kuppusamy</surname>
<given-names>U. R.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Gene regulation in &#x3b2;-sitosterol-mediated stimulation of adipogenesis, glucose uptake, and lipid mobilization in rat primary adipocytes</article-title>. <source>Genes Nutr.</source> <volume>6</volume> (<issue>2</issue>), <fpage>181</fpage>&#x2013;<lpage>188</lpage>. <pub-id pub-id-type="doi">10.1007/s12263-010-0196-4</pub-id>
</citation>
</ref>
<ref id="B19">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>Y.-C.</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>M.-H.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.-F.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Hsiao</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Glucose transporter 4: insulin response mastermind, glycolysis catalyst and treatment direction for cancer progression</article-title>. <source>Cancer Lett.</source> <volume>563</volume>, <fpage>216179</fpage>. <pub-id pub-id-type="doi">10.1016/j.canlet.2023.216179</pub-id>
</citation>
</ref>
<ref id="B20">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Abaydula</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Taurine ameliorates oxidative stress by regulating PI3K/Akt/GLUT4 pathway in HepG2 cells and diabetic rats</article-title>. <source>J. Funct. Foods</source> <volume>85</volume>, <fpage>104629</fpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2021.104629</pub-id>
</citation>
</ref>
<ref id="B21">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>New insights into the biological activities of Chrysanthemum morifolium: natural flavonoids alleviate diabetes by targeting &#x3b1;-glucosidase and the PTP-1B signaling pathway</article-title>. <source>Eur. J. Med. Chem.</source> <volume>178</volume>, <fpage>108</fpage>&#x2013;<lpage>115</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2019.05.083</pub-id>
</citation>
</ref>
<ref id="B22">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Effects of resveratrol on the amelioration of insulin resistance in KKAy mice</article-title>. <source>Can. J. Physiol. Pharmacol.</source> <volume>90</volume> (<issue>2</issue>), <fpage>237</fpage>&#x2013;<lpage>242</lpage>. <pub-id pub-id-type="doi">10.1139/y11-123</pub-id>
</citation>
</ref>
<ref id="B23">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cheng</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Quercetin and d-chiro-inositol combined alleviate hepatic insulin resistance</article-title>. <source>Food Biosci.</source> <volume>43</volume>, <fpage>101255</fpage>. <pub-id pub-id-type="doi">10.1016/j.fbio.2021.101255</pub-id>
</citation>
</ref>
<ref id="B24">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chi</surname>
<given-names>T. C.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W. P.</given-names>
</name>
<name>
<surname>Chi</surname>
<given-names>T. L.</given-names>
</name>
<name>
<surname>Kuo</surname>
<given-names>T. F.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>J. T.</given-names>
</name>
<etal/>
</person-group> (<year>2007</year>). <article-title>Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats</article-title>. <source>Life Sci.</source> <volume>80</volume> (<issue>18</issue>), <fpage>1713</fpage>&#x2013;<lpage>1720</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2007.02.002</pub-id>
</citation>
</ref>
<ref id="B25">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pedersen</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Kongstad</surname>
<given-names>K. T.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Staerk</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Antidiabetic constituents of Dendrobium officinale as determined by high-resolution profiling of radical scavenging and &#x3b1;-glucosidase and &#x3b1;-amylase inhibition combined with HPLC-PDA-HRMS-SPE-NMR analysis</article-title>. <source>Phytochem. Lett.</source> <volume>31</volume>, <fpage>47</fpage>&#x2013;<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/j.phytol.2019.03.002</pub-id>
</citation>
</ref>
<ref id="B26">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cui</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Aloin protects against chronic alcoholic liver injury via attenuating lipid accumulation, oxidative stress and inflammation in mice</article-title>. <source>Arch. Pharm. Res.</source> <volume>37</volume> (<issue>12</issue>), <fpage>1624</fpage>&#x2013;<lpage>1633</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-014-0370-0</pub-id>
</citation>
</ref>
<ref id="B27">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dai</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Ginsenoside Rb2 promotes glucose metabolism and attenuates fat accumulation via AKT-dependent mechanisms</article-title>. <source>Biomed. Pharmacother.</source> <volume>100</volume>, <fpage>93</fpage>&#x2013;<lpage>100</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2018.01.111</pub-id>
</citation>
</ref>
<ref id="B28">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Das</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vasan</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Sil</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Taurine exerts hypoglycemic effect in alloxan-induced diabetic rats, improves insulin-mediated glucose transport signaling pathway in heart and ameliorates cardiac oxidative stress and apoptosis</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>258</volume> (<issue>2</issue>), <fpage>296</fpage>&#x2013;<lpage>308</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2011.11.009</pub-id>
</citation>
</ref>
<ref id="B29">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deng</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>J. P.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>L. S.</given-names>
</name>
<name>
<surname>Hung</surname>
<given-names>L. M.</given-names>
</name>
</person-group> (<year>2008</year>). <article-title>Activation of estrogen receptor is crucial for resveratrol-stimulating muscular glucose uptake via both insulin-dependent and -independent pathways</article-title>. <source>Diabetes</source> <volume>57</volume> (<issue>7</issue>), <fpage>1814</fpage>&#x2013;<lpage>1823</lpage>. <pub-id pub-id-type="doi">10.2337/db07-1750</pub-id>
</citation>
</ref>
<ref id="B30">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dewanjee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chakraborty</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Bhattacharya</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chacko</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chaudhary</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Altered glucose metabolism in Alzheimer&#x27;s disease: role of mitochondrial dysfunction and oxidative stress</article-title>. <source>Free Radic. Biol. Med.</source> <volume>193</volume> (<issue>Pt 1</issue>), <fpage>134</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.09.032</pub-id>
</citation>
</ref>
<ref id="B31">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dhanya</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Quercetin for managing type 2 diabetes and its complications, an insight into multitarget therapy</article-title>. <source>Biomed. Pharmacother.</source> <volume>146</volume>, <fpage>112560</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112560</pub-id>
</citation>
</ref>
<ref id="B32">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Loureirin B attenuates insulin resistance in HepG2 cells by regulating gluconeogenesis signaling pathway</article-title>. <source>Eur. J. Pharmacol.</source> <volume>910</volume>, <fpage>174481</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2021.174481</pub-id>
</citation>
</ref>
<ref id="B33">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>I. S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Astragaloside IV inhibits adipose lipolysis and reduces hepatic glucose production via akt dependent PDE3B expression in HFD-fed mice</article-title>. <source>Front. Physiol.</source> <volume>9</volume>, <fpage>15</fpage>. <pub-id pub-id-type="doi">10.3389/fphys.2018.00015</pub-id>
</citation>
</ref>
<ref id="B34">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Durg</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Veerapur</surname>
<given-names>V. P.</given-names>
</name>
<name>
<surname>Neelima</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Dhadde</surname>
<given-names>S. B.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Antidiabetic activity of Embelia ribes, embelin and its derivatives: a systematic review and meta-analysis</article-title>. <source>Biomed. Pharmacother.</source> <volume>86</volume>, <fpage>195</fpage>&#x2013;<lpage>204</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2016.12.001</pub-id>
</citation>
</ref>
<ref id="B35">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elango</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dornadula</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Paulmurugan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Ramkumar</surname>
<given-names>K. M.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Pterostilbene ameliorates streptozotocin-induced diabetes through enhancing antioxidant signaling pathways mediated by Nrf2</article-title>. <source>Chem. Res. Toxicol.</source> <volume>29</volume> (<issue>1</issue>), <fpage>47</fpage>&#x2013;<lpage>57</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.5b00378</pub-id>
</citation>
</ref>
<ref id="B36">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elekofehinti</surname>
<given-names>O. O.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Saponins: anti-diabetic principles from medicinal plants - a review</article-title>. <source>Pathophysiology</source> <volume>22</volume> (<issue>2</issue>), <fpage>95</fpage>&#x2013;<lpage>103</lpage>. <pub-id pub-id-type="doi">10.1016/j.pathophys.2015.02.001</pub-id>
</citation>
</ref>
<ref id="B37">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>The glucuronide metabolites of kaempferol and quercetin, targeting to the AKT PH domain, activate AKT/GSK3&#x3b2; signaling pathway and improve glucose metabolism</article-title>. <source>J. Funct. Foods</source> <volume>82</volume>, <fpage>104501</fpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2021.104501</pub-id>
</citation>
</ref>
<ref id="B38">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Niu</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Loureirin B promotes insulin secretion through GLP-1R and AKT/PDX1 pathways</article-title>. <source>Eur. J. Pharmacol.</source> <volume>936</volume>, <fpage>175377</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.175377</pub-id>
</citation>
</ref>
<ref id="B39">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fang</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>C.-H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>T.-H.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>S.-Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>
<italic>In vivo</italic> rodent models of type 2 diabetes and their usefulness for evaluating flavonoid bioactivity</article-title>. <source>Nutrients</source> <volume>11</volume> (<issue>3</issue>), <fpage>530</fpage>. <pub-id pub-id-type="doi">10.3390/nu11030530</pub-id>
</citation>
</ref>
<ref id="B40">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fruman</surname>
<given-names>D. A.</given-names>
</name>
<name>
<surname>Chiu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>B. D.</given-names>
</name>
<name>
<surname>Bagrodia</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>L. C.</given-names>
</name>
<name>
<surname>Abraham</surname>
<given-names>R. T.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>The PI3K pathway in human disease</article-title>. <source>Cell</source> <volume>170</volume> (<issue>4</issue>), <fpage>605</fpage>&#x2013;<lpage>635</lpage>. <pub-id pub-id-type="doi">10.1016/j.cell.2017.07.029</pub-id>
</citation>
</ref>
<ref id="B41">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Jia</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Gilbert</surname>
<given-names>E.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Baicalein protects against type 2 diabetes via promoting islet &#x3b2;-cell function in obese diabetic mice</article-title>. <source>Int. J. Endocrinol.</source> <volume>2014</volume>, <fpage>846742</fpage>. <pub-id pub-id-type="doi">10.1155/2014/846742</pub-id>
</citation>
</ref>
<ref id="B42">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandhi</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Jothi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Antony</surname>
<given-names>P. J.</given-names>
</name>
<name>
<surname>Balakrishna</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Paulraj</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Ignacimuthu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPAR&#x3b3; in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway</article-title>. <source>Eur. J. Pharmacol.</source> <volume>745</volume>, <fpage>201</fpage>&#x2013;<lpage>216</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2014.10.044</pub-id>
</citation>
</ref>
<ref id="B43">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gandhi</surname>
<given-names>G. R.</given-names>
</name>
<name>
<surname>Stalin</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Balakrishna</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ignacimuthu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Paulraj</surname>
<given-names>M. G.</given-names>
</name>
<name>
<surname>Vishal</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Insulin sensitization via partial agonism of PPAR&#x3b3; and glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway by embelin in type 2 diabetic rats</article-title>. <source>Biochim. Biophys. Acta</source> <volume>1830</volume> (<issue>1</issue>), <fpage>2243</fpage>&#x2013;<lpage>2255</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbagen.2012.10.016</pub-id>
</citation>
</ref>
<ref id="B44">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ge</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Qin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Lou</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Fisetin supplementation prevents high fat diet-induced diabetic nephropathy by repressing insulin resistance and RIP3-regulated inflammation</article-title>. <source>Food and Funct.</source> <volume>10</volume> (<issue>5</issue>), <fpage>2970</fpage>&#x2013;<lpage>2985</lpage>. <pub-id pub-id-type="doi">10.1039/c8fo01653d</pub-id>
</citation>
</ref>
<ref id="B45">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ghosh</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rajanan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Suresh</surname>
<given-names>A. J.</given-names>
</name>
<name>
<surname>Raut</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Kundu</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Natural coumarins: preclinical evidence-based potential candidates to alleviate diabetic nephropathy</article-title>. <source>Phytomedicine Plus</source> <volume>2</volume> (<issue>4</issue>), <fpage>100379</fpage>. <pub-id pub-id-type="doi">10.1016/j.phyplu.2022.100379</pub-id>
</citation>
</ref>
<ref id="B46">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Diosmetin ameliorate type 2 diabetic mellitus by up-regulating Corynebacterium glutamicum to regulate IRS/PI3K/AKT-mediated glucose metabolism disorder in KK-Ay mice</article-title>. <source>Phytomedicine</source> <volume>87</volume>, <fpage>153582</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2021.153582</pub-id>
</citation>
</ref>
<ref id="B47">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gregersen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jeppesen</surname>
<given-names>P. B.</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Hermansen</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Antihyperglycemic effects of stevioside in type 2 diabetic subjects</article-title>. <source>Metabolism</source> <volume>53</volume> (<issue>1</issue>), <fpage>73</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1016/j.metabol.2003.07.013</pub-id>
</citation>
</ref>
<ref id="B48">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hajiaghaalipour</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Khalilpourfarshbafi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Arya</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Modulation of glucose transporter protein by dietary flavonoids in type 2 diabetes mellitus</article-title>. <source>Int. J. Biol. Sci.</source> <volume>11</volume> (<issue>5</issue>), <fpage>508</fpage>&#x2013;<lpage>524</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.11241</pub-id>
</citation>
</ref>
<ref id="B49">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>An</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2015</year>). <article-title>Curcumin attenuates palmitate-induced apoptosis in MIN6 pancreatic &#x3b2;-cells through PI3K/Akt/FoxO1 and mitochondrial survival pathways</article-title>. <source>Apoptosis</source> <volume>20</volume> (<issue>11</issue>), <fpage>1420</fpage>&#x2013;<lpage>1432</lpage>. <pub-id pub-id-type="doi">10.1007/s10495-015-1150-0</pub-id>
</citation>
</ref>
<ref id="B50">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hay</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Akt isoforms and glucose homeostasis - the leptin connection</article-title>. <source>Trends Endocrinol. Metab.</source> <volume>22</volume> (<issue>2</issue>), <fpage>66</fpage>&#x2013;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1016/j.tem.2010.09.003</pub-id>
</citation>
</ref>
<ref id="B51">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hong</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>D. G.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>D. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C. H.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Effects of resveratrol on the insulin signaling pathway of obese mice</article-title>. <source>J. Vet. Sci.</source> <volume>15</volume> (<issue>2</issue>), <fpage>179</fpage>&#x2013;<lpage>185</lpage>. <pub-id pub-id-type="doi">10.4142/jvs.2014.15.2.179</pub-id>
</citation>
</ref>
<ref id="B52">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Xi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Hirsutine ameliorates hepatic and cardiac insulin resistance in high-fat diet-induced diabetic mice and <italic>in vitro</italic> models</article-title>. <source>Pharmacol. Res.</source> <volume>177</volume>, <fpage>105917</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2021.105917</pub-id>
</citation>
</ref>
<ref id="B53">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>D. W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>W. C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J. S.</given-names>
</name>
<name>
<surname>Shih</surname>
<given-names>R. W.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>S. C.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Gallic acid ameliorates hyperglycemia and improves hepatic carbohydrate metabolism in rats fed a high-fructose diet</article-title>. <source>Nutr. Res.</source> <volume>36</volume> (<issue>2</issue>), <fpage>150</fpage>&#x2013;<lpage>160</lpage>. <pub-id pub-id-type="doi">10.1016/j.nutres.2015.10.001</pub-id>
</citation>
</ref>
<ref id="B54">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Ko</surname>
<given-names>C. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C. T.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>A comparison of food-grade folium mori (sang ye) extract and 1-deoxynojirimycin for glycemic control and renal function in streptozotocin-induced diabetic rats</article-title>. <source>J. Tradit. Complement. Med.</source> <volume>4</volume> (<issue>3</issue>), <fpage>162</fpage>&#x2013;<lpage>170</lpage>. <pub-id pub-id-type="doi">10.4103/2225-4110.131639</pub-id>
</citation>
</ref>
<ref id="B55">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>The PI3K/AKT pathway in obesity and type 2 diabetes</article-title>. <source>Int. J. Biol. Sci.</source> <volume>14</volume> (<issue>11</issue>), <fpage>1483</fpage>&#x2013;<lpage>1496</lpage>. <pub-id pub-id-type="doi">10.7150/ijbs.27173</pub-id>
</citation>
</ref>
<ref id="B56">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inam</surname>
<given-names>U. L.</given-names>
</name>
<name>
<surname>Piao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Aadil</surname>
<given-names>R. M.</given-names>
</name>
<name>
<surname>Suleman</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Ameliorative effects of taurine against diabetes: a review</article-title>. <source>Amino Acids</source> <volume>50</volume> (<issue>5</issue>), <fpage>487</fpage>&#x2013;<lpage>502</lpage>. <pub-id pub-id-type="doi">10.1007/s00726-018-2544-4</pub-id>
</citation>
</ref>
<ref id="B57">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jahandideh</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>A review on mechanisms of action of bioactive peptides against glucose intolerance and insulin resistance</article-title>. <source>Food Sci. Hum. Wellness</source> <volume>11</volume> (<issue>6</issue>), <fpage>1441</fpage>&#x2013;<lpage>1454</lpage>. <pub-id pub-id-type="doi">10.1016/j.fshw.2022.06.001</pub-id>
</citation>
</ref>
<ref id="B58">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shaukat</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Barbaloin protects against lipopolysaccharide (LPS)-induced acute lung injury by inhibiting the ROS-mediated PI3K/AKT/NF-&#x3ba;B pathway</article-title>. <source>Int. Immunopharmacol.</source> <volume>64</volume>, <fpage>140</fpage>&#x2013;<lpage>150</lpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2018.08.023</pub-id>
</citation>
</ref>
<ref id="B59">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jiang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Hirsutine ameliorates myocardial ischemia-reperfusion injury through improving mitochondrial function via CaMKII pathway</article-title>. <source>Clin. Exp. Hypertens.</source> <volume>45</volume> (<issue>1</issue>), <fpage>2192444</fpage>. <pub-id pub-id-type="doi">10.1080/10641963.2023.2192444</pub-id>
</citation>
</ref>
<ref id="B60">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jitrapakdee</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Transcription factors and coactivators controlling nutrient and hormonal regulation of hepatic gluconeogenesis</article-title>. <source>Int. J. Biochem. Cell Biol.</source> <volume>44</volume> (<issue>1</issue>), <fpage>33</fpage>&#x2013;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1016/j.biocel.2011.10.001</pub-id>
</citation>
</ref>
<ref id="B61">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jung</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Seong</surname>
<given-names>S. H.</given-names>
</name>
<name>
<surname>Ali</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Min</surname>
<given-names>B. S.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H. A.</given-names>
</name>
<name>
<surname>Choi</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>&#x3b1;-Methyl artoflavanocoumarin from Juniperus chinensis exerts anti-diabetic effects by inhibiting PTP1B and activating the PI3K/Akt signaling pathway in insulin-resistant HepG2 cells</article-title>. <source>Arch. Pharm. Res.</source> <volume>40</volume> (<issue>12</issue>), <fpage>1403</fpage>&#x2013;<lpage>1413</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-017-0992-0</pub-id>
</citation>
</ref>
<ref id="B62">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kalaiarasi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kaviarasan</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Pugalendi</surname>
<given-names>K. V.</given-names>
</name>
</person-group> (<year>2009</year>). <article-title>Hypolipidemic activity of 18beta-glycyrrhetinic acid on streptozotocin-induced diabetic rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>612</volume> (<issue>1-3</issue>), <fpage>93</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2009.04.003</pub-id>
</citation>
</ref>
<ref id="B63">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>C. W.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>H. J.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Mulberry (morus alba L.) leaf extract and 1-deoxynojirimycin improve skeletal muscle insulin resistance via the activation of IRS-1/PI3K/akt pathway in db/db mice</article-title>. <source>Life (Basel)</source> <volume>12</volume> (<issue>10</issue>), <fpage>1630</fpage>. <pub-id pub-id-type="doi">10.3390/life12101630</pub-id>
</citation>
</ref>
<ref id="B64">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kang</surname>
<given-names>K. S.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J. H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Eom</surname>
<given-names>D.-W.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Protective effect of esculin on streptozotocin-induced diabetic renal damage in mice</article-title>. <source>J. Agric. Food Chem.</source> <volume>62</volume> (<issue>9</issue>), <fpage>2069</fpage>&#x2013;<lpage>2076</lpage>. <pub-id pub-id-type="doi">10.1021/jf403840c</pub-id>
</citation>
</ref>
<ref id="B65">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kashyap</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Shikha</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Thakur</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Aneja</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Functionality of apigenin as a potent antioxidant with emphasis on bioavailability, metabolism, action mechanism and <italic>in vitro</italic> and <italic>in vivo</italic> studies: a review</article-title>. <source>J. Food Biochem.</source> <volume>46</volume> (<issue>4</issue>), <fpage>e13950</fpage>. <pub-id pub-id-type="doi">10.1111/jfbc.13950</pub-id>
</citation>
</ref>
<ref id="B66">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>G. W.</given-names>
</name>
<name>
<surname>Imm</surname>
<given-names>J. Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Promotion of glucose uptake in C2C12 myotubes by cereal flavone tricin and its underlying molecular mechanism</article-title>. <source>J. Agric. Food Chem.</source> <volume>65</volume> (<issue>19</issue>), <fpage>3819</fpage>&#x2013;<lpage>3826</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.7b00578</pub-id>
</citation>
</ref>
<ref id="B67">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Rouse</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Gonzalez-Mariscal</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Egan</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>O&#x27;Connell</surname>
<given-names>J. F.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Dietary curcumin enhances insulin clearance in diet-induced obese mice via regulation of hepatic PI3K-AKT axis and IDE, and preservation of islet integrity</article-title>. <source>Nutr. Metab. (Lond)</source> <volume>16</volume>, <fpage>48</fpage>. <pub-id pub-id-type="doi">10.1186/s12986-019-0377-0</pub-id>
</citation>
</ref>
<ref id="B68">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Knop</surname>
<given-names>F. K.</given-names>
</name>
<name>
<surname>Konings</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Timmers</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Schrauwen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Holst</surname>
<given-names>J. J.</given-names>
</name>
<name>
<surname>Blaak</surname>
<given-names>E. E.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects</article-title>. <source>Diabet. Med.</source> <volume>30</volume> (<issue>10</issue>), <fpage>1214</fpage>&#x2013;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1111/dme.12231</pub-id>
</citation>
</ref>
<ref id="B69">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Go</surname>
<given-names>G.-W.</given-names>
</name>
<name>
<surname>Imm</surname>
<given-names>J.-Y.</given-names>
</name>
</person-group> (<year>2016</year>). <article-title>Tricin, a methylated cereal flavone, suppresses fat accumulation by downregulating AKT and mTOR in 3T3-L1 preadipocytes</article-title>. <source>J. Funct. Foods</source> <volume>26</volume>, <fpage>548</fpage>&#x2013;<lpage>556</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2016.08.023</pub-id>
</citation>
</ref>
<ref id="B70">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>H. Y.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Bang</surname>
<given-names>M.-H.</given-names>
</name>
<name>
<surname>Imm</surname>
<given-names>J.-Y.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Anti-adipogenic effect of oat hull extract containing tricin on 3T3-L1 adipocytes</article-title>. <source>Process Biochem.</source> <volume>50</volume> (<issue>12</issue>), <fpage>2314</fpage>&#x2013;<lpage>2321</lpage>. <pub-id pub-id-type="doi">10.1016/j.procbio.2015.09.019</pub-id>
</citation>
</ref>
<ref id="B71">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Anti-diabetic effect of hydroxybenzoic acid derivatives in free fatty acid-induced HepG2 cells via miR-1271/IRS1/PI3K/AKT/FOXO1 pathway</article-title>. <source>J. Food Biochem.</source> <volume>45</volume> (<issue>12</issue>), <fpage>e13993</fpage>. <pub-id pub-id-type="doi">10.1111/jfbc.13993</pub-id>
</citation>
</ref>
<ref id="B72">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Poncirin ameliorates cardiac ischemia-reperfusion injury by activating PI3K/AKT/PGC-1&#x3b1; signaling</article-title>. <source>Eur. J. Pharmacol.</source> <volume>917</volume>, <fpage>174759</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.174759</pub-id>
</citation>
</ref>
<ref id="B73">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Ding</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Curcumin metabolites contribute to the effect of curcumin on ameliorating insulin sensitivity in high-glucose-induced insulin-resistant HepG2 cells</article-title>. <source>J. Ethnopharmacol.</source> <volume>259</volume>, <fpage>113015</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.113015</pub-id>
</citation>
</ref>
<ref id="B74">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>1-Deoxynojirimycin modulates glucose homeostasis by regulating the combination of IR-GlUT4 and ADIPO-GLUT4 pathways in 3T3-L1 adipocytes</article-title>. <source>Mol. Biol. Rep.</source> <volume>46</volume> (<issue>6</issue>), <fpage>6277</fpage>&#x2013;<lpage>6285</lpage>. <pub-id pub-id-type="doi">10.1007/s11033-019-05069-y</pub-id>
</citation>
</ref>
<ref id="B75">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Ling</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Exploring the underlying mechanisms of fisetin in the treatment of hepatic insulin resistance via network pharmacology and <italic>in vitro</italic> validation</article-title>. <source>Nutr. Metabolism</source> <volume>20</volume> (<issue>1</issue>), <fpage>51</fpage>. <pub-id pub-id-type="doi">10.1186/s12986-023-00770-z</pub-id>
</citation>
</ref>
<ref id="B76">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>W. L.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H. C.</given-names>
</name>
<name>
<surname>Bukuru</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>De Kimpe</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2004</year>). <article-title>Natural medicines used in the traditional Chinese medical system for therapy of diabetes mellitus</article-title>. <source>J. Ethnopharmacol.</source> <volume>92</volume> (<issue>1</issue>), <fpage>1</fpage>&#x2013;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2003.12.031</pub-id>
</citation>
</ref>
<ref id="B77">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Geng-Ji</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>L.-M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Q.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Role of potential bioactive metabolites from traditional Chinese medicine for type 2 diabetes mellitus: an overview</article-title>. <source>Front. Pharmacol.</source> <volume>13</volume>, <fpage>1023713</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2022.1023713</pub-id>
</citation>
</ref>
<ref id="B78">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Gu</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Yamahara</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Oleanolic acid supplement attenuates liquid fructose-induced adipose tissue insulin resistance through the insulin receptor substrate-1/phosphatidylinositol 3-kinase/Akt signaling pathway in rats</article-title>. <source>Toxicol. Appl. Pharmacol.</source> <volume>277</volume> (<issue>2</issue>), <fpage>155</fpage>&#x2013;<lpage>163</lpage>. <pub-id pub-id-type="doi">10.1016/j.taap.2014.03.016</pub-id>
</citation>
</ref>
<ref id="B79">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Shangguan</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Puerarin protects pancreatic &#x3b2;-cell survival via PI3K/Akt signaling pathway</article-title>. <source>J. Mol. Endocrinol.</source> <volume>53</volume> (<issue>1</issue>), <fpage>71</fpage>&#x2013;<lpage>79</lpage>. <pub-id pub-id-type="doi">10.1530/JME-13-0302</pub-id>
</citation>
</ref>
<ref id="B80">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yao</surname>
<given-names>K.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Tetramethylpyrazine: a review on its mechanisms and functions</article-title>. <source>Biomed. Pharmacother.</source> <volume>150</volume>, <fpage>113005</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.113005</pub-id>
</citation>
</ref>
<ref id="B81">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lin</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Zeng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Naringenin protects pancreatic &#x3b2; cells in diabetic rat through activation of estrogen receptor &#x3b2;</article-title>. <source>Eur. J. Pharmacol.</source> <volume>960</volume>, <fpage>176115</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2023.176115</pub-id>
</citation>
</ref>
<ref id="B82">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Guan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sun-Waterhouse</surname>
<given-names>D.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Enhanced alleviation of insulin resistance via the IRS-1/Akt/FOXO1 pathway by combining quercetin and EGCG and involving miR-27a-3p and miR-96&#x2013;5p</article-title>. <source>Free Radic. Biol. Med.</source> <volume>181</volume>, <fpage>105</fpage>&#x2013;<lpage>117</lpage>. <pub-id pub-id-type="doi">10.1016/j.freeradbiomed.2022.02.002</pub-id>
</citation>
</ref>
<ref id="B83">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.-P.</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>L.-F.</given-names>
</name>
<name>
<surname>Shang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.-B.</given-names>
</name>
<etal/>
</person-group> (<year>2014</year>). <article-title>Maslinic acid modulates glycogen metabolism by enhancing the insulin signaling pathway and inhibiting glycogen phosphorylase</article-title>. <source>Chin. J. Nat. Med.</source> <volume>12</volume> (<issue>4</issue>), <fpage>259</fpage>&#x2013;<lpage>265</lpage>. <pub-id pub-id-type="doi">10.1016/S1875-5364(14)60052-2</pub-id>
</citation>
</ref>
<ref id="B84">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Inhibition of the pyroptosis-associated inflammasome pathway: the important potential mechanism of ginsenosides in ameliorating diabetes and its complications</article-title>. <source>Eur. J. Med. Chem.</source> <volume>253</volume>, <fpage>115336</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejmech.2023.115336</pub-id>
</citation>
</ref>
<ref id="B85">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>G.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>1-Deoxynojirimycin alleviates insulin resistance via activation of insulin signaling PI3K/AKT pathway in skeletal muscle of db/db mice</article-title>. <source>Molecules</source> <volume>20</volume> (<issue>12</issue>), <fpage>21700</fpage>&#x2013;<lpage>21714</lpage>. <pub-id pub-id-type="doi">10.3390/molecules201219794</pub-id>
</citation>
</ref>
<ref id="B86">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>J.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Synergetic HepG2 cells suppression efficacy of Tripterygium wilfordii and Scutellaria barbata through EGFR/PI3K/Akt pathway</article-title>. <source>Pharmacol. Res. - Mod. Chin. Med.</source> <volume>4</volume>, <fpage>100130</fpage>. <pub-id pub-id-type="doi">10.1016/j.prmcm.2022.100130</pub-id>
</citation>
</ref>
<ref id="B87">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Mogroside derivatives exert hypoglycemics effects by decreasing blood glucose level in HepG2 cells and alleviates insulin resistance in T2DM rats</article-title>. <source>J. Funct. Foods</source> <volume>63</volume>, <fpage>103566</fpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2019.103566</pub-id>
</citation>
</ref>
<ref id="B88">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Puerarin suppresses the hepatic gluconeogenesis via activation of PI3K/Akt signaling pathway in diabetic rats and HepG(2) cells</article-title>. <source>Biomed. Pharmacother.</source> <volume>137</volume>, <fpage>111325</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111325</pub-id>
</citation>
</ref>
<ref id="B89">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lv</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.-F.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Pang</surname>
<given-names>J.-X.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.-Q.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Effect of astragaloside IV on hepatic glucose-regulating enzymes in diabetic mice induced by a high-fat diet and streptozotocin</article-title>. <source>Phytotherapy Res.</source> <volume>24</volume> (<issue>2</issue>), <fpage>219</fpage>&#x2013;<lpage>224</lpage>. <pub-id pub-id-type="doi">10.1002/ptr.2915</pub-id>
</citation>
</ref>
<ref id="B90">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maki</surname>
<given-names>K. C.</given-names>
</name>
<name>
<surname>Curry</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Reeves</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Toth</surname>
<given-names>P. D.</given-names>
</name>
<name>
<surname>McKenney</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Farmer</surname>
<given-names>M. V.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus</article-title>. <source>Food Chem. Toxicol.</source> <volume>46</volume> (<issue>7</issue>), <fpage>S47</fpage>&#x2013;<lpage>S53</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2008.05.007</pub-id>
</citation>
</ref>
<ref id="B91">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Malik</surname>
<given-names>S. A.</given-names>
</name>
<name>
<surname>Acharya</surname>
<given-names>J. D.</given-names>
</name>
<name>
<surname>Mehendale</surname>
<given-names>N. K.</given-names>
</name>
<name>
<surname>Kamat</surname>
<given-names>S. S.</given-names>
</name>
<name>
<surname>Ghaskadbi</surname>
<given-names>S. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Pterostilbene reverses palmitic acid mediated insulin resistance in HepG2 cells by reducing oxidative stress and triglyceride accumulation</article-title>. <source>Free Radic. Res.</source> <volume>53</volume> (<issue>7</issue>), <fpage>815</fpage>&#x2013;<lpage>827</lpage>. <pub-id pub-id-type="doi">10.1080/10715762.2019.1635252</pub-id>
</citation>
</ref>
<ref id="B92">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Development of PI3K inhibitors: advances in clinical trials and new strategies (Review)</article-title>. <source>Pharmacol. Res.</source> <volume>173</volume>, <fpage>105900</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2021.105900</pub-id>
</citation>
</ref>
<ref id="B93">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meng</surname>
<given-names>F.-D.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>D.-J.</given-names>
</name>
<name>
<surname>Che</surname>
<given-names>M.-Y.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>S.-Z.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>D.-D.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Exploring the targets and molecular mechanism of glycyrrhetinic acid against diabetic nephropathy based on network pharmacology and molecular docking</article-title>. <source>World J. Diabetes</source> <volume>14</volume> (<issue>11</issue>), <fpage>1672</fpage>&#x2013;<lpage>1692</lpage>. <pub-id pub-id-type="doi">10.4239/wjd.v14.i11.1672</pub-id>
</citation>
</ref>
<ref id="B94">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Miao</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Cheong</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Garcia-Oliveira</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Prieto</surname>
<given-names>M. A.</given-names>
</name>
<etal/>
</person-group> (<year>2023</year>). <article-title>Anti-diabetic potential of apigenin, luteolin, and baicalein via partially activating PI3K/Akt/Glut-4 signaling pathways in insulin-resistant HepG2 cells</article-title>. <source>Food Sci. Hum. Wellness</source> <volume>12</volume> (<issue>6</issue>), <fpage>1991</fpage>&#x2013;<lpage>2000</lpage>. <pub-id pub-id-type="doi">10.1016/j.fshw.2023.03.021</pub-id>
</citation>
</ref>
<ref id="B95">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mirza-Aghazadeh-Attari</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ekrami</surname>
<given-names>E. M.</given-names>
</name>
<name>
<surname>Aghdas</surname>
<given-names>S. A. M.</given-names>
</name>
<name>
<surname>Mihanfar</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hallaj</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Yousefi</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: implication for cancer therapy</article-title>. <source>Life Sci.</source> <volume>255</volume>, <fpage>117481</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2020.117481</pub-id>
</citation>
</ref>
<ref id="B96">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mo</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Coumarins ameliorate diabetogenic action of dexamethasone via Akt activation and AMPK signaling in skeletal muscle</article-title>. <source>J. Pharmacol. Sci.</source> <volume>139</volume> (<issue>3</issue>), <fpage>151</fpage>&#x2013;<lpage>157</lpage>. <pub-id pub-id-type="doi">10.1016/j.jphs.2019.01.001</pub-id>
</citation>
</ref>
<ref id="B97">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohammed</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tajuddeen</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ibrahim</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Isah</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Aliyu</surname>
<given-names>A. B.</given-names>
</name>
<name>
<surname>Islam</surname>
<given-names>M. S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Potential of diterpenes as antidiabetic agents: evidence from clinical and pre-clinical studies</article-title>. <source>Pharmacol. Res.</source> <volume>179</volume>, <fpage>106158</fpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106158</pub-id>
</citation>
</ref>
<ref id="B98">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moore</surname>
<given-names>W. T.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Kaempferol improves glucose uptake in skeletal muscle via an AMPK-dependent mechanism</article-title>. <source>Food Sci. Hum. Wellness</source> <volume>12</volume> (<issue>6</issue>), <fpage>2087</fpage>&#x2013;<lpage>2094</lpage>. <pub-id pub-id-type="doi">10.1016/j.fshw.2023.03.028</pub-id>
</citation>
</ref>
<ref id="B99">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naseem</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ahmad</surname>
<given-names>M. F.</given-names>
</name>
<name>
<surname>Imam</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ahsan</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Siddiqui</surname>
<given-names>W. A.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>The potential of esculin as a therapeutic modality in diabetes mellitus and its complications</article-title>. <source>Hum. Nutr. Metabolism</source> <volume>33</volume>, <fpage>200207</fpage>. <pub-id pub-id-type="doi">10.1016/j.hnm.2023.200207</pub-id>
</citation>
</ref>
<ref id="B100">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naz</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Imran</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Rauf</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Orhan</surname>
<given-names>I. E.</given-names>
</name>
<name>
<surname>Shariati</surname>
<given-names>M. A.</given-names>
</name>
<name>
<surname>Iahtisham Ul</surname>
<given-names>H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Chrysin: pharmacological and therapeutic properties</article-title>. <source>Life Sci.</source> <volume>235</volume>, <fpage>116797</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.116797</pub-id>
</citation>
</ref>
<ref id="B101">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nirmalan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Nirmalan</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Hormonal control of metabolism: regulation of plasma glucose</article-title>. <source>Anaesth. Intensive Care Med.</source> <volume>24</volume> (<issue>10</issue>), <fpage>618</fpage>&#x2013;<lpage>623</lpage>. <pub-id pub-id-type="doi">10.1016/j.mpaic.2023.07.001</pub-id>
</citation>
</ref>
<ref id="B102">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Norton</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gastaldelli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>DeFronzo</surname>
<given-names>R. A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Insulin: the master regulator of glucose metabolism</article-title>. <source>Metabolism</source> <volume>129</volume>, <fpage>155142</fpage>. <pub-id pub-id-type="doi">10.1016/j.metabol.2022.155142</pub-id>
</citation>
</ref>
<ref id="B103">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nurcahyanti</surname>
<given-names>A. D. R.</given-names>
</name>
<name>
<surname>Jap</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Lady</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Prismawan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Sharopov</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Daoud</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Function of selected natural antidiabetic compounds with potential against cancer via modulation of the PI3K/AKT/mTOR cascade</article-title>. <source>Biomed. Pharmacother.</source> <volume>144</volume>, <fpage>112138</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.112138</pub-id>
</citation>
</ref>
<ref id="B104">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Onyango</surname>
<given-names>A. N.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Excessive gluconeogenesis causes the hepatic insulin resistance paradox and its sequelae</article-title>. <source>Heliyon</source> <volume>8</volume> (<issue>12</issue>), <fpage>e12294</fpage>. <pub-id pub-id-type="doi">10.1016/j.heliyon.2022.e12294</pub-id>
</citation>
</ref>
<ref id="B105">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Orhan</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Berkkan</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Deliorman Orhan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Aslan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ergun</surname>
<given-names>F.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Effects of Juniperus oxycedrus ssp. oxycedrus on tissue lipid peroxidation, trace elements (Cu, Zn, Fe) and blood glucose levels in experimental diabetes</article-title>. <source>J. Ethnopharmacol.</source> <volume>133</volume> (<issue>2</issue>), <fpage>759</fpage>&#x2013;<lpage>764</lpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2010.11.002</pub-id>
</citation>
</ref>
<ref id="B106">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pari</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Satheesh</surname>
<given-names>M. A.</given-names>
</name>
</person-group> (<year>2006</year>). <article-title>Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotinamide-induced diabetic rats</article-title>. <source>Life Sci.</source> <volume>79</volume> (<issue>7</issue>), <fpage>641</fpage>&#x2013;<lpage>645</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2006.02.036</pub-id>
</citation>
</ref>
<ref id="B107">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J.-E.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J.-S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>HM-chromanone, a major homoisoflavonoid in Portulaca oleracea L., improves palmitate-induced insulin resistance by regulating phosphorylation of IRS-1 residues in L6 skeletal muscle cells</article-title>. <source>Nutrients</source> <volume>14</volume> (<issue>18</issue>), <fpage>3815</fpage>. <pub-id pub-id-type="doi">10.3390/nu14183815</pub-id>
</citation>
</ref>
<ref id="B108">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>HM-chromanone reverses the blockade of insulin signaling induced by high glucose levels in human HepG2 cells</article-title>. <source>Eur. J. Pharmacol.</source> <volume>937</volume>, <fpage>175358</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2022.175358</pub-id>
</citation>
</ref>
<ref id="B109">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J. Y.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>A new chromanone isolated from Portulaca oleracea L. increases glucose uptake by stimulating GLUT4 translocation to the plasma membrane in 3T3-L1 adipocytes</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>123</volume>, <fpage>26</fpage>&#x2013;<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2018.10.206</pub-id>
</citation>
</ref>
<ref id="B110">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Park</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>HM-chromanone, a component of Portulaca oleracea L., stimulates glucose uptake and glycogen synthesis in skeletal muscle cell</article-title>. <source>Phytomedicine</source> <volume>83</volume>, <fpage>153473</fpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2021.153473</pub-id>
</citation>
</ref>
<ref id="B111">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Petersen</surname>
<given-names>M. C.</given-names>
</name>
<name>
<surname>Shulman</surname>
<given-names>G. I.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Mechanisms of insulin action and insulin resistance</article-title>. <source>Physiol. Rev.</source> <volume>98</volume> (<issue>4</issue>), <fpage>2133</fpage>&#x2013;<lpage>2223</lpage>. <pub-id pub-id-type="doi">10.1152/physrev.00063.2017</pub-id>
</citation>
</ref>
<ref id="B112">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ponnulakshmi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shyamaladevi</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Vijayalakshmi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Selvaraj</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>
<italic>In silico</italic> and <italic>in vivo</italic> analysis to identify the antidiabetic activity of beta sitosterol in adipose tissue of high fat diet and sucrose induced type-2 diabetic experimental rats</article-title>. <source>Toxicol. Mech. Methods</source> <volume>29</volume> (<issue>4</issue>), <fpage>276</fpage>&#x2013;<lpage>290</lpage>. <pub-id pub-id-type="doi">10.1080/15376516.2018.1545815</pub-id>
</citation>
</ref>
<ref id="B113">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pu</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. A.</given-names>
</name>
<name>
<surname>Salim</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>L. H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K. J.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Baicalein, a natural product, selectively activating AMPK&#x3b1;(2) and ameliorates metabolic disorder in diet-induced mice</article-title>. <source>Mol. Cell Endocrinol.</source> <volume>362</volume> (<issue>1-2</issue>), <fpage>128</fpage>&#x2013;<lpage>138</lpage>. <pub-id pub-id-type="doi">10.1016/j.mce.2012.06.002</pub-id>
</citation>
</ref>
<ref id="B114">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punithavathi</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Prince</surname>
<given-names>P. S.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Selvakumari</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Antihyperglycaemic, antilipid peroxidative and antioxidant effects of gallic acid on streptozotocin induced diabetic Wistar rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>650</volume> (<issue>1</issue>), <fpage>465</fpage>&#x2013;<lpage>471</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.08.059</pub-id>
</citation>
</ref>
<ref id="B115">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punithavathi</surname>
<given-names>V. R.</given-names>
</name>
<name>
<surname>Stanely Mainzen Prince</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>M. R.</given-names>
</name>
<name>
<surname>Selvakumari</surname>
<given-names>C. J.</given-names>
</name>
</person-group> (<year>2011</year>). <article-title>Protective effects of gallic acid on hepatic lipid peroxide metabolism, glycoprotein components and lipids in streptozotocin-induced type II diabetic Wistar rats</article-title>. <source>J. Biochem. Mol. Toxicol.</source> <volume>25</volume> (<issue>2</issue>), <fpage>68</fpage>&#x2013;<lpage>76</lpage>. <pub-id pub-id-type="doi">10.1002/jbt.20360</pub-id>
</citation>
</ref>
<ref id="B116">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qin</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ren</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>Apigenin and naringenin ameliorate PKC&#x3b2;II-associated endothelial dysfunction via regulating ROS/caspase-3 and NO pathway in endothelial cells exposed to high glucose</article-title>. <source>Vasc. Pharmacol.</source> <volume>85</volume>, <fpage>39</fpage>&#x2013;<lpage>49</lpage>. <pub-id pub-id-type="doi">10.1016/j.vph.2016.07.006</pub-id>
</citation>
</ref>
<ref id="B117">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rai</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kosuru</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S. P.</given-names>
</name>
<name>
<surname>Birla</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>V.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Tetramethylpyrazine prevents diabetes by activating PI3K/Akt/GLUT-4 signalling in animal model of type-2 diabetes</article-title>. <source>Life Sci.</source> <volume>236</volume>, <fpage>116836</fpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2019.116836</pub-id>
</citation>
</ref>
<ref id="B118">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rai</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Kosuru</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Prakash</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Tiwari</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>S.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Tetramethylpyrazine alleviates diabetic nephropathy through the activation of Akt signalling pathway in rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>865</volume>, <fpage>172763</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172763</pub-id>
</citation>
</ref>
<ref id="B119">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Saravanan</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Efficacy of asiatic acid, a pentacyclic triterpene on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-induced diabetic rats</article-title>. <source>Phytomedicine</source> <volume>20</volume> (<issue>3-4</issue>), <fpage>230</fpage>&#x2013;<lpage>236</lpage>. <pub-id pub-id-type="doi">10.1016/j.phymed.2012.09.023</pub-id>
</citation>
</ref>
<ref id="B120">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Saravanan</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Asiatic acid prevents lipid peroxidation and improves antioxidant status in rats with streptozotocin-induced diabetes</article-title>. <source>J. Funct. Foods</source> <volume>5</volume> (<issue>3</issue>), <fpage>1077</fpage>&#x2013;<lpage>1087</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2013.03.003</pub-id>
</citation>
</ref>
<ref id="B121">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ramachandran</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Saravanan</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Glucose uptake through translocation and activation of GLUT4 in PI3K/Akt signaling pathway by asiatic acid in diabetic rats</article-title>. <source>Hum. Exp. Toxicol.</source> <volume>34</volume> (<issue>9</issue>), <fpage>884</fpage>&#x2013;<lpage>893</lpage>. <pub-id pub-id-type="doi">10.1177/0960327114561663</pub-id>
</citation>
</ref>
<ref id="B122">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rashid</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Das</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sil</surname>
<given-names>P. C.</given-names>
</name>
</person-group> (<year>2013</year>). <article-title>Taurine ameliorate alloxan induced oxidative stress and intrinsic apoptotic pathway in the hepatic tissue of diabetic rats</article-title>. <source>Food Chem. Toxicol.</source> <volume>51</volume>, <fpage>317</fpage>&#x2013;<lpage>329</lpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2012.10.007</pub-id>
</citation>
</ref>
<ref id="B123">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sadi</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Pektas</surname>
<given-names>M. B.</given-names>
</name>
<name>
<surname>Koca</surname>
<given-names>H. B.</given-names>
</name>
<name>
<surname>Tosun</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Koca</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Resveratrol improves hepatic insulin signaling and reduces the inflammatory response in streptozotocin-induced diabetes</article-title>. <source>Gene</source> <volume>570</volume> (<issue>2</issue>), <fpage>213</fpage>&#x2013;<lpage>220</lpage>. <pub-id pub-id-type="doi">10.1016/j.gene.2015.06.019</pub-id>
</citation>
</ref>
<ref id="B124">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Samarghandian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Farkhondeh</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Azimi-Nezhad</surname>
<given-names>M.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Protective effects of chrysin against drugs and toxic agents</article-title>. <source>Dose Response</source> <volume>15</volume> (<issue>2</issue>), <fpage>1559325817711782</fpage>. <pub-id pub-id-type="doi">10.1177/1559325817711782</pub-id>
</citation>
</ref>
<ref id="B125">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sandeep</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Nandhini</surname>
<given-names>C. D.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Influence of quercetin, naringenin and berberine on glucose transporters and insulin signalling molecules in brain of streptozotocin-induced diabetic rats</article-title>. <source>Biomed. Pharmacother.</source> <volume>94</volume>, <fpage>605</fpage>&#x2013;<lpage>611</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2017.07.142</pub-id>
</citation>
</ref>
<ref id="B126">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savova</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Mihaylova</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Tews</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wabitsch</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Georgiev</surname>
<given-names>M. I.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Targeting PI3K/AKT signaling pathway in obesity</article-title>. <source>Biomed. Pharmacother.</source> <volume>159</volume>, <fpage>114244</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2023.114244</pub-id>
</citation>
</ref>
<ref id="B127">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Savova</surname>
<given-names>M. S.</given-names>
</name>
<name>
<surname>Vasileva</surname>
<given-names>L. V.</given-names>
</name>
<name>
<surname>Mladenova</surname>
<given-names>S. G.</given-names>
</name>
<name>
<surname>Amirova</surname>
<given-names>K. M.</given-names>
</name>
<name>
<surname>Ferrante</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Orlando</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Ziziphus jujuba Mill. leaf extract restrains adipogenesis by targeting PI3K/AKT signaling pathway</article-title>. <source>Biomed. Pharmacother.</source> <volume>141</volume>, <fpage>111934</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2021.111934</pub-id>
</citation>
</ref>
<ref id="B128">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Seo</surname>
<given-names>Y. H.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>H. J.</given-names>
</name>
<name>
<surname>Shin</surname>
<given-names>H. T.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>Y. M.</given-names>
</name>
<name>
<surname>Yim</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>H. Y.</given-names>
</name>
<etal/>
</person-group> (<year>2008</year>). <article-title>Enhanced glycogenesis is involved in cellular senescence via GSK3/GS modulation</article-title>. <source>Aging Cell</source> <volume>7</volume> (<issue>6</issue>), <fpage>894</fpage>&#x2013;<lpage>907</lpage>. <pub-id pub-id-type="doi">10.1111/j.1474-9726.2008.00436.x</pub-id>
</citation>
</ref>
<ref id="B129">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shahwan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Alhumaydhi</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Ashraf</surname>
<given-names>G. M.</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>P. M. Z.</given-names>
</name>
<name>
<surname>Shamsi</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Role of polyphenols in combating Type 2 Diabetes and insulin resistance</article-title>. <source>Int. J. Biol. Macromol.</source> <volume>206</volume>, <fpage>567</fpage>&#x2013;<lpage>579</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijbiomac.2022.03.004</pub-id>
</citation>
</ref>
<ref id="B130">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shao</surname>
<given-names>J.-W.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>J.-L.</given-names>
</name>
<name>
<surname>Zou</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.-Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>F.-M.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.-J.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Therapeutic potential of ginsenosides on diabetes: from hypoglycemic mechanism to clinical trials</article-title>. <source>J. Funct. Foods</source> <volume>64</volume>, <fpage>103630</fpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2019.103630</pub-id>
</citation>
</ref>
<ref id="B131">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Shangguan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Peng</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Inhibitory effect of fisetin on &#x3b1;-glucosidase activity: kinetic and molecular docking studies</article-title>. <source>Molecules</source> <volume>26</volume> (<issue>17</issue>), <fpage>5306</fpage>. <pub-id pub-id-type="doi">10.3390/molecules26175306</pub-id>
</citation>
</ref>
<ref id="B132">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Natural product puerarin activates Akt and ameliorates glucose and lipid metabolism dysfunction in hepatic cells</article-title>. <source>J. Funct. Foods</source> <volume>55</volume>, <fpage>296</fpage>&#x2013;<lpage>304</lpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2019.02.035</pub-id>
</citation>
</ref>
<ref id="B133">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Resveratrol upregulates mmu-miR-363-3p via the PI3K-akt pathway to improve insulin resistance induced by a high-fat diet in mice</article-title>. <source>Diabetes Metab. Syndr. Obes.</source> <volume>13</volume>, <fpage>391</fpage>&#x2013;<lpage>403</lpage>. <pub-id pub-id-type="doi">10.2147/DMSO.S240956</pub-id>
</citation>
</ref>
<ref id="B134">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>&#x160;mahelov&#xe1;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hy&#x161;pler</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Haas</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Tich&#xe1;</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bl&#xe1;ha</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Zad&#xe1;k</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2005</year>). <article-title>Effect of atorvastatin on non-cholesterol sterols in patients with type 2 diabetes mellitus and cardiovascular disease</article-title>. <source>Pharmacol. Res.</source> <volume>51</volume> (<issue>1</issue>), <fpage>31</fpage>&#x2013;<lpage>36</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2004.07.007</pub-id>
</citation>
</ref>
<ref id="B135">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sok Yen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Shu Qin</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Tan Shi Xuan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Jia Ying</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Yi Le</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Darmarajan</surname>
<given-names>T.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Hypoglycemic effects of plant flavonoids: a review</article-title>. <source>Evid. Based Complement. Altern. Med.</source> <volume>2021</volume>, <fpage>2057333</fpage>. <pub-id pub-id-type="doi">10.1155/2021/2057333</pub-id>
</citation>
</ref>
<ref id="B136">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sujatha</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Anand</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sangeetha</surname>
<given-names>K. N.</given-names>
</name>
<name>
<surname>Shilpa</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lakshmi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Balakrishnan</surname>
<given-names>A.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Biological evaluation of (3&#x3b2;)-STIGMAST-5-EN-3-OL as potent anti-diabetic agent in regulating glucose transport using <italic>in vitro</italic> model</article-title>. <source>Int. J. Diabetes Mellitus</source> <volume>2</volume> (<issue>2</issue>), <fpage>101</fpage>&#x2013;<lpage>109</lpage>. <pub-id pub-id-type="doi">10.1016/j.ijdm.2009.12.013</pub-id>
</citation>
</ref>
<ref id="B137">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Long</surname>
<given-names>S. R.</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Antidiabetic effects of pterostilbene through PI3K/Akt signal pathway in high fat diet and STZ-induced diabetic rats</article-title>. <source>Eur. J. Pharmacol.</source> <volume>859</volume>, <fpage>172526</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.172526</pub-id>
</citation>
</ref>
<ref id="B138">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Saeedi</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Karuranga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pinkepank</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ogurtsova</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Duncan</surname>
<given-names>B. B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045</article-title>. <source>Diabetes Res. Clin. Pract.</source> <volume>183</volume>, <fpage>109119</fpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2021.109119</pub-id>
</citation>
</ref>
<ref id="B139">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Protective effects of asiatic acid in a spontaneous type 2 diabetic mouse model</article-title>. <source>Mol. Med. Rep.</source> <volume>16</volume> (<issue>2</issue>), <fpage>1333</fpage>&#x2013;<lpage>1339</lpage>. <pub-id pub-id-type="doi">10.3892/mmr.2017.6684</pub-id>
</citation>
</ref>
<ref id="B140">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>The beneficial effects of Zn on Akt-mediated insulin and cell survival signaling pathways in diabetes</article-title>. <source>J. Trace Elem. Med. Biol.</source> <volume>46</volume>, <fpage>117</fpage>&#x2013;<lpage>127</lpage>. <pub-id pub-id-type="doi">10.1016/j.jtemb.2017.12.005</pub-id>
</citation>
</ref>
<ref id="B141">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Cao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>Resveratrol attenuates dapagliflozin-induced renal gluconeogenesis via activating the PI3K/Akt pathway and suppressing the FoxO1 pathway in type 2 diabetes</article-title>. <source>Food Funct.</source> <volume>12</volume> (<issue>3</issue>), <fpage>1207</fpage>&#x2013;<lpage>1218</lpage>. <pub-id pub-id-type="doi">10.1039/d0fo02387f</pub-id>
</citation>
</ref>
<ref id="B142">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szakiel</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Paczkowski</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pensec</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Bertsch</surname>
<given-names>C.</given-names>
</name>
</person-group> (<year>2012</year>). <article-title>Fruit cuticular waxes as a source of biologically active triterpenoids</article-title>. <source>Phytochem. Rev.</source> <volume>11</volume> (<issue>2-3</issue>), <fpage>263</fpage>&#x2013;<lpage>284</lpage>. <pub-id pub-id-type="doi">10.1007/s11101-012-9241-9</pub-id>
</citation>
</ref>
<ref id="B143">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Szkudelska</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Szkudelski</surname>
<given-names>T.</given-names>
</name>
</person-group> (<year>2010</year>). <article-title>Resveratrol, obesity and diabetes</article-title>. <source>Eur. J. Pharmacol.</source> <volume>635</volume> (<issue>1-3</issue>), <fpage>1</fpage>&#x2013;<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2010.02.054</pub-id>
</citation>
</ref>
<ref id="B144">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tan</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Tseng</surname>
<given-names>H. H. L.</given-names>
</name>
<name>
<surname>Zhong</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Vong</surname>
<given-names>C. T.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Glycyrrhizic acid and its derivatives: promising candidates for the management of type 2 diabetes mellitus and its complications</article-title>. <source>Int. J. Mol. Sci.</source> <volume>23</volume> (<issue>19</issue>), <fpage>10988</fpage>. <pub-id pub-id-type="doi">10.3390/ijms231910988</pub-id>
</citation>
</ref>
<ref id="B145">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>Dendrobium officinale Kimura et Migo: A Review on Its Ethnopharmacology, Phytochemistry, Pharmacology, and Industrialization</article-title>. <source>Evidence-Based Complementary Altern. Med.</source> <volume>2017</volume>, <fpage>7436259</fpage>&#x2013;<lpage>7436319</lpage>. <pub-id pub-id-type="doi">10.1155/2017/7436259</pub-id>
</citation>
</ref>
<ref id="B146">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tang</surname>
<given-names>R. Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q. H.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>S. M.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Q. F.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Preventive or curative administration of taurine regulates lipid metabolism in the liver of rats with alcoholic liver disease</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1155</volume>, <fpage>119</fpage>&#x2013;<lpage>131</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-13-8023-5_11</pub-id>
</citation>
</ref>
<ref id="B147">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Teli</surname>
<given-names>D. M.</given-names>
</name>
<name>
<surname>Gajjar</surname>
<given-names>A. K.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Glycogen synthase kinase-3: a potential target for diabetes</article-title>. <source>Bioorg. Med. Chem.</source> <volume>92</volume>, <fpage>117406</fpage>. <pub-id pub-id-type="doi">10.1016/j.bmc.2023.117406</pub-id>
</citation>
</ref>
<ref id="B148">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thakur</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Partap</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kumar</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Warghat</surname>
<given-names>A. R.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Understandings of bioactive composition, molecular regulation, and biotechnological interventions in the development and usage of specialized metabolites as health-promoting substances in Siraitia grosvenorii (Swingle) C. Jeffrey</article-title>. <source>J. Food Compos. Analysis</source> <volume>116</volume>, <fpage>105070</fpage>. <pub-id pub-id-type="doi">10.1016/j.jfca.2022.105070</pub-id>
</citation>
</ref>
<ref id="B149">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L.-Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.-Q.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X.-W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Z.-Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Derivatives of glycyrrhetinic acid with amino acid: modifications, structural characterization, hypoglycemic activity and mechanism</article-title>. <source>Process Biochem.</source> <volume>134</volume>, <fpage>186</fpage>&#x2013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1016/j.procbio.2023.10.005</pub-id>
</citation>
</ref>
<ref id="B150">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Abdelkader</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2015</year>). <article-title>Combination therapy with oleanolic acid and metformin as a synergistic treatment for diabetes</article-title>. <source>J. Diabetes Res.</source> <volume>2015</volume>, <fpage>973287</fpage>. <pub-id pub-id-type="doi">10.1155/2015/973287</pub-id>
</citation>
</ref>
<ref id="B151">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wei</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Deng</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>D.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Ginsenoside Rg5 relieves type 2 diabetes by improving hepatic insulin resistance in db/db mice</article-title>. <source>J. Funct. Foods</source> <volume>71</volume>, <fpage>104014</fpage>. <pub-id pub-id-type="doi">10.1016/j.jff.2020.104014</pub-id>
</citation>
</ref>
<ref id="B152">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W. B.</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>The underlying mechanisms of curcumin inhibition of hyperglycemia and hyperlipidemia in rats fed a high-fat diet combined with STZ treatment</article-title>. <source>Molecules</source> <volume>25</volume> (<issue>2</issue>), <fpage>271</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25020271</pub-id>
</citation>
</ref>
<ref id="B153">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xia</surname>
<given-names>Z. H.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>S. Y.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y. S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>W. B.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y. Q.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Curcumin anti-diabetic effect mainly correlates with its anti-apoptotic actions and PI3K/Akt signal pathway regulation in the liver</article-title>. <source>Food Chem. Toxicol.</source> <volume>146</volume>, <fpage>111803</fpage>. <pub-id pub-id-type="doi">10.1016/j.fct.2020.111803</pub-id>
</citation>
</ref>
<ref id="B154">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>2,3,5,6-Tetramethylpyrazine improves diet-induced whole-body insulin resistance via suppressing white adipose tissue lipolysis in mice</article-title>. <source>Biochem. Biophys. Res. Commun.</source> <volume>532</volume> (<issue>4</issue>), <fpage>605</fpage>&#x2013;<lpage>612</lpage>. <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.08.099</pub-id>
</citation>
</ref>
<ref id="B155">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Geng</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2017</year>). <article-title>Chemical constituents of supercritical extracts from Alpinia officinarum and the feeding deterrent activity against <italic>Tribolium castaneum</italic>
</article-title>. <source>Molecules</source> <volume>22</volume> (<issue>4</issue>), <fpage>647</fpage>. <pub-id pub-id-type="doi">10.3390/molecules22040647</pub-id>
</citation>
</ref>
<ref id="B156">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X. L.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J. M.</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>W. Q.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Polyphenols isolated from lychee seed inhibit Alzheimer&#x27;s disease-associated Tau through improving insulin resistance via the IRS-1/PI3K/Akt/GSK-3&#x3b2; pathway</article-title>. <source>J. Ethnopharmacol.</source> <volume>251</volume>, <fpage>112548</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.112548</pub-id>
</citation>
</ref>
<ref id="B157">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>K. J.</given-names>
</name>
<name>
<surname>Tso</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Xiong</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>G.</given-names>
</name>
<etal/>
</person-group> (<year>2010</year>). <article-title>Antiobesity and antihyperglycemic effects of ginsenoside Rb1 in rats</article-title>. <source>Diabetes</source> <volume>59</volume> (<issue>10</issue>), <fpage>2505</fpage>&#x2013;<lpage>2512</lpage>. <pub-id pub-id-type="doi">10.2337/db10-0315</pub-id>
</citation>
</ref>
<ref id="B158">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>H. M.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>L.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>A new hypoglycemic mechanism of catalpol revealed by enhancing MyoD/MyoG-mediated myogenesis</article-title>. <source>Life Sci.</source> <volume>209</volume>, <fpage>313</fpage>&#x2013;<lpage>323</lpage>. <pub-id pub-id-type="doi">10.1016/j.lfs.2018.08.028</pub-id>
</citation>
</ref>
<ref id="B159">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Schwab</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marette</surname>
<given-names>A.</given-names>
</name>
</person-group> (<year>2014</year>). <article-title>Role of protein tyrosine phosphatases in the modulation of insulin signaling and their implication in the pathogenesis of obesity-linked insulin resistance</article-title>. <source>Rev. Endocr. Metab. Disord.</source> <volume>15</volume> (<issue>1</issue>), <fpage>79</fpage>&#x2013;<lpage>97</lpage>. <pub-id pub-id-type="doi">10.1007/s11154-013-9282-4</pub-id>
</citation>
</ref>
<ref id="B160">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Xuezheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Bing</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haoqiang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Chunyu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yali</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Jing</surname>
<given-names>W.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>The effects of emodin on insulin resistance in KKAy mice with diabetes mellitus</article-title>. <source>Pharmacogn. Mag.</source> <volume>14</volume> (<issue>56</issue>), <fpage>344</fpage>. <pub-id pub-id-type="doi">10.4103/pm.pm_362_17</pub-id>
</citation>
</ref>
<ref id="B161">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Z.</given-names>
</name>
<etal/>
</person-group> (<year>2018</year>). <article-title>Catalpol ameliorates hepatic insulin resistance in type 2 diabetes through acting on AMPK/NOX4/PI3K/AKT pathway</article-title>. <source>Pharmacol. Res.</source> <volume>130</volume>, <fpage>466</fpage>&#x2013;<lpage>480</lpage>. <pub-id pub-id-type="doi">10.1016/j.phrs.2017.12.026</pub-id>
</citation>
</ref>
<ref id="B162">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>N.</given-names>
</name>
</person-group> (<year>2017</year>). <article-title>A glimpse of membrane transport through structures&#x2014;advances in the structural biology of the GLUT glucose transporters</article-title>. <source>J. Mol. Biol.</source> <volume>429</volume> (<issue>17</issue>), <fpage>2710</fpage>&#x2013;<lpage>2725</lpage>. <pub-id pub-id-type="doi">10.1016/j.jmb.2017.07.009</pub-id>
</citation>
</ref>
<ref id="B163">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yan</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Quan</surname>
<given-names>Z.-S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>Q.-K.</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>H.-Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Bioactivities and structure&#x2010;activity relationships of maslinic acid derivatives: a review</article-title>. <source>Chem. Biodivers.</source> <volume>21</volume>, <fpage>e202301327</fpage>. <pub-id pub-id-type="doi">10.1002/cbdv.202301327</pub-id>
</citation>
</ref>
<ref id="B164">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Erianin suppresses hepatocellular carcinoma cells through down-regulation of PI3K/AKT, p38 and ERK MAPK signaling pathways</article-title>. <source>Biosci. Rep.</source> <volume>40</volume> (<issue>7</issue>). <pub-id pub-id-type="doi">10.1042/BSR20193137</pub-id>
</citation>
</ref>
<ref id="B165">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>The anti-diabetic activity of licorice, a widely used Chinese herb</article-title>. <source>J. Ethnopharmacol.</source> <volume>263</volume>, <fpage>113216</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2020.113216</pub-id>
</citation>
</ref>
<ref id="B166">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>S.-C.</given-names>
</name>
<name>
<surname>Hsu</surname>
<given-names>C.-Y.</given-names>
</name>
<name>
<surname>Chou</surname>
<given-names>W.-L.</given-names>
</name>
<name>
<surname>Fang</surname>
<given-names>J.-Y.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>S.-Y.</given-names>
</name>
</person-group> (<year>2020</year>). <article-title>Bioactive agent discovery from the natural compounds for the treatment of type 2 diabetes rat model</article-title>. <source>Molecules</source> <volume>25</volume> (<issue>23</issue>), <fpage>5713</fpage>. <pub-id pub-id-type="doi">10.3390/molecules25235713</pub-id>
</citation>
</ref>
<ref id="B167">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Y.-Y.</given-names>
</name>
<name>
<surname>Qi</surname>
<given-names>J.-J.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>S.-Y.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>L.</given-names>
</name>
</person-group> (<year>2024</year>). <article-title>Esculin ameliorates obesity-induced insulin resistance by improving adipose tissue remodeling and activating the IRS1/PI3K/AKT/GLUT4 pathway</article-title>. <source>J. Ethnopharmacol.</source> <volume>319</volume>, <fpage>117251</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2023.117251</pub-id>
</citation>
</ref>
<ref id="B168">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Baicalein improves glucose metabolism in insulin resistant HepG2 cells</article-title>. <source>Eur. J. Pharmacol.</source> <volume>854</volume>, <fpage>187</fpage>&#x2013;<lpage>193</lpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2019.04.005</pub-id>
</citation>
</ref>
<ref id="B169">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yap</surname>
<given-names>K. H.</given-names>
</name>
<name>
<surname>Yee</surname>
<given-names>G. S.</given-names>
</name>
<name>
<surname>Candasamy</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>S. C.</given-names>
</name>
<name>
<surname>Md</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Abdul Majeed</surname>
<given-names>A. B.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Catalpol ameliorates insulin sensitivity and mitochondrial respiration in skeletal muscle of type-2 diabetic mice through insulin signaling pathway and AMPK/SIRT1/PGC-1&#x3b1;/PPAR-&#x3b3; activation</article-title>. <source>Biomolecules</source> <volume>10</volume> (<issue>10</issue>), <fpage>1360</fpage>. <pub-id pub-id-type="doi">10.3390/biom10101360</pub-id>
</citation>
</ref>
<ref id="B170">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yingrui</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Guoyan</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Hongjie</surname>
<given-names>W.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Research progress of active ingredients of Scutellaria baicalensis in the treatment of type 2 diabetes and its complications</article-title>. <source>Biomed. Pharmacother.</source> <volume>148</volume>, <fpage>112690</fpage>. <pub-id pub-id-type="doi">10.1016/j.biopha.2022.112690</pub-id>
</citation>
</ref>
<ref id="B171">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yoo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>J. E.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>J. S.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>HMC ameliorates hyperglycemia via acting PI3K/AKT pathway and improving FOXO1 pathway in ob/ob mice</article-title>. <source>Nutrients</source> <volume>15</volume> (<issue>9</issue>), <fpage>2023</fpage>. <pub-id pub-id-type="doi">10.3390/nu15092023</pub-id>
</citation>
</ref>
<ref id="B172">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yousof Ali</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Zaib</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mizanur Rahman</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Jannat</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Iqbal</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kyu Park</surname>
<given-names>S.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Poncirin, an orally active flavonoid exerts antidiabetic complications and improves glucose uptake activating PI3K/Akt signaling pathway in insulin resistant C2C12 cells with anti-glycation capacities</article-title>. <source>Bioorg. Chem.</source> <volume>102</volume>, <fpage>104061</fpage>. <pub-id pub-id-type="doi">10.1016/j.bioorg.2020.104061</pub-id>
</citation>
</ref>
<ref id="B173">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>X.</given-names>
</name>
<etal/>
</person-group> (<year>2006</year>). <article-title>Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats</article-title>. <source>Can. J. Physiology Pharmacol.</source> <volume>84</volume> (<issue>6</issue>), <fpage>579</fpage>&#x2013;<lpage>587</lpage>. <pub-id pub-id-type="doi">10.1139/y06-015</pub-id>
</citation>
</ref>
<ref id="B174">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases</article-title>. <source>Front. Pharmacol.</source> <volume>14</volume>, <fpage>1240820</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2023.1240820</pub-id>
</citation>
</ref>
<ref id="B175">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zeng</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y. P.</given-names>
</name>
<name>
<surname>Cantley</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Iseli</surname>
<given-names>T. J.</given-names>
</name>
<name>
<surname>Molero</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Hegarty</surname>
<given-names>B. D.</given-names>
</name>
<etal/>
</person-group> (<year>2012</year>). <article-title>Oleanolic acid reduces hyperglycemia beyond treatment period with Akt/FoxO1-induced suppression of hepatic gluconeogenesis in type-2 diabetic mice</article-title>. <source>PLoS One</source> <volume>7</volume> (<issue>7</issue>), <fpage>e42115</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0042115</pub-id>
</citation>
</ref>
<ref id="B176">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Jiang</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2020</year>). <article-title>Inhibition of PI3K/Akt/NF-&#x3ba;B signaling by Aloin for ameliorating the progression of osteoarthritis: <italic>in vitro</italic> and <italic>in vivo</italic> studies</article-title>. <source>Int. Immunopharmacol.</source> <volume>89</volume> (<issue>Pt B</issue>), <fpage>107079</fpage>. <pub-id pub-id-type="doi">10.1016/j.intimp.2020.107079</pub-id>
</citation>
</ref>
<ref id="B177">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Ameliorating effect on glycolipid metabolism and chemical profile of Millettia speciosa champ. extract</article-title>. <source>Extr. J. Ethnopharmacol.</source> <volume>279</volume>, <fpage>114360</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2021.114360</pub-id>
</citation>
</ref>
<ref id="B178">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>W. N.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>R. N.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>L. L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>W. W.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>R.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Structural characterization and <italic>in vitro</italic> hypoglycemic activity of a glucan from Euryale ferox Salisb. seeds</article-title>. <source>Carbohydr. Polym.</source> <volume>209</volume>, <fpage>363</fpage>&#x2013;<lpage>371</lpage>. <pub-id pub-id-type="doi">10.1016/j.carbpol.2019.01.044</pub-id>
</citation>
</ref>
<ref id="B179">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Su</surname>
<given-names>Z.</given-names>
</name>
</person-group> (<year>2018</year>). <article-title>Unraveling the regulation of hepatic gluconeogenesis</article-title>. <source>Front. Endocrinol. (Lausanne)</source> <volume>9</volume>, <fpage>802</fpage>. <pub-id pub-id-type="doi">10.3389/fendo.2018.00802</pub-id>
</citation>
</ref>
<ref id="B180">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Dong</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>F.</given-names>
</name>
<etal/>
</person-group> (<year>2021</year>). <article-title>DPHC from Alpinia officinarum ameliorates oxidative stress and insulin resistance via activation of Nrf2/ARE pathway in db/db mice and high glucose-treated HepG2 cells</article-title>. <source>Front. Pharmacol.</source> <volume>12</volume>, <fpage>792977</fpage>. <pub-id pub-id-type="doi">10.3389/fphar.2021.792977</pub-id>
</citation>
</ref>
<ref id="B181">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>X. G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>A. X.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y. X.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>M. Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X. Y.</given-names>
</name>
<name>
<surname>Fu</surname>
<given-names>M. H.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>A diarylheptanoid compound from Alpinia officinarum Hance ameliorates high glucose-induced insulin resistance by regulating PI3K/AKT-Nrf2-GSK3&#x3b2; signaling pathways in HepG2 cells</article-title>. <source>J. Ethnopharmacol.</source> <volume>295</volume>, <fpage>115397</fpage>. <pub-id pub-id-type="doi">10.1016/j.jep.2022.115397</pub-id>
</citation>
</ref>
<ref id="B182">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Ye</surname>
<given-names>R.</given-names>
</name>
</person-group> (<year>2022</year>). <article-title>Astragaloside IV regulates insulin resistance and inflammatory response of adipocytes via modulating CTRP3 and PI3K/AKT signaling</article-title>. <source>Diabetes Ther.</source> <volume>13</volume> (<issue>11-12</issue>), <fpage>1823</fpage>&#x2013;<lpage>1834</lpage>. <pub-id pub-id-type="doi">10.1007/s13300-022-01312-1</pub-id>
</citation>
</ref>
<ref id="B183">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>He</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Hou</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Glycyrrhetinic acid improves insulin-response pathway by regulating the balance between the ras/MAPK and PI3K/akt pathways</article-title>. <source>Nutrients</source> <volume>11</volume> (<issue>3</issue>), <fpage>604</fpage>. <pub-id pub-id-type="doi">10.3390/nu11030604</pub-id>
</citation>
</ref>
<ref id="B184">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Akt activation: a potential strategy to ameliorate insulin resistance</article-title>. <source>Diabetes Res. Clin. Pract.</source> <volume>156</volume>, <fpage>107092</fpage>. <pub-id pub-id-type="doi">10.1016/j.diabres.2017.10.004</pub-id>
</citation>
</ref>
<ref id="B185">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>D. D.</given-names>
</name>
<name>
<surname>Lv</surname>
<given-names>Q. F.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>J. C.</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>G. F.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Q. H.</given-names>
</name>
<etal/>
</person-group> (<year>2019</year>). <article-title>Taurine improves lipid metabolism and skeletal muscle sensitivity to insulin in rats fed with high sugar and high fat diet</article-title>. <source>Adv. Exp. Med. Biol.</source> <volume>1155</volume>, <fpage>133</fpage>&#x2013;<lpage>146</lpage>. <pub-id pub-id-type="doi">10.1007/978-981-13-8023-5_12</pub-id>
</citation>
</ref>
<ref id="B186">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhao</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Shu</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>H.</given-names>
</name>
</person-group> (<year>2019</year>). <article-title>Effect of resveratrol on blood lipid levels in patients with type 2 diabetes: a systematic review and meta-analysis</article-title>. <source>Obes. (Silver Spring)</source> <volume>27</volume> (<issue>1</issue>), <fpage>94</fpage>&#x2013;<lpage>102</lpage>. <pub-id pub-id-type="doi">10.1002/oby.22348</pub-id>
</citation>
</ref>
<ref id="B187">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zheng</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Ke</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Feng</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>Y.</given-names>
</name>
<etal/>
</person-group> (<year>2016</year>). <article-title>The mechanism by which amentoflavone improves insulin resistance in HepG2 cells</article-title>. <source>Molecules</source> <volume>21</volume> (<issue>5</issue>), <fpage>624</fpage>. <pub-id pub-id-type="doi">10.3390/molecules21050624</pub-id>
</citation>
</ref>
<ref id="B188">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhong</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Xie</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<etal/>
</person-group> (<year>2022</year>). <article-title>Anti-diabetic effect of aloin via JNK-IRS1/PI3K pathways and regulation of gut microbiota</article-title>. <source>Food Sci. Hum. Wellness</source> <volume>11</volume> (<issue>1</issue>), <fpage>189</fpage>&#x2013;<lpage>198</lpage>. <pub-id pub-id-type="doi">10.1016/j.fshw.2021.07.019</pub-id>
</citation>
</ref>
<ref id="B189">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Gong</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease</article-title>. <source>Eur. J. Pharmacol.</source> <volume>898</volume>, <fpage>173976</fpage>. <pub-id pub-id-type="doi">10.1016/j.ejphar.2021.173976</pub-id>
</citation>
</ref>
<ref id="B190">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Konigsberg</surname>
<given-names>W. H.</given-names>
</name>
<name>
<surname>Hao</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Pan</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X.</given-names>
</name>
</person-group> (<year>2023</year>). <article-title>Bioactivity and mechanisms of flavonoids in decreasing insulin resistance</article-title>. <source>J. Enzyme Inhib. Med. Chem.</source> <volume>38</volume> (<issue>1</issue>), <fpage>2199168</fpage>. <pub-id pub-id-type="doi">10.1080/14756366.2023.2199168</pub-id>
</citation>
</ref>
<ref id="B191">
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>Y. J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>X. C.</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y. Y.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>S. W.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>Y. N.</given-names>
</name>
</person-group> (<year>2021</year>). <article-title>Chrysin improves glucose and lipid metabolism disorders by regulating the AMPK/PI3K/AKT signaling pathway in insulin-resistant HepG2 cells and HFD/STZ-Induced C57bl/6J mice</article-title>. <source>J. Agric. Food Chem.</source> <volume>69</volume> (<issue>20</issue>), <fpage>5618</fpage>&#x2013;<lpage>5627</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jafc.1c01109</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>